updated 10/2/02 - school of medicine | university of...

Updated 12/11/2015CURRICULUM VITAE

GREGORY T. EVERSON, M.D., F.A.C.P.

PROFESSOR OF MEDICINE PHONE (720) 848-2245DIRECTOR, SECTION OF HEPATOLOGY FAX: (303) [email protected]

DIVISION OF GASTROENTEROLOGY & HEPATOLOGYUNIVERSITY OF COLORADO SCHOOL OF MEDICINETRANSPLANT CENTER & HEPATOLOGY CLINICUNIVERSITY OF COLORADO HOSPITAL AOP1635 AURORA CT. B154AURORA, COLORADO 80045

EDUCATION University of North Dakota 1968 - 1972 B.S. (Chemistry) Cornell University Medical College 1972 - 1976 M.D.

MEDICAL TRAINING1976-1977 Intern, Internal Medicine, Creighton UniversityAffiliated Hospitals, Omaha, Nebraska

1977-1979 Resident, Internal Medicine, Creighton UniversityAffiliated Hospitals, Omaha, Nebraska

1979-1982 Fellow, Division of Gastroenterology,University of Colorado School of Medicine,Denver, Colorado

ACADEMIC APPOINTMENTS1982-1988 Assistant Professor of MedicineDivision of Gastroenterology & HepatologyUniversity of Colorado School of MedicineDenver, Colorado

1988-1996 Associate Professor of Medicine Division of Gastroenterology & HepatologyUniversity of Colorado School of MedicineDenver, Colorado

1996-PRESENT Professor of MedicineDivision of Gastroenterology & HepatologyUniversity of Colorado School of MedicineDenver, Colorado

1990-PRESENT Director, Section of HepatologyUniversity of Colorado School of MedicineDenver, CO

1

mailto:[email protected]

BOARD CERTIFICATIONInternal Medicine, 1979 Certificate Number: 72225Gastroenterology, 1982 Certificate Number: 72225Transplant Hepatology, 2006 Certificate Number: 72225

LICENSURE Colorado 22430 (1979)

MEMBERSHIPS American Association for the Study of Liver Disease American College of Physicians American Gastroenterological Association American Society of Transplant Physicians International Association for the Study of Liver Disease

HONORS Phi Beta Kappa Best Doctors in America Award, 1999 - 2015 Fellow, American College of Physicians (FACP), 1999

Peak Performer Award Winner 2012Fellow, American Association for the Study of Liver Disease (FAASLD) 2014Fellow, American Gastroenterological Association (AGA)

INVITED LECTURESAASLD meeting “Meet the Professor”, November, 1995AASLD meeting “Meet the Professor”, November, 1998American Liver Foundation Meeting 1998Participant University Health Talk Radio Show, October, 1998St. Mary’s Hospital 21st Annual Winter Symposium, Grand Junction, CO, January, 1999Medical University of South Carolina 4th Annual Liver Disease and Transplantation Symposium, Charleston, SC, February, 1999University of Maryland 3rd Annual Liver Disease Seminar, Baltimore, MD, April, 1999American Osteopathic College of Occupational & Preventive Medicine, Kansas City, MO, April, 1999Bonfils Blood Center, Denver, CO, May, 1999

Faculty Presenter; Educational Advisory Board, “Treating Hepatitis C: Solutions for a Critical Need” UCHSC, June, 1999American College of Physicians, State Conference, Kalispell, MT, August, 1999American College of Chest Physicians/Society of Critical Care Medicine, Orlando, FL, August, 1999University of North Carolina Grand Rounds, Chapel Hill, NC, October, 1999Rush-Presbyterian Hospital Grand Rounds, Chicago, IL, October, 1999American College of Gastroenterology, Phoenix, AZ, October, 1999Poudre Valley Hospital, Ft. Collins, CO, Grand Rounds, December, 1999European Association of Critical Care Physicians, Linz, Austria, Dr. Kurt Lenz, September, 1999University of Utah, Park City, UT, Advances in Internal Medicine, February, 2000AST Transplant 2000, May, 2000Denver VA Hep C Program, June, 2000AASLD/ILTS Transplant Course Director and Speaker, Dallas, TX October, 2000.NIH Workshop on Living Donor Liver Transplantation, Member and Speaker, Washington, DC, November, 2000

2

Long-Term Risk Factors for Solid Organ Transplant Recipients, Phoenix, AZ, November, 2000Brown University, Rhode Island Hospital, Providence, RI, December, 2000Controversies In Transplantation, Breckenridge, CO, March, 2001Fifth Annual Liver Symposium, Medical College of Virginia, Richmond, VA, March, 2001Rush-Presbyterian Continuing Medical Education Program, Treatment Strategies in Managing Chronic HCV, Houston, TX, March, 2001Hepatobiliary Diseases in Clinical Practice Annual Course/Meeting, Living Related Donors, March, 2001, University of Miami School of Medicine, Miami, FLFt. Collins/Greeley/Loveland, Colorado Gut Club and Hep C Connection, Hepatitis C: What Does the Future Hold, June, 2001Faculty/Speaker, University of Wisconsin Medical School/AdvancedMed, LLC, CME course “Augmenting Adherence to Therapy, Denver, CO, July, 2001Controversies in Transplantation, Breckenridge, CO. March, 2002Gastroenterology Pathophysiology Course, 2001-2002. University of Colorado Health Sciences Center, Denver, CO.Southwest Regional Hepatitis C Symposium, Good Samaritan Regional Medical Center, Phoenix AZ, June, 2002.American Council of Life Insurers/University of Colorado Health Sciences Center CME Course, “Epidemiology & Mortality Trends-Global Perspectives of HIV/AIDS & HCV”, Denver, CO, June, 2002American College of Chest Physicians/Society of Critical Care Medicine, “Upper & Lower GI Bleeding, Hepatic Failure”, Chicago, IL, August, 2002Denver STD/HIV Prevention Annual Update, Denver, CO, September, 2002University of Colorado Hospital Outreach/CME Program, “Update on Hepatitis C”, Montrose/Delta, CO, September, 2002Cornell University Alumni Reunion, ‘Current Status of Living Donor Liver Transplantation in the United States” New York, NY, October, 2002American College of Gastroenterology Postgraduate Course, Seattle, WA, October, 2002Good Samaritan Regional Medical Center Internal Medicine Grand Rounds, “Current Therapy of Hepatitis C, An Update”, Phoenix, AZ, October, 2002University of Iowa Grand Rounds, “Adult to Adult Liver Transplantation”, Iowa City, IA, October, 2002American Association of the Study of Liver Disease Postgraduate Course, Boston, MA, October, 2002Pegasys® Speakers Bureau, “Point/Counterpoint: Controversies in Hepatitis C Therapy, Does the Patient Really Need Treatment, Does the Patient Really Need a Liver Biopsy?” Roche Laboratories, Half Moon Bay, CA, January, 2003Memorial Hospital Grand Rounds, “The Vital Role of Vaccination Against Hepatitis A and B”Colorado Springs, CO, February, 2003ILTS Single Topic and Consensus Development Conference on Liver Transplantation and Hepatitis C, “Treatment of HCV Patients on the Waiting List”, Phoenix, AZ, March, 2003Eighteenth Annual Conference New Treatments in Chronic Liver Disease, “Challenges in Treating the Patient with Advances Hepatitis C”, LaJolla, CA, April, 2003Advancmed CME Course Co-Chair “Maximizing Treatment Outcomes for Patients with HCV”, Denver, CO, April, 2003 American Academy of Physicians Assistants Controversies in Hepatitis C Therapy, CME Course Moderator, New Orleans, LA, May, 2003 American Academy of Physicians Assistants Controversies in Hepatitis C Therapy, CME Course Moderator, Atlanta, May, 2003 Hepatitis C Depression Symposium, “Controversies in Hepatitis C Therapy: Debating the Options for Patients with Depression, Alcoholism, or Substance Abuse”, Anaheim, CA, June, 2003Prague Hepatology Meeting, “Outcomes Beyond the First Post-Transplant Year: Causes of Death in Relation to Graft Function”, Prague, CZ, June, 2003Rush Presbyterian Hospital Grand Rounds, Emerging Advances in HCV Management: A Pegasys®

3

Educational Program, Chicago, IL, July, 2003AASLD Liver Meeting Wrap-Up, University of Louisville, “Update in Hepatitis C”, Louisville, KY, December, 2003Hepatitis Open Forum, Hepatitis Neighborhood Organization, Orlando, FL, January 20, 2004.Roth Visiting Professorship, “Current Issues in Pre and Post-Transplant Management of Hepatitis C,” Montreal Canada, September 2, 2004.Adult Clinical Medicine Course for UCHSC PA Program, “Liver Diseases” Denver, CO November 23, 2005.Department of Medicine Research Conference, University of Colorado Health Sciences Center, “Noninvasive Assessment of the Portal Circulation in Man” Denver, CO, April 12, 2007.National Institute of Diabetes and Digestive and Kidney Diseases, Liver Disease Branch, Monthly Visiting lectureship, “Clinical Approach to the Patient” Bethesda, MD, April 25-26, 2007.Hepatitis B & C Training Program. Scripps Conference. October 27, 2012AASLD The Liver Meeting HCV Symposium. November 12, 2012—TASL "Modern Medicine in Chronic Hepatitis C" conference. December 19, 20127th Annual Southwest Liver Disease Symposium: GTE and LE. November 30, 2012- Baylor Medical School. Invited speaker. January 9, 2013.Medical Surgery/GI Meeting/Aspen, Colorado. HCV/HBV January 26, 2013Best Practice HCV Preceptorship Program. Doha, Qatar, April 10, 2013.EASL International Liver Congress. Amsterdam/Netherlands, April 22, 2013.DDW 2013/Orlando, Florida May 2013American Transplant Congress, Seattle, WA. May 2013University of Pennsylvania. May 2013.Argentinean Association for the Study of Liver Diseases. June 5, 2013ILTS 19th Annual International Congress. Sydney, Australia. June 12, 2013Internal Medicine for Primary Care: Gastroenterology/Neurology/Dermatology/Adolescent Medicine March 15-21, 2014Post EASL Advisory Board, May 2014HCV US National Advisory Committee's US Advisory Board, June 2014World Transplant Congress, July 2014Simply Speaking Hepatitis and Grand Rounds Lecture, September, 2014The American College of Gastroenterology, October 2014Univeristy of Califonia San Diego, January 2015John Hopkins University, January 2015Banner Liver Disease Symposium, February 2015Latin American Meeting on Treatment of Viral Hepatitis, March 2015EASL International Liver Congress, April 2015Duke University of Medicine, July 2015Lahey Hospital & medical Center, July 2015Chroinic Liver Disease Foundation, August 2015CLBS Liver Symposium, New Delhi, October 2015Miami Transplant International Symposium, October 2015Drexel University College of Medicine, November 2015EDITORIAL BOARDS Abstract Reviewer for AASLDAbstract reviewer for DDWAbstract Reviewer for ASTAbstract Reviewer for ILTS

REFEREE FOR FOLLOWING JOURNALS (CURRENT)

4

American Journal of GastroenterologyAmerican Journal of PhysiologyAnnals of Internal MedicineGastroenterologyGutHepatologyJournal of Clinical InvestigationJournal of HepatologyObstetrics and GynecologyDigestive Diseases and SciencesJournal of Lipid ResearchLiver Transplantation and SurgeryTransplantationNew England Journal of Medicine

DATA AND SAFETY MONITORING BOARDSGalectin Studies

FELLOWS AND RESIDENTS TRAINEDMichael LawsonAntal NemethDon ZoggRoshan ShresthaJohn-Paul MorfinClark KuligSaroj BangarouBryan KimJeff FrankTom TrouillotAimee TruesdaleBrett FortuneJoel WeddAmanda WielandLiyun Yuan

MENTORSHIPS/SPONSORSHIPS: MEDICAL STUDENTSStudent: Adam Braddock

Project Title: Gender and Age Difference in Serum Fatty Acid Ethyl Ester Levels in a Hospital-Based Population with Positive Ethanol Screenings.

NIH Short-Term Training Grant 5T35 DK07496-19Dates: 6/04-8/04

Student: Michael MartucciProject Title: Deconvolutional analysis on clearance curves of simultaneously administered oral and

intravenous doses of 2,2,4,4-2H cholate and 24-13C cholate: minimal model to determine first-pass hepatic extraction of cholate in humans.

NIH Short-Term Training Grant 5T35 DK07496Dates: 6/04-8/04

Steve Sanko, M.D., Project Title: HCV replication in peripheral monocytes

5

Robinson-Durst Scholarship Dates: 8/05-7/06

PAST RESEARCH SUPPORT Serum Bile Acid Kinetics and Regulation of Biosynthesis

NIH K08 AM 01156 NIADDK Clinical Investigator Award Gregory T. Everson, M.D., Principal Investigator

Period of Funding: 4/1/83-3/31/86 Total Budget: $150,000

Serum Bile Acid Kinetics Research Award, American Gastroenterological Association Gregory T. Everson, M.D., Principal Investigator

Period of Funding: 1/1/83-12/31/83 Total Budget: $15,000

Research and Teaching Scholarship American College of Physicians Gregory T. Everson, M.D., Principal Investigator

Period of Funding: 1983-1986Total Budget: $150,000

Estrogen Effects on Biliary Lipids and Bile Acid Kinetics NIH 2R01 DK 19605 Gregory T. Everson, M.D., Principal Investigator

Period of Funding: 6/87-5/91Total Budget: $421,733

Liver Function in Polycystic Liver Disease NIH 5P01 DK 34039 Patricia Gabow, M.D. (Program Project), Principal Investigator Gregory T. Everson, M.D. (Sub-Project), Principal Investigator

Period of Funding: 10/85-3/90Total Budget: $365,143

Hepatobiliary Research Center: GC/MS Core NIH 5P 30 DK 34914

Francis Simon, M.D. (Center), Principal Investigator Gregory T. Everson, M.D. and Paul Fennessy, M.D. (Core)

Period of Funding: 9/85-8/90 Total Budget: $242,446

Effects of Psyllium Mucitloid on Hepatic Lipid Metabolism (Proctor and Gamble) Gregory T. Everson, M.D., Principal Investigator

Period of Funding: 9/88-8/90 Total Budget: $155,424

Functional Characteristics of Hepatic Cystic Epithelium in Autosomal Dominant Polycystic Disease (Pilot Feasibility Study)

6

NIH 5P30 DK34914Period of Funding: 12/91-3/92Total Budget: $4,738

Hepatobiliary Function in Sickle Cell Disease (Pilot Feasibility Study) NIH 5P30 DK34914

Period of Funding: 1987-1989

Bile Acid Synthesis by Liver Cell Hybrids (Pilot Feasibility Study) NIH 5P30 DK34914

Period of Funding: 1987-1989

Schering-Plough Trials for Treatment of Hepatitis: a.) C89-9-140: Dose - Response Study of Intron A in Chronic Hepatitis C

Gregory T. Everson, M.D., Principal InvestigatorTotal Project Period: 1/31/91-94Budget: Approximately $400/pt/yr, 4 pts.

b.) C92-131: Randomized, Open Trial of PEG-IFN Vs Intron in Treatment of Chronic Hepatitis C

Gregory T. Everson, M.D., Principal InvestigatorTotal Project Period: 8/28/92-12/94 Budget: $61,372 (Note: Study canceled early; exact budget unclarified)

An Open-Label, Randomized, Multicenter, Comparison of the Efficacy and Safety of Twenty-Four and Forty-Eight Weeks of De-escalating Regimen of Roferon-A (Interferon Alpha-2a, Recombinant/Roche) in the Treatment of Patients with Chronic Hepatitis C (Equivalence Study) (Hoffman-LaRoche)

Gregory T. Everson, M.D., Principal InvestigatorProject Period: 6/94-5/96Total Direct: $195,100(maximum allowable, dependent upon patient recruitment)

Effects) of Multiple Oral Administration of Orlistat on Bile Composition in Obese Volunteers (Hoffmann-LaRoche)

Gregory T. Everson, M.D., Principal InvestigatorProject Period: 8/94-7/95Total Direct: $241,716

Phase I, Multiple Dose, Open Study Designed to Compare Safety and Disposition of Ziprasidone in Subjects with Normal Hepatic Function to Subject with Hepatic Impairment (Pfizer, Inc.)

Gregory T. Everson, M.D., Principal Investigator Project Period: 7/95 - 6/96

Total Direct: $108,382

NIH 5P30 DK34914: Hepatobiliary Research Center Francis R. Simon, M.D., Principal Investigator Gregory T. Everson, M.D., Director, Bile Acid GC/MS Core Laboratory

Total Project Period: 12/90-11/95 Total Direct: $187,071

7

C92-130: Randomized, Open Trial of Zn-IFN Versus Intron in the Treatment of Chronic Hepatitis C (Schering-Plough) Gregory T. Everson, M.D., Principal Investigator

Total Project Period: 8/28/92-12/94 Budget: $53,699

Polycystic Kidney Research Foundation Grant Gregory T. Everson, M.D., Principal Investigator

Current Project Period: 6/94-5/95Total Direct: $18,360

A Study of Lamivudine or Placebo in Patients with Chronic Hepatitis B Infection whoare Treatment Naïve” (Glaxo Inc.)

Gregory T. Everson, M.D., Principal InvestigatorProject Period: 7/95 - 6/97Total Direct: No funding

Placebo Controlled Study of Lamivudine and Intron A in Patients with ChronicHepatitis B Infection Who are Interferon Alpha Non-responders (Glaxo, Inc.)

Gregory T. Everson, M.D., Principal InvestigatorProject Period: 7/95 - 6/97Total Direct: No funding

Screening Procedure for Identification of Patients for Participation in Research Protocols Evaluating Intron A, Alone or In Combination with Other Agents for the Treatment of Chronic Hepatitis C (Schering-Plough Research Institute)

Gregory T. Everson, M.D. - Principal InvestigatorProject Period: 1/96 - 3/96

Total Direct: No Funding

Assessment of the Health-Related Quality of Life in Adult Chronic Hepatitis C (CHC) Patients with Different Categories of Disease and Sustained Responders to INTRON A (Schering-Plough) Gregory T. Everson, M.D., Principal Investigator

Project Period: 9/95 - 8/96Total Direct: $12,500

A Phase III, Open Label, Randomized, Multicenter Trial to Determine the Efficacy of Recombinant-Methionyl Interferon-Consensus (r-metIFN-Con1) in Patients with ChronicHepatitis C Virus (HCV) after Prior Treatment with r-metIFN-Con1 or Interferon alfa-2bRecombinant (Amgen) Gregory T. Everson, M.D., Principal Investigator

Project Period: 8/94 - 7/98Total Direct: $122,900 (Dependent upon patient recruitment)Grant: 2531433

Intron A monotherapy vs. Intron A + Ribavirin for treatment of chronic hepatitis C in interferon naïve patients (Schering-Plough, 95-132) Gregory T. Everson, M.D. - Principal Investigator

Project Period: 3/96-6/98Total Direct: $278,399 (Dependent upon patient recruitment)

8

Grant: 2531942

Intron A monotherapy vs. Intron A + Ribavirin for the treatment of relapse in patients with chronic hepatitis C (Schering-Plough, 95-144) Gregory T. Everson, M.D. - Principal Investigator

Project Period: 3/96-6/98Total Direct: $187,708 (Dependent upon patient recruitment)Grant: 2531945

Lamivudine Hepatitis B Open Label Treatment Program for Subjects with Three Life-Threatening Forms of Hepatitis B Infection Gregory T. Everson, M.D. - Principal Investigator

Total Direct: No funding

Intron A monotherapy vs. Intron A Plus Ribavirin at Varying Doses for Treatment of Chronic Hepatitis C in Interferon Naive Patients (Schering-Plough, 96-114) Gregory T. Everson, M.D. - Principal Investigator

Project Period: 1/97-8/98 Total Direct: $154,912 (Dependent upon patient recruitment) Grant: 2532319

Treatment of Relapse in Patients with Chronic Hepatitis C Comparing Intron A monotherapy vs. Intron A Plus Ribavirin (Schering-Plough, 96-318)

Gregory T. Everson, M.D. - Principal InvestigatorProject Period: 4/97-5/98Total Direct: $91,416 (Dependent upon patient recruitment)

NV15489: A Phase II Open-Label, Randomized, Multicenter, Ascending Dose Study Evaluating Safety and Efficacy of PEG-Interferon -2a (Ro 25-8310) versus Roferon7-A in the Treatment of Non-Cirrhotic Patients with Chronic Hepatitis C

Gregory T. Everson, M.D. - Principal InvestigatorProject Period: 3/97-9/98Total Direct: $227,353 (Dependent upon patient recruitment)Grant: 2532318

A Phase III Study to Compare the Safety and Efficacy of Alferon7 N injection to Intron7A in Previously Untreated Patient with Chronic Hepatitis Infection (Interferon Sciences Inc. IFN9503)

Gregory T. Everson, M.D. - Principal InvestigatorProject Period: 6/96-3/99Total Direct: $140,000 (Dependent upon patient recruitment)Grant: 2532047

96L-05: A Pivotal Phase II/III, Multicenter, Randomized, Controlled, Parallel Group Study of the HepatAssist Liver Assist System (LAS) Compared to Standard SICU Care in Patients with Acute Hepatic Failure

Gregory T. Everson, M.D. – Principal Investigator Project Period: 6/98 – 4/99 Total Direct: $49,823.00

PEG-rHuMGDF 980132: A Dose Ranging Study of Pegylated Recombinant Human Magakaryocyte Growth and Development Factor (PEG-rHuMGDF) in Thrombocytopenic

9

Patients with Cirrhotic Liver Disease Gregory T. Everson, M.D. – Principal Investigator Project Period: 4/98 – 12/98 Total Direct: No funding

IFN 9701: Evaluation of the Safety and Efficacy Alferon N Injection in the Treatment of SubjectsCo-Infected with HIV and Hepatitis C

Gregory T. Everson, M.D. - Principal Investigator Project Period: 9/98 – 3/99

C93-007Continuing Versus 24 Week Courses of Intron A Therapy for Treatment in Patients with Chronic Active Hepatitis C (Schering-Plough) Gregory T. Everson, M.D., Principal Investigator

Total Project Period: 9/94-9/99 Budget: $654,000 (dependent upon patient recruitment)

Grant: 2532198

Comparison of PEG-IFN vs. Intron A for Treatment of Adult Subjects with Chronic Hepatitis C not previously Treated with Interferon: Dose Finding Study (Schering-Plough, 97-010)

Gregory T. Everson, M.D. - Principal InvestigatorProject Period: 6/97-9/99

Total Direct: $459,930 (Dependent upon patient recruitment) Grant: 2531507

Intron A plus Ribavirin for the Treatment of Patients with Chronic Hepatitis C not previously treated with Interferon (Schering-Plough, 97-024)

Gregory T. Everson, M.D. - Principal InvestigatorProject Period: 10/97-12/99Total Direct: No fundingGrant: 2531682

R96-419: Intron A + Ribavirin for Treatment of Patients with Interferon-Refractory or Interferon- Relapsed Chronic Hepatitis C

Gregory T. Everson, M.D. - Principal InvestigatorProject Period: 9/97-6/00

Total Direct: $195,000 (Dependent upon patient recruitment)Grant: 2531515

A Double-blind placebo controlled, randomized dose ranging study of recombinant human Interlukin-10 (Tenovil) for treatment of hepatic fibrosis in patients with chronic hepatitis C who failed to respond previous combination therapy (Interferon alfa –2b plus ribavirin) (Schering-Plough)

Gregory T. Everson, M.D., Principal Investigator Project Period: 12/99 – 12/00

Total Direct: $85,853Grant: 2531668

A Randomized, Double-Blind, Double-Dummy, Active Comparator Controlled Multicenter Study of the Efficacy and Safety of Valganciclovir vs. Oral Gangcyclovir for Prevention of Cytomegalovirus Disease in High Risk Heart, Liver, and Kidney Allograft Recipients (Pfizer)

Gregory Everson, M.D., Principal Investigator

10

Project Period: 3/00 – 8/02Total Direct: $60,940Grant: 2531800

Long Term Follow Up to Assess Patients After Completing 24 Weeks of Follow Up in a SPRI Clinical Trial for the Treatment of Chronic Hepatitis C (Schering-Plough 97-501/ 9703908, C97-139)

Gregory T. Everson, M.D., Principal InvestigatorProject Period: 10/97 – 8/02Total Direct: $124,500Grant: 2531573

A Phase III Dose Escalation Trial of Heptazyme Alone and in Combination with Infergen in Patients with Chronic Hepatitis C Virus (HCV) Infection (Ribozyme RPI0006)

Gregory T. Everson, M.D., Principal InvestigatorProject Period: 9/01 – 6/03 (discontinued by sponsor, 7/02)Total Direct: $168,160 Grant: 2597018

PR00-30-019: A Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effect of PROCRIT® (Epoetin alfa) Once –a-Week Versus Placebo in the Treatment of Anemia and Maintenance of Optimal Ribavirin Dose in Hepatitis C Virus Infected Patient Treated with Combination Ribavirin/Interferon or Ribavirin/Pegylated Interferon (Scripps Clinic Liver Consortium/Ortho-BioTech)

Total Direct: $321,254Grant: 2532080Gregory T. Everson, M.D., Principal InvestigatorProject Period: 9/01 – 8/02Total Direct: $82,542Grant: 2597017

NR-15997: A randomized, open-label, multicenter, efficacy and safety study of Pegasys for the treatment of hepatitis C virus infection administered to patients six to sixty months post liver transplantation (Roche NR15997)


A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Interferon-Gamma 1B (IFN-1B) in Patients with Severe Liver Fibrosis or Compensated Cirrhosis Due to Hepatitis C

Gregory Everson, M.D., Co-Principal InvestigatorProject Period: 1/02 – 5/04Total Direct: $84,923Grant: 2597023

A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Escalation Doses of Albuferon Recombinant Human Albumin-Interferon Alpha Fusion Protein in Subjects with Chronic Hepatitis C (Human Genome Sciences HC-01)

11


A Randomized, Double-Blind Trial of Telbivudine (LDT) versus Lamivudine in Adults with Decompensated Chronic Hepatitis B and Evidence of Cirrhosis (Idenix)

Gregory Everson, M.D., Principal InvestigatorProject Period: 6/04 – 6/05Total Direct: $94,130Grant: 2597058

A double-blind, randomized, placebo-controlled, multi-centre, dose-ranging, parallel group, phase II study to assess efficacy, safety/tolerability, and pharmacokinetics of a thrombopoietin receptor agonist, SB-497115-GR, when administered as 30, 50, and 75 mg once daily for 12 weeks in subjects with chronic hepatitis C–related thrombocytopenia who are potential candidates for antiviral treatment with pegylated interferon and ribavirin (GlaxoSmithKline)


A double-blind, placebo-controlled, randomized phase III study of intravenous terlipressin in patients with hepatorenal syndrome type 1 (Orphan Therapeutics, LLC)


A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects with Decompensated Liver Disease and in the Prevention of Hepatitis B Recurrence Post-Transplantation (Gilead Sciences, Inc).

Gregory Everson, M.D., Principal InvestigatorProject Period: 5/06 – 5/08Total Direct: $35,576

Grant:

Pre-Study Serial Histology as a Predictor of Response to Continuous Therapy During the HALT-C Trial *Ancillary Study to HALT-C (above)

Gregory Everson, M.D., Principal InvestigatorProject Period: 8/02 – 5/03Total Direct: No additional fundingGrant: none assigned

A Prospective, Randomized, Multicenter, Open-Label, Comparative Safety and Efficacy Study of Prophylactically Administered Pegylated Interferon alfa-2a (Pegasys®) Plus Ribavirin vs. No Prophylaxis Following Liver Transplantation for Hepatitis C (Roche)


12

Grant: 2597066

Hepatitis C: Gene Expression Profiling of Host Response to Infection and Response to Standard Therapy (Source MDx).


Grant: 2597101

A Multiple-Center, Observer-Blinded, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Food Effect of RO5024048 in Healthy Volunteers and in Patients with Chronic HCV Infection of Genotype I (Pharmasset, Inc)


A Phase 1 Double-Blind, Placebo Controlled, Dose-Escalation, Multi-center Therapeutic Trial of the Safety, Immunogenicity, and Efficacy of GI-5005; an Inactivated RecombinantSaccharomyces cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, in Patients with Chronic Hepatitis C Infection (GlobeImmune).


Grant: 2597083

A Phase 2 Study of VX-950 in Combination with Peginterferon alfa-2a (Pegasys®) With Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C who have not Received Prior Treatment - VX05-950-104 (Vertex Pharmaceuticals Inc.)


A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alaf-2B (ALB-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2A (Pegasys or Peg-IFN2A) in Combination with Ribavirin in Interferon Alfa Naive Subjects with Chronic Hepatitis C Genotype 1. Achieve -1 (Human Genome Sciences)


Studies of Primary Sclerosing Cholangitis (STOPSC), (Morgan Foundation/EMMES Corp.).Gregory Everson, M.D., Principal InvestigatorProject Period: 10/07 – 12/09Total Direct: $9,540Grant: 2597146

Randomized, placebo-controlled, double-blind, parallel group, multicenter, dose response trial

13

utilizing four doses of CTS-1027, administered orally once daily, in outpatients with chronic hepatitis C virus (HCV) infection - CTS-1027-0, (Conatus Pharmaceuticals).


98-4: NIH-NIDDK 9-2327 Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial (HALT-C): National Institute of Health. A randomized controlled trial to evaluate the safety and efficacy of long-term Peg-interferon alfa-2a for treatment of chronic hepatitis C in patients who failed to respond to previous interferon therapy (NIH/Roche)

Gregory T. Everson, M.D. - Principal InvestigatorProject Period: 5/99 – 4/10Total Direct: $2,868,238Grant: 2532385

Quantitative Assessment of Hepatic Function in Chronics HCV. (QLFT). Ancillary study of 98-4: NIH-NIDDK 9-2327 Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial (HALT-C) (study above) (Roche/NIH-NIDDK)

Gregory T. Everson, M.D., Principal InvestigatorProject Period: 5/00 – 4/08Total Direct: $1,243,471

Grant: 2532080

A Phase 2 Study of Telaprevir (VX-950) in Combination with Peginterferon Alfa2A (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C who have not Achieved Sustained Viral Response with a Prior Course of Interferon Based Therapy-VX06-950-106 (Vertex Pharmaceuticals, Inc)


A Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2A (PEGASYS®) and Ribavirin (COPEGUS®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106 who did not Achieve or Maintain an Undetectable HCV RNA Level Through Sustained Viral Response-VX06-950-107 (Vertex Pharmaceuticals)


A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2B (ALB-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2A (PEGASYS® or PEG-IFN2A) in Combination with Ribavirin in Interferon Alfa Naive Subjects with Chronic Hepatitis C Genotype 2 or 3 –Achieve 2/3 (Human Genome Sciences)


14

Grant: 2597133

A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating TheEfficacy And Safety Of The HCV Polymerase Inhibitor Prodrug (RO4588161) When Given InCombination With Pegasys® And Copegus® Versus The Currently Approved CombinationOf Pegasys® And Copegus® In Treatment-Naive Patients With Chronic Hepatitis CGenotype 1 Virus Infection-NV19865 (Hoffmann LaRoche).


The A2ALL LADR Protocol: Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Living Donor Liver Transplantation (National Institute of Health - NIDDK, Schering-Plough, and Ortho-Biotech.


Restoration of Hepatic Function in Living Liver Donors (An Ancillary Study of A2ALL), National Institute of Health (NIH).

Gregory Everson, M.D., Principal InvestigatorProject Period: 5/06-8/08Total Direct: $109,.324

Grant: 2597140

A Phase 2 Randomized, Open Label, Multi-Center, Therapeutic Trial Of The Efficacy, Immunogenicity, And Safety Of GI-5005; An Inactivated Recombinant Saccharomyces Cerevisiae Expressing A Hepatitis C Virus NS3-Core Fusion Protein, Combined With Pegylated Interferon Plus Ribavirin Standard Of Care Therapy Versus Standard Of Care Alone, And GI-5005 Salvage Of Standard Of Care Failures, In Patients With Genotype 1 Chronic Hepatitis C Infection (GlobeImmune).


A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures-ELEVATE (TPL104054), (GlaxoSmithKline).


An Open-Label, Multicenter Protocol Providing Pegylated Interferon Alfa-2a (PEGASYS®) As Monotherapy Or In Combination With Ribavirin (COPEGUS®) For Patients With Chronic Hepatitis C Who Have Participated In Previous Roche Or Roche Partner Protocols- NV17590B

15

(Hoffmann LaRoche).Gregory Everson, M.D., Principal InvestigatorProject Period: 10/07 – 9/10Total Direct: $19,826Grant: 2597150

Trial of CTS-1027 in Interferon-Naïve Hepatitis C Patients - CTS-1027-03 (Conatus Pharmaceuticals)


A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C - VX07-950-108 (Vertex Pharmaceuticals)


A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1” P05216-166 (Schering Plough)


A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in Combination with Pegasys and Copegus for 12 or 24 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection,” #NV21075 (Roche).


A Randomized, Placebo-Controlled, Multi-Centre Study To Assess The Efficacy And Safety Of Eltrombopag In Thrombocytopenic Subjects With Hepatitis C Virus (Hcv) Infection Who Are Otherwise Eligible To Initiate Antiviral Therapy (Peginterferon Alfa-2a Plus Ribavirin)-Enable 1 (GlaxoSmithKline).


Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2b plus ribavirin)-ENABLE 2

16

(GlaxoSmithKline).Gregory Everson, M.D., Principal InvestigatorProject Period: 9/09 – 9/12Total Direct: $38,132Grant: 2597209

A Single-Arm Study to Provide Boceprevir Treatment inSubjects with Chronic Hepatitis C Genotype 1 Deemed Nonresponders toPeginterferon/Ribavirin in Previous Schering-Plough Boceprevir Studies. P05514-84 (Schering Plough).


A randomized, double-blind, placebo-controlled Phase III trial of telaprevir with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) in subjects with genotype 1 chronic hepatitis C infection who did not achieve sustained virologic response following prior treatment with pegylated interferon plus ribavirin -VX950-TiDP24-C216 (Tibotec)


A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C who Achieve an Extended Rapid Viral Response (eRVR) While Receiving Telaprevir, Peginterferon Alfa2a (Pegasys®) and Ribavirin (Copegus®) – VX07-950-111 (Vertex Pharmaceuticals)


Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination with Ribavirin to Treatment-Naive Subjects with Chronic Hepatitis C Virus Infection” to be conducted pursuant to Protocol #526H04 (Zymogenetics and BMS).


A Blinded, Randomized, Placebo-controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-450 with Ritonavir (ABT-450/r), ABT-333 or ABT-072 Each Administered Alone and in Combination with Peginterferon α-2a and Ribavirin (PegIFN/RBV) in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection – M11-602 (Abbott).


17

An Open-Label Trial of Pegylated Interferon plus Ribavirin in Combination with CTS-1027 in HCV Null-Responders - CTS-1027-04 (Conatus Pharmaceuticals).


Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Filibuvir Plus Pegylated Interferon Alfa-2A and Ribavirin in Treatment Naive, HCV Genotype 1 Infected Subjects - A8121014 (Pfizer).


A Parallel, Open-Label, Randomized, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-790052 and BMS-650032 in Combination in Null Responders to Standard of Care Infected with Chronic Hepatitis C Virus Genotype 1-AI447-011 (Bristol Myers Squibb)


A Phase 2a Study of BMS-790052 in Combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects with Chronic Hepatitis C Virus Genotype 1 Infection-AI444-014 (Bristol Myers Squibb)


A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and Infection-AI444-010 (Bristol Myers Squibb)


A Phase 2B Study of BMS-790052 in Combination with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Prior Treatment with Peginterferon Alfa plus Ribavirin Therapy-AI444-011 (Bristol Myers Squibb)


2U01DK062536-08-NIH Adult to Adult Living Donor Liver Transplantation Cohort Study (A2ALL)Gregory T. Everson, M.D., Principal InvestigatorProject Period: 9/09 – 8/14

18

Total Direct: $1,417,054Grant: 2597202

EXTEND: A 3-Year Virology Follow-up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies - VX08-950-112 (Vertex Pharmaceuticals).


An Open-Label, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Antiviral Activity of VX-222 and Telaprevir in Combination With and Without Peginterferon-Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C - VX09-222-103 (Vertex Pharmaceuticals).


A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated with DAA-containing regimens for chronic hepatitis C infection (CHC),” #NV22688 (Roche).


A Randomized, Open label, Multicenter, Dose and Duration-Finding Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir (RO5190591) Boosted with Low Dose Ritonavir (danoprevir/r) in Combination with Pegasys® and Copegus® versus

Pegasys® and Copegus® alone in Treatment-Naïve Patients with Chronic-NV22776 (Roche) Gregory Everson, M.D., Principal InvestigatorProject Period: 11/10 – 11/13Total Direct: $193,778Grant: 2597233

A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in treatment-naïve, genotype 1 hepatitis C-infected subjects–TMC435-TiDP16-C208 (Tibotec)


A Phase III, randomized, double-blind, placebo controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C, genotype 1 infected subjects who relapsed after previous interferon-based therapy–TMC435HPC3007 (Tibotec)

Gregory Everson, M.D., Principal InvestigatorProject Period: 11/10 – 10/13

19

Total Direct: $76,065Grant: 2597240

A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C virus infection -VX950-C211 (Tibotec)


An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of ABT-450 with Ritonavir (ABT_450/r) Dosed in Combination with ABT-333 and Ribavirin (RBV) in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection - M12-746 (Abbott Pharmaceuticals) Gregory Everson, M.D., Principal Investigator

Project Period: 3/14/11-3/13/14Total Direct: $37,998Grant: 2597241

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys) and Ribavirin (RBV, Copegus) With and Without Tegobuvir (GS 9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection - GS-US196-0140 (Gilead Sciences)

Gregory Everson, M.D., Principal InvestigatorProject Period: 01/15/11-01/14/14Total Direct: $99,167Grant: 2597243

A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS-790052 or BMS-650032) versus Pegasys administered with Ribavirin (Part A) and of Pegylated Interferon Lambda (BMS-914143) administered with or without Ribavirin plus 2 direct antiviral agents (BMS 790052 and BMS-650032) (Part B) in chronic hepatitis C genotype-1 treatment naïve subjects - AI452-008 (Bristol-Myers Squibb, Inc.)


A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (DNV/r) and Copegus, in Combination with the HCV Polymerase Inhibitor Prodrug RO5024048 and/or Pegasys in Chronic Hepatitis C Genotype 1 Patients Who Failed with a Previous Course of Peginterferon alfa plus Ribavirin Combination Therapy - WV21913 (F. Hoffmann-La Roche, Ltd)


20

A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, andPharmacokinetics, of ABT-450 with Ritonavir (ABT-450/r) in Combination with ABT-267 and/or ABT-333 With and Without Ribavirin (RBV) for 8, 12 or 24 Weeks in Treatment-Naïve and Null Responder Subjects with Genotype 1 Chronic Hepatitis C Virus Infection – M11-652 (Abbott Pharmaceuticals)


A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS-9451) with Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection - GS-US-256-0124 (Gilead Sciences, Inc.)


A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 Alone or in Combination with GS-9451 or GS-9256 with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection - GS-US-256-0148, (Gilead Sciences, Inc.)


Open-Label, Multiple-Dose, Dose Escalation Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Co-administration of BMS-650032, BMS-790052, and BMS-791325 when administered for 24 or 12 weeks in Treatment-Naïve Subjects Infected with Hepatitis C Virus Genotype 1 – AI443-014, (Bristol-Myers Squibb, Inc.) Gregory Everson, M.D., Principal Investigator

Project Period: 11/9/11-10/31/14Total Direct: $121,238Grant: 2597264

An Open-Label, Sequential Arm, Multicenter Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of ABT-450 with Ritonavir(ABT-450/r) Dosed in Combination with ABT-267 With and Without Ribavirin (RBV) in Treatment-Naïve Subjects with Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) Infection – M12-998, (Abbott Pharmaceuticals)


A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects with Chronic Genotype 1a or 1b HCV Infection - GS-US-248-0132, (Gilead Sciences, Inc.)

21


A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I) - M11-646 (AbbVie)

Gregory Everson, M.D., Principal InvestigatorProject Period: 10/15/12 – 10/15/15Total Direct: $232,365Grant: 2597296

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatment-Experienced Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II) - M13-098 (AbbVie)


An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C – AI444-026 (Bristol-Myers Squibb)


A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatitis C - AI444046 (Bristol-Myers Squibb)


A Phase 3 Study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects with Chronic Hepatitis C Genotype 1b Infection - AI447-028 – (Bristol-Myers Squibb)


A Phase 3, Open-Label Study with Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who are Null or Partial Responders to Peginterferon Alfa-2a or 2b Plus Ribavirin with Chronic Hepatitis

22

C Genotypes 1 or 4 Infection - AI447-029 (Bristol-Myers Squibb)Gregory Everson, M.D., Principal InvestigatorProject Period: 5/1/12 – 5/1/15Total Direct: $94,441Grant: 2597227

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Subjects with ChronicGenotype 2 or 3 HCV Infection who are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon - GS-US-334-0107 (Gilead Sciences)


A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Treatment Experienced Subjects with Chronic Genotype 2 or 3 HCV Infection - GS-US-334-0108 (Gilead Sciences)


An Open-Label Study to Evaluate the Safety of GS-7977+ Ribavirin for 12 Weeks in Subjects with Chronic HCV Infection Who Participated in Prior Studies Evaluating GS-7977 GS-US-334-0109 (Gilead Sciences)


A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977 +Ribavirin for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1, 4, 5 or 6 HCV Infection - GS-US-334-0110 (Gilead Sciences)


A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 24 weeks in Patients Infected with Chronic HCV with Cirrhosis and Portal Hypertension with or without Liver Decompensation - GS-US-334-0125 (Gilead Sciences)


A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection - GS-US-337-0102 (Gilead Sciences)

23


A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks inTreatment-Experienced Subjects with Chronic Genotype 1 HCV Infection – GS-US-337-0109 (Gilead Sciences)


A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naïve Subjects with Chronic HCVInfection- GS-US- 342-0102 (Gilead Sciences)


A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection- GS-US-337-0108 (Gilead Sciences)


A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment Experienced Subjects with ChronicHCV Infection- GS-US-342-0109 (Gilead Sciences)


A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection- GS-US-334-0153 (Gilead Sciences)


A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination inSubjects with Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis—AI443-113 (Bristol Myers Squibb)

Gregory Everson, M.D., Principal Investigator

24

Project Period: 12/01/13 – 12/01/15Total Direct: $72,780Grant: 2597334

A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination inNon-cirrhotic Subjects with Genotype 1 Chronic Hepatitis C—AI443-102 Bristol Myers Squibb)

Gregory Everson, M.D., Principal InvestigatorProject Period: 12/01/13 – 12/01/15Total Direct: $72,426Grant:

CURRENT RESEARCH SUPPORT

A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection andChild-Pugh Class B Cirrhosis—GS-US-342-1137 (Gilead Sciences)


An Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin For 12 or 24 Weeks In Chronic Genotype 1 HCV Infected Subjects Who Participated In A Prior Gilead-SponsoredHCV Treatment Study—GS-US- 337-1118 (Gilead Sciences)


A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection--M14-868

Gregory Everson, M.D., Principal Investigator Project Period: 10/14/14-10/13/17 Total Direct: $122,107

Grant: 2597364

An Open-Label Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered with Sofosbuvir (SOF)With and Without Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection--M14-224


Grant: 2597366

A Phase 2, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Genotype 1 HCV Infection--GS-US-367-1168

25


Grant: 2597371

A Phase 2, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Non-Genotype 1 HCV Infection-- GS-US-367-1169


Grant: 2597375

An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection--GS-US-342-1446


Grant: 2597372

An Open Label Study to Evaluate The Efficacy And Safety Of Sofosbuvir/GS-5816 Fixed Dose Combination With Ribavirin For 24 Weeks In Chronic HCV Infected Subjects Who Participated In A Prior Gilead Sponsored HCV Treatment Study--GS-US-342-1553


Grant: 2597368

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 weeks in Subjects with Chronic Genotype 3 HCV Infection--GS-US-342-1140


Grant: 2597347

An Open-Label, Multicenter Study to Evaluate Long-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection--M14-222


Grant: 2597358

An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis--M14-490


Grant: 2597363

26

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV Infection--GS-US-342-1138


Grant: 2597355 A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of BT450/Ritonavir/ABT-267 and ABT-333 with Ribavirin in Adults with Genotype 1 Chronic Hepatitis C Virus Infection andDecompensated Cirrhosis-- M14-227


Grant: 2597357

Publications

MANUSCRIPTS IN PEER REVIEWED JOURNALS1. Everson GT, Braverman DZ, Johnson ML, Kern F Jr. A Critical Evaluation of

Real-time Ultrasonography for the Study of Gallbladder Volume and Contraction. Gastroenterology, 79(1):40-46, 1980.

2. Nair CK, Runco V, Everson GT, Boghairi A, Mooss AN, Mohiuddin SM, Sketch MH. conduction Defects and Mitral Annulus Calcification. Brit Heart J, 44(2):162-167, 1980.

3. Everson GT, Kern F, Jr. Quantitative Cholescintigraphy. Gastroenterology 1981;80(5 pt. 1): 1084-5.

4. Kern F Jr, Everson GT, DeMark B, McKinley C, Showalter R, Erfling W, Braver-man DZ, Szczepanik- VanLeeuwen P, Klein PD. Biliary lipids, Bile Aids and Gallbladder Function in the Human Female: Effects of Pregnancy and the Ovulatory Cycle. J Clin Invest, 68:1229-1242, 1981.

5. Everson GT, McKinley C, Lawson M, Johnson M, Kern F Jr. Gallbladder Function in the Human Female: Effect of the Ovulatory Cycle, Pregnancy and Contraceptive Steroids. Gastroenterology, 82:711-719, 1982.

6. DeMark BR, Everson GT, Klein PD, Showalter RB, Kern F Jr. A Method for the Accurate Measurement of Isotope Ratios of Chenodeoxycholic and Cholic Aid in Serum. J Lipid Res, 23(1):204-210, 1982.

7. Kern F Jr, Everson GT, DeMark B, McKinley C, Showalter R, Braverman DZ, Szczepanik-VanLeeuwen P, Klein PD. Biliary lipids, Bile Acids and Gallbladder Function in the Human Female: Effects of Contraceptive Steroids. J Lab Clin Med, 99(6):798-805, 1982.

8. Everson GT, Lawson MJ, McKinley C, Showalter R, Kern F Jr. Gallbladder and

27

Small Intestinal Regulation on Biliary Lipid Secretion During Intraduodenal Infusion of Standard Stimuli. J Clin Invest, 71:596-604, 1983.

9. Lawson M, Everson GT, Klingensmith W, Kern F Jr. Coordination of Gastric and Gallbladder Emptying After Ingestion of a Regular Meal. Gastroenterology, 85:866-870, 1983.

10. Lawson M, Everson GT, Kern F Jr. Gastrointestinal Transit Time in Human Pregnancy: Prolongation in the Second and Third Trimesters Followed by Postpar-tum Normalization. Gastroenterology, 89:996-999, 1985.

11. Everson GT, Polokoff M. HepG2: A Human Hepatoblastoma Cell Line Exhibiting Defects in Bile Acid Synthesis and Conjugation. J Biol Chem, 261(5):2197-2201, 1986.

12. Perino LP, Shuffler MD, Mehta SJ, Everson GT. Radiation-induced Intestinal Pseudo-obstruction. Gastroenterology, 91:994-998, 1986.

13. Polokoff MA, Everson GT. Hepatocyte-hepatoma Cell hybrids: Characterization and Demonstration of Bile Acid Synthesis. J Biol Chem, 261(9):4085-4089, 1986.

14. Everson GT. Steady-state Kinetics of Serum Bile Acids in Healthy Human Subjects: Single and Dual Isotope Techniques Using Stable Isotopes and Mass Spectrometry. J Lipid Res, 28:238-252, 1987.

15. Kern F, Everson GT. Contraceptive Steroids Increase Cholesterol in Bile: Mecha-nisms of Action. J Lipid Res, 28:828-839, 1987.

16. Everson GT, Fennessey R, Kern F. Contraceptive Steroids Alter the Steady-state Kinetics of Bile Acids. J Lipid Res, 29:68-76, 1988.

17. Everson GT, Scherzinger A, Berger-Leff N, Reichen J, Lezotte D, Manco-Johnson M, Gabow P. Polycystic Liver Disease: Quantitation of Parenchymal and Cyst Volumes from Computed Tomography Images and Clinical Correlates of Hepatic Cysts. Hepatology, 8(6):1627-1634, 1988.

18. Rector WG, Hoefs JC, Hossack KF, Everson GT. Hepatofugal Portal flow in Cirrhosis: Observations on Hepatic Hemodynamics and the Nature of the Arterio-portal Communications. Hepatology, 8(1):16-20, 1988.

19. Everson GT, Ahnen D, Harper PC, Krawitt E. Benign Recurrent Intrahepatic Cholestasis: Treatment with S-adenosylmethionine (Brief Report). Gastroenterology, 96:1354-1357, 1989.

20. Everson GT, Nemeth A, Kourourian S, Zogg D, Leff N, Dixon D, Githens J, Pretorius D. Gallbladder function is Altered in Sickle Hemoglobinopathy. Gastroenterology, 96:1307-1316, 1989.

21. Everson GT, Emmett M, Brown WR, Redmond P, Thickman D. Functional Similarities of Hepatic Cystic and Biliary Epithelium: Studies of Fluid Constituents and in Vivo Secretion in Response to Secretion. Hepatology, 1(4):557-565, 1990.

28

22. Everson GT. Hepatic Cysts in Autosomal Dominant Polycystic Kidney Disease (Editorial). Mayo Clinic Proceedings, 65:1020-1025, 1990.

23. Gabow PA, Johnson AM, Kaehny WD, Manco-Johnson M, Duley IT, Everson GT. Risk Factors for the Development of Hepatic Cysts in Autosomal Dominant Polycystic Kidney Disease. Hepatology, 11(6):1033-1037, 1990.

24. Rector WG Jr, Lewis F, Robertson AD, Everson GT. Renal Sodium Retention Complicating Alcoholic Liver Disease: Relation to Portal-systemic Shunting and Liver Function. Hepatology, 12(3):455-459, 1990.

25. Reveille RM, Stiegmann GV, Everson GT. Increased Secondary Bile Acids in the Contents of a Choledochal Cyst: Possible Role in the Development of Biliary Metaplasia and Carcinoma. Gastroenterology, 99:525-527, 1990.

26. Straka MS, Junker LH, Zacarro L, Zogg DL, Dueland S, Everson GT, Davis RA. Substrate stimulation of 7alpha-hydroxylase, An Enzyme Located in the Cholesterol-poor Endoplasmic Reticulum. J Biol Chem, 265(13):7145-7149, 1990.

27. DeRoche GM, Portz B, Rector WG Jr, Everson GT. Simultaneous Determination of Caffeine and Antipyrine in Plasma and Saliva Using HPLC. J Liquid Chromatography, 13(17):3493-3505, 1990.

28. Everson GT, McKinley C, Kern F Jr. Mechanisms of Gallstone Formation in Women: Effects of Exogenous Estrogen (PremarinR) and Dietary Cholesterol on Hepatic Lipid Metabolism. J Clin Invest, 87:237-246, 1991.

29. Everson GT. Gallbladder function in Gallstone Disease. Gastroenterol Clin North Am, 20(1):85-110, 1991.

30. Lewis FW, Adair O, Hossack KF, Everson GT, White C, Rector WG Jr. Plasma Glucagon Concentration in Cirrhosis is Related to Liver Function But Not to Portal-systemic Shunting, Systemic Vascular Resistance, or Urinary Sodium Excretion. J Lab Clin Med, 117:67-75, 1991.

31. Everson GT, Krawitt EL. Trial of S-adenosylmethionine in Patients in Two Families with Cholestatic Syndromes. Gastroenterology 100(6):1784, 1991

32. Dueland S, Reichen J, Everson GT, Davis RA. Regulation of Cholesterol and Bile Acid Homeostasis in Bile- obstructed Rats. Biochem J, 280:373-377, 1991.

33. Kaehny W, Everson GT. Extra-renal Manifestations of ADPKD. Semin Nephrol, 11(6):661-670, 1991.

34. Axelson M, Mörk B, Everson GT. Bile acid synthesis in Cultured Human Hepatoblastoma Cells. J Biol Chem, 266(27):17770-7, 1991.

35. Panini SR, Everson GT, Spencer TA. Effects of Specific Inhibition of Sterol Biosynthesis on the Uptake and Utilization of Low Density Lipoprotein Cholesterol by HepG2 Cells. J Lipid Res, 32:1657-1665, 1991.

29

36. Everson GT, Daggy BP, Story JA, McKinley C. Effects of Psyllium Hydrophilic Mucilloid on LDL-cholesterol and Bile Acid Synthesis in Hypercholesterolemic Men. J Lipid Res 1992; 33:1183-1192.

37. Everson GT. Gastrointestinal motility in pregnancy. Gastroenterol Clin North Am 1992; 21(4):751-776.

38. Everson GT. Bile acid metabolism and Its Role in Human Cholesterol Balance. Semin Liv Dis 1992; 12(4): 420-428.

39. Everson GT. Pregnancy and Gallstones (Editorial). Hepatology 1993; 17(1):159-161.

40. Everson GT. Hepatic Cysts in Autosomal Dominant Polycystic Kidney Disease. American J of Kidney Diseases 1993; 22(4):520-525.

41. Cooper AD, Craig WY, Taniguchi T, Everson GT. Characteristics and Regulation of Bile Salt Synthesis and Secretion by Human Hepatoma HepG2 Cells. Hepatology, 20(6):1522-1531, 1994.

42. Rector, WG., Jr., Everson, GT, Robertson, A. Sodium Retention Does Not Occur at a Critical Threshold of Liver Function in Alcoholic Cirrhosis. J Lab Clin Med, 1994; 123:218-24.

43. Durham J, LaBerge J, Altman S, Kam I, Everson G, Gordon R, Kumpe D. Portal Vein Thrombolysis and Closure of Competitive Shunts Following Liver Transplanta-tion. Journal of Vascular and Interventional Radiology, 5(4):611-617, 1994.

44. Everson GT. Mechanism of Gallstone Formation in Obese Women Undergoing Weight Loss. Liver Update, Vol. 8(No. 1):5-6, 1994.

45. Stegall M, Everson GT, Schroter G, Bilir BM, Karrer F, Kam I, University of Colorado Medical Center, Denver, CO. Metabolic Complications After Liver Transplantation: Diabetes, Hypercholesterolemia, Hypertension, and Obesity. Transplantation 1995; 60(9):1057-60.

46. Shrestha R, McKinley C, Bilir BM, Everson GT. Possible Idiopathic Thrombocytopenic Purpura Associated with Natural Alpha Interferon Therapy for Chronic Hepatitis C (HCV) Infection. American Journal of Gastroenterology, 90(7):1146-47, 1995.

47. Lawrence SP, Lezotte DC, Durham JD, Everson GT, Bilir BM. Course of Thrombocytopenia of Chronic Liver Disease After Transjugular Intrahepatic Porto systemic Shunts (TIPS): A Retrospective Analysis. Digestive Diseases and Sciences, 40(7):1575-1580, 1995.

48. Shrestha R, Bilir BM, Everson GT, Steinberg SE. Endoscopic Stenting of Gallbladder for Symptomatic Cholelithiasis in Patients with End Stage Liver Disease Awaiting Orthotopic Liver Transplantation. American Journal of Gastroenterology 1996; 91:595-598.

30

49. Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, Perrillo RP, Tamburro CH, Goff JS, Everson GT, Silva M, Katkov WN, Goodman Z, Lau J, Maertens G, Gogate J, Sanghvi B, Albrecht J, Hepatitis Interventional Therapy Group. Response to Higher Doses of Interferon Alfa-2b in Patients with Chronic Hepatitis C: A Randomized Multicenter Trial. Hepatology 1996; 24(5):1034-1040.

50. Kaur S, Rybicki L, Bacon BR, Gollan JL, Rustgi BK, Carey WD, and the National Hepatitis Surveillance Group. [Everson GT]. Performance Characteristics and Results of a large-scale Screening Program for Viral Hepatitis and Risk Factors Associated with Exposure to Viral Hepatitis B and C: Results of the National Hepatitis Screening Survey. Hepatology 1996; 24:979-986.

51. Durham JD, LaBerge JM, Altman S, Kam I, Everson GT, Gordon RL, Kumpe DA. Portal vein thrombolysis and closure of competitive shunts following liver transplantation. Journal of Vascular & Interventional Radiology 1996; 5:611-5.

52. Lau JY, Davis GL, Prescott LE, Maertens G. Lindsay KL, Qian K, Mizokami M, Simmonds P, Hepatitis Interventional Therapy Group [Everson GT]. Distribution of Hepatitis C Virus Genotypes Determined by Line Probe Assay in Patients with Chronic Hepatitis C Seen at Tertiary Referral Centers in the United States. Annals of Internal Medicine, 124(10):868-76 May, 1996.

53. Shrestha R, McKinley C, Showalter R, Wilner K, Marsano L, Vivian B, Everson GT. Quantitative Liver Function Tests (QLFTs) define the functional severity of liver disease in early stage cirrhosis. Liver Transplantation and Surgery 1997; 3:166-173.

54. Everson G, Bharadhwaj G, House R, Talamantes M, Bilir B, Shrestha R, Kam I, Wachs M, Karrer F, Fey B, Ray C, Steinberg T, Morgan C, Beresford T. Long-Term Follow-up of patients with alcoholic liver disease who underwent hepatic transplantation. Liver Transplantation and Surgery 1997; 3:263-274.

55. Simon DM, Gordon SC, Kaplan MM, Koff R, Regenstein F, Everson G, Lee YM, Weiner F, Silverman A, Plasse T, Fedorczyk D, Liao MJ. Treatment of Chronic Hepatitis C with Interferon Alfa-n3: A Multicenter, Randomized, Open-label Trial. Hepatology 1997; Feb 25:445-8.

56. Stegall M, Everson G, Schroter G, Karrer F, Bilir B, Sternberg T, Shrestha R, Wachs M, Kam I. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. Hepatology Jan 1997; 25:173-7.

57. Shrestha R, McKinley C, Russ P, Scherzinger A, Bonner T, Showalter R, Everson GT. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with Autosomal dominant polycystic kidney disease. Hepatology 1997; 26:1282-86.

58. Everson GT. A hepatologist’s perspective on the management of coagulation disorders prior to liver transplantation. Liver Transplantation and Surgery, 1997; 3(6):646-52

31

59. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, Kneteman NM, Lake JR, Martin P, McDiarmid SV, Rakela J, Shiffman ML, So SK, Wiesner RH. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg. 1997 Nov;3(6):628-37

60. Shrestha R, Durham JD, Wachs M, Bilir BM, Kam I, Trouillot T, Everson GT. Use of Transjugular Intrahepatic Porto systemic shunt as a bridge to transplantation in fulminant hepatic failure from Budd-Chiari Syndrome. Amer J of Gastroenterology 1997 Dec; 92(12):2304-6.

61. Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, Karrer F, Kam I. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997; 64:1755-1760.

62. Sokol RJ, McKim JM Jr., Goff, MC, Ruyle SZ, Devereaux MW, Han D, Packer L, Everson G. Vitamin E Reduces Oxidant Injury to Mitochondria and the Hepatotoxicity of Taurochenodeoxycholic Acid in the Rat. Gastroenterology 1997; 114:164-174.

63. Everson GT, Kam I. Liver transplantation: current status and unresolved controversies. (Review). Advances in Internal Medicine, 42:505-53, 1997.

64. Heathcote EJL, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert DG, Jr., Witt K, Blatt LM, and Consensus Interferon Study Group*. Retreatment of chronic hepatitis C with consensus interferon. Hepatology 1998; 27:1136-1143.

65. Everson GT, Lin TC, Overview of viral hepatitis. Gastroenterology & Endoscopy News 1998; 1:1-4.

66. Everson GT, Lin TC, Overview of viral hepatitis. Pharmacy Practice News 1998; 1: 1-4

67. Everson GT, Lin TC, Overview of viral hepatitis. Infectious Disease Special Edition 1998; 1: 1-4.

68. DiBisceglie A, Everson GT, Herrine S, Jeffers L, Nikias G, Hepatitis C: containing an invisible epidemic. Patient Care 1998; 32:96-119.

69. Everson GT. Liver problems in pregnancy: part 2 –managing pre-existing and pregnancy-induced liver disease. (Review) Medscape Women’s Health, 3(2):2 March, 1998.

70. Everson GT. Liver problems in pregnancy: distinguishing normal from abnormal hepatic changes. (Review), Medscape Women’s Health, 3(2): 3, March 1998.

71. Ryu R, Lin TC, Kumpe D, Krysl J, Durham JD, Goff JS, Everson GT, Kam I, Wachs M, Russ P, Shrestha R, Bilir B. Percutaneus mesenteric venous thrombectomy and thrombolysis: successful treatment followed by liver transplantation. Liver Transplantation and Surgery, 4(3) 222-5, May, 1998.

72. Goff, JS, Hamman RF, Wamboldt FS, Lezotte DC, Steinberg T, Talamantes M, Kam

32

I, Wachs M, Everson GT, Bilir BM. Quality of life after liver transplantation: the effect of hepatitis C status. Submitted to Liver Transplantation and Surgery, June 1998.

73. Everson GT. Ob-Gyn interactive case challenge-liver disease in the third trimester of pregnancy. Medscape Women’s Health, 3(4):2, July, 1998.

74. Shivaram KN, Winklhofer-Roob BM, Straka MS, Devereaux MW, Everson GT, Mierau GE, Sokol RJ. The Effect of Idebenone, a Coenzyme Q Analogue, on Hydrophobic Bile Acid Toxicity to Isolated Red Hepatocytes and Hepatic Mitochondria. Free Radical Biology & Medicine, 25(4):480-92 September, 1998.

75. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keefe EB, Kneteman NM, Lake JR, Martin P, Rakela J, Shiffman ML, So S, Wiesner RH. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Transplantation, 66(7):956-62, October, 1998.

76. Wachs ME, Bak TE, Karrer FM, Everson GT, Shrestha R Trouillot T, Mandell MS, Steinberg TG, Kam I. Adult living donor liver transplantation using a right hepatic lobe. Transplantation, 66(10):1313-6, November, 1998.

77. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C, Shiffman Ml, Zeuzern S, Craxi A, Ling MH, Albrecht J, International Hepatitis Interventional Therapy Group. Recombinant interferon alfa-2b (Intron A) alone or in combination with ribavirin (Rebetol) for Retreatment of interferon relapse in chronic hepatitis C. N Engl J Med, November, 1998; 339(21):1432-9.

78. McHutchison JG, Grodon S, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman Z, Ling MH, Albrecht J, Hepatitis Interventional Therapy Group. Interferon alfa-2b monotherapy versus interferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C: Results of a US Multicenter randomized controlled trial N Engl J Med, November, 1998; 339(21)suppl:1485.

79. Ryu RK, Durham JD, Krysl J, Shrestha R, Everson GT, Stephens J, Kam I, Wachs ME, Kumpe DA. Role of TIPS as a bridge to hepatic transplantation in Budd-Chiari syndrome. Journal of Vascular & Interventional Radiology, 10(6): 799-805, June, 1999.

80. Everson GT, Jensen D, Craig JR, van Leeuwen D, Bain V, Ehrinpreis M, Albert D, Joh T, Witt K, Consensus Interferon Study Group*. Efficacy of Interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotic, fibrotics, or nonfibrotic. Hepatology, July, 1999. 30:1;271-276.

81. Shrestha R, Trouillot T, Everson GT. Endoscopic Stenting of the Gallbladder for Symptomatic Gallbladder Disease in Patients with End-stage Liver Disease Awaiting Orthotopic Liver Transplantation. Liver Transplantation and Surgery, July 1999; 5:4 275-281.

82. Everson GT, Trouillot T, Wachs M, Bak T, Steinberg T, Kam I, Shrestha R, Stegal M. Early Steroid Withdrawal in Liver Transplantation is Safe and Beneficial. Liver

33

Transplantation and Surgery, July 1999; 5; 4; S48-S57.

83. Jenny E, Heathcote L, James S, Mullen KD, Hauser SC, Rosenblate H, Albert D, Consensus Interferon Study Group*. Chronic Hepatitis C Virus Patients with Breakthroughs During Interferon Treatment Can Successfully Be Retreated with Consensus Interferon. Hepatology, August 1999:30:2; 562-566.

84. Keeffe EB, Dusheiko GM, James SP, Mullen KD, Everson GT, Pimstone NR, Donovan J, Albert D, Consensus Interferon Study Group*. Utility of hepatitis C virus serotypes in predicting response to treatment of chronic hepatitis C. Cytokines, Cellular & Molecularly Therapy, August 1999; 5,207-210.

85. Trouillot T, Shrestha R, Kam I, Wachs M, Everson GT. Successful Withdrawal of Prednisone After Adult Liver Transplantation for Autoimmune Hepatitis. Liver Transplantation and Surgery, 5:5; 375-380, September, 1999.

86. Dienstag J, Schiff E, Wright T, Perrillo R, Hie-Won H, Goodman Z, Crowthers L, Condreay L, Woessner M, Rubin M, Brown N, U.S. Lamivudine Investigator Group. Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States. New England Journal of Medicine, 341:17; 1256-1263, October, 1999.

87. Everson GT, Lasseter KC, Anderson KE, Bauer LA, Carithens RL, Wilner KD, Johnson A, Anziano RJ, Smolarek TA, Turncliff RZ. The Pharmacokinetics of Ziprasidone in Subjects with Normal and Impaired Hepatic Function. British Journal of Clinical Pharmacology, 49, 1:7, 21S-26S supplemental, December, 1999.

88. Jensen DM, Krawitt EL, Keefe EB, Hollinger FB, James SP, Mullen K, Everson GT, Hoefs JC, Fromm H, Black M, Foust RT, Pimstone NR, Heathcote EJ, Albert D, Consensus Interferon Study Group*. Biochemical and Viral Response to Consensus Interferon (CIFN) Therapy in Chronic Hepatitis C Patients: Effect of Baseline Viral Concentration. American Journal of Gastroenterology, 94(12):3583-8, December, 1999.

89. McHutchison J, Blatt L, Medina M, Craig J, Conrad A, Schiff E, Tong M, *Consensus Interferon Study Group. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Journal of Gastroenterology and Hepatology, 2000(15); 945-951.

90. Keeffe E, Dusheiko G, Tong M, Hollinger FB, Heathcote EJ, McHutchison J, Albert D, Consensus Interferon Study Group*. Genotype Does Not Affect Pattern of HCV RNA Decrease Among Responders During Interferon Treatment of Chronis Hepatitis C. Cytokines, Cellular & Molecular Therapy 1999; 5:211-216.

91. Keeffe E, Dusheiko G, James S, Mullen K, Everson GT, Pimstone N, Donovan J, Albert D, Consensus Interferon Study Group*. Utility of Hepatitis C Virus Stereotypes in Predicting Response to Treatment of Chronic Hepatitis C. Cytokines, Cellular & Molecular Therapy 1999; 5:207-210.

92. Trotter JF, Wachs M, Trouillot T, Steinberg T, Bak T, Everson GT, Kam I. Evaluation of 100 Patients for Living Donor Liver Transplantation. Liver Transplantation 6 ;

34

( 3):290-295, May, 2000.

93. Stephens J, Everson GT, McCune C, Kam I, Wachs M, Haney J, Bartlett S, Franklin W. Fatal transfer of malignant melanoma from multi-organ donor to four allograft recipients. Transplantation 70(1):232-236, July, 2000.

94. Nieto Y, Russ P, Everson GT, Bearman SI, Cagnoni PJ, Jones RB, Shpall EJ. Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 2002 Jul: 26(1):109-11.

95. Trotter JF, Bak T, Wachs M, Everson GT, Kam I. Combined liver-pancreas transplantation in a patient with primary sclerosing cholangitis and insulin-dependent diabetes mellitus. Transplantation, 2000 Nov27; 70 (8):1469-71.

96. Everson GT. Maintenance Interferon for Chronic Hepatitis C: More Issues Than Answers? Editorial for Hepatology, 2000, Aug:32(2):426-8.

97. Beresford, T, Everson GT. Liver Transplantation for Alcoholic Liver Disease: Bias, Beliefs, 6 Month Rule, and Relapse; But “Where’s the Data?” Liver Transplantation, Editorial, August 2000.

98. Everson GT. Increasing Incidence and Pre-transplantation Screening of Hepatocellular Carcinoma. Liver Transplantation Suppl 2; 6 (6):S2-S10, November, 2000.

99. Everson GT. Advances and controversies in liver transplantation: Hepatocellular cancer (Part I), viral hepatitis (Part II), and living donor liver transplantation in adults (Part III). Liver Transpl. 2000 Nov; 6(6 Suppl 2);S1

100. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson GT, Reindollar R, Fried M, Purdum PP, Jensen D, Smith C, Lee W, Pedder S, DePamphilis J. Efficacy and Safety of Pegylated Interferon -2a Compared with Interferon -2a in Non-Cirrhotic Patients with Chronic Hepatitis C. Hepatology; 33(2):2: 433-438, February, 2001.

101. Trotter JF, Everson GT. Benign focal lesions of the liver. Clin Liver Dis. 2001 Feb;5(1):17-42.

102. Trotter JF, Wachs M, Bak T, Trouillot TE, Stolpman N, Everson GT, Kam I. Liver Transplantation Using Sirolumus and Minimal Corticosteroids (3-Day Taper). Liver Transplantation 7(4):343-351, April, 2001.

103. Sokol R, Straka MS, Dahl R, Devereaux MW, Yerushalmi B. Gumpricht E, Everson GT. Role of Oxidant Stress in the Permability Transition Induced in Rat Hepatic Mitochondria by Hydrophobic Bile Acids. Pediatr Res, 2001, April; 49(4):519-31.

104. Sandhu IS, Jarvis C, Everson GT. Total parenteral nutrition and cholestasis. Clin Liver Dis. 1999 Aug;3(3):489-508, viii.

105. Trotter JF, Wachs M, Trouillot TE, Bak T, Kugelmas M, Kam I, Everson GT. Dyslipidemia During Sirolumus Therapy in Liver Transplant Recipients Occurs With

35

Concomitant Cyclosporine But Not Tacrolimus. Liver Transplantation 7; (5):401-408, May, 2001.

106. Trouillot TE, Pace DG, McKinley C, Cockey L, Zhi J, Haeussler J, Guerciolini R, Showalter R, Everson GT. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. Am J Gastroenterol. 2001 Jun;96(6):1888-94.

107. Trotter JF, Talamantes M, McClure M, Wachs M, Bak T, Trouillot T, Kugelmas M, Everson GT, Kam I. Right Hepatic Lobe Donation for Living Donor Liver Transplantation: Impact on Donor Quality of Life. Liver Transplantation. 7(6); 485-493; June, 2001.

108. Fontana R, Hann HW, Wright T, Everson GT, Baker A, Schiff E, Riely C, Anschuetz G, Hopkins M, Brown N, Lamivudine Compassionate Use Study Group. A US Compassionate Use Study of Lamivudine Treatment in Non-transplant Candidates with Decompensate Hepatitis B Virus-Related Cirrhosis. Liver Transplantation 7(6); 504-510; June, 2001.

109. Lindsay K, Trepo C, Heintges T, Shiffman M, Gordon S, Hoefs J, Schiff E, Goodman Z, Laughlin M, Yao R, Albrecht J, for the Hepatitis Interventional Therapy Group.* A Randomized, Double-Blind Trial Comparing Pegylated Interferon Alfa-2b to Interferon Alfa-2b as Initial Treatment for Chronic Hepatitis C. Hepatology 34(2); 395-409; August, 2001.

110. Bak T, Wachs M, Trotter J, Everson G, Troulliot T, Kugelmas M, Steinberg T, Kam I. Adult-to-adult living donor liver transplantation using right-lobe grafts: Results and lessons learned from a single-center experience. Liver Transplantation 7(8):680-686, August 2001.

111. Trouillot TE, Pace DG, McKinley C, Cockey L, Zhi J, Haeussler J, Guerciolini R, Showalter R, Everson GT. Orlistat maintains biliary composition and hepatobiliary function in obese subjects undergoing moderate weight loss. American Journal of Gastroenterology June, 2001; 96:1888-1894.

112. Manns M, McHuthison J, Gordon S, Rustgi V, Shiffman M, Reindollar R, Goodman Z, Koury K, Ling M, Albrecht J, International Hepatitis Interventional Therapy Group*. Peg interferon alfa-2b plus Ribavirin with interferonalfa-2b plus Ribavirin for initial treatment of chronic hepatitis C: a randomized trial. The Lancet 358; (9286); 958-965, September, 2001.

113. Trotter JF, Everson GT. Transference of Peanut Allergy Through Liver Transplantation. Liver Transplantation, Letter to the Editors, October, 2001.

114. Trotter JF, Schiano T, Wachs M, Kim-Schluger L, Bak T, Kugelmas M, Trouillot T, Everson GT, Miller C, Kam I. Living Donor Liver Transplantation in Hepatitis C Patients: Short-Term Results Compared to Cadaveric Transplantation. Am J Tranpl 2001; 1S:316A.

115. Trotter JF, Everson GT, Bock SA, Wachs M, Bak T, Kam I. Transference of peanut allergy through liver transplantation. Liver Transpl. 2001 Dec;7(12):1088-9.

36

116. Shiffman M, Brown R, Olthoff K, Everson GT, Miller C, Siegler M, Hoofnagel J. Living Donor Liver Transplantation: Summary of a Conference at the National Institute of Health. Liver Transplantation February, 2002; 8:2; 174-188.

117. Trotter JF, Stolpman N, Wachs M, Bak T, Kugelmas, Kam I, Everson GT. Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients. Liver Transplantation 8(3):212-218, March 2002.

118. Trotter JF, Wachs M, Everson GT, Kam I. Adult-to-Adult transplantation of the right hepatic lobe from a living donor. New Engl J Med, 2002 April 4;346(14):1074-82.

119. Bostom A, Brown R, Chavers B, Coffman T, Cosia F, Culver K, Curtis J, Danovitch G, Everson G, First R, Garvey C, Grimm R, Hertz M, Hricik D, Hunsicker L, Ibrahim H, Kasiske B, Kennedy M, Klag M, Knatterud M, Koschigawa J, Lake J, Light J, Matas A, McDiarmid S, Miller L, Payne W, Rosenson R, Sutherland D, Tajani A, Textor S, Valantine H Wiesner R. Prevention of Post-Transplant Cardiovascular Disease-Report and Recommendations of an Ad Hoc Group. American Journal of Transplantation, 2002, 2:491-500.

120. Everson GT. Treatment of Hepatitis C. American College of Gastroenterology, 2002 Annual Postgraduate Course Board Review and Update in Clinical Gastroenterology: 571-597, October, 2002.

121. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl. 2002 Oct;8(10 Suppl 1):S19-27.

122. Hann HW, Fontana RJ, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G, Gardner SD, Brown N, Griffiths D; United States Lamivudine Compassionate Use Study Group. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl. 2003 Jan;9(1):49-56.

123. Everson GT. MELD: The Answer or Just More Questions? Editorial, Gastroenterology 2003; 124(1):251-4.

124. Trotter JT, Mackenzie S, Wachs M, Bak T, Steinberg T, Polsky P, Kam I, Everson GT. Comprehensive Cost Comparison of Adult-to-Adult Right Hepatic Lobe Living-Donor Liver Transplantation with Cadaveric Transplantation. Transplantation 2003 Feb 27, 75(4):473-6.

125. Everson, GT. Treating Hepatitis, An Update. Gastroenterology & Endoscopy News, April, 2003.

126. Dunkelberg J, Trotter J, Wachs M, Bak T, Kugelmas M, Steinberg T, Everson G and I. Kam. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transplantation 2003 May; 9(5):463-468.

127. Kugelmas M, Spiegelman P, Osgood MJ, Young DA, Trotter JF, Steinberg T, Wachs ME, Bak T, Kam I, Everson GT. Different Immunosuppressive Regimens and

37

Recurrence of Primary Sclerosing Cholangitis after Liver Transplantation. Liver Transplantation 2003 Jul; 9:727-732.

128. Hayashi PH, Forman L, Steinberg T, Bak T, Wachs M, Kugelmas M, Everson GT, Kam I, Trotter JF. Model of End-Stage Liver Disease Score Does Not Predict Patient or Graft Survival in Living Donor Liver Transplant Recipients. Liver Transplantation 2003;9:737-740.

129. Everson GT, Trotter J. Role of Adult Living Donor Liver Transplantation (LDLT) in Patients with Hepatitis C. Liver Transplantation 2003 9S1:S64-S68.

130. Everson GT. Treatment of Patients with Hepatitis C Virus on the Waiting List. Liver Transplantation 2003 9(11):S3:S90-S94.

131. Everson GT, Trotter JF, Kugelmas M, Forman L. Immunosuppression in liver transplantation. Minerva Chir. 2003 Oct;58(5):725-40.

132. Shiffman ML, Vargas HE, Everson GT. Controversies in the Management of Hepatitis C Virus Infection After Liver Transplantation. Liver Transplantation 2003 9(11):1129-1144.

133. Kugelmas M, Osgood M, Trotter JF, Bak T, Wachs M, Forman L, Kam I, Everson GT. Hepatitis C Virus Therapy, Hepatocyte Drug Metabolism, and Risk for Acute Cellular Rejections. Liver Transplantation 2003;9(11):1159-65.

134. Hayashi P, Trotter JF, Everson GT. Hepatocellular Carcinoma Extension Into the Right Atrium. Liver Transplantation 2003 9(11):1225-1226.

135. Mandell, MS, Durham J, Kumpe D, Trotter JF, Everson GT, Niemann CU. The Effects of Desflurane and Propofol on Portosystemic Pressure in Patients with Portal Hypertension. Anesth. Analg 2003; Dec; 97(6):1573-7.

136. Medeiros BC, Seligman PA, Everson GT, Forman LM. Possible autoimmune thrombocytopenia associated with pegylated interferon-alpha2a plus ribavarin treatment for hepatitis C. J Clin Gastroenterol. 2004 Jan;38(1):84-6.

137. Hayashi PH, Trotter JF, Forman L, Kugelmas M, Steinberg T, Russ P, Wachs M, Bak T, Kam I, Everson GT. Impact of Pretransplant Diagnosis of Hepatocellular Carcinoma on Cadaveric Liver Allocation in the Era of MELD. Liver Transpl 2004; 10:42-48.

138. Shiffman JL, Di Bisceglie AM, Lindsay KL, Morishima C, Wrigth EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MC, Goodman ZD, Everhart JE, HALT-C Trial Group. Peginterferon Alfa-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Failed Prior Treatment. Gastroenterology 2004;126:1015-1023.

139. Fontana RJ, Everson GT, Tuteja S, Vargas HE, Shiffman ML. Controversies in the Management of Hepatitis C Patients with Advanced Fibrosis and Cirrhosis. Clinical Gastroenterology and Hepatology 2004;2:183-197.

38

140. Hayashi PH, Ludkowski M, Forman LM, Osgood M, Johnson S, Kugelmas M, Trotter JF, Bak T, Wachs M, Kam I, Durham J, Everson GT. Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant. 2004 May;4(5):782-7.

141. Hayashi PH, Mao J, Slater K, Liao R, Durham JD, Carroll J, Everson GT, Kam I, Forman LM. Atrial septal perforation from TIPS stent migration. J Vasc Interv Radiol. 2004 Jun;15(6):629-32.

142. Everson GT. Treatment of Chronic Hepatitis C in Patients with Decompensated Cirrhosis. Rev Gastroenterol Disord. 2004; 4(suppl 1): S31-S38.

143. Demetriou AA, Brown RS Jr, Busuttil RW, Fair J, McGuire BM, Rosenthal P, AmEsch JS 2nd, Lerut J, Nyberg SL, Salizzoni M, Fagan EA, de Hemptinne B, Broelsch CE, Muraca M, Salmeron JM, Rabkin JM, Metselaar HJ, Pratt D, De La Mata M,McChesney LP, Everson GT, Lavin PT, Stevens AC, Pitkin Z, Solomon BA. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg. 2004 May;239(5):660-7; discussion 667-70.

144. Everson GT. Shifting Paradigms in Liver Transplantation. Syllabus, DDW Conference, New Orleans, May 2004.

145. Everson GT. Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Rev Gastroenterol Disord 2004; 4 Suppl 1:S31-8.

146. Kleinschmidt-DeMaster BK, Mardar B, Levi M, Laird SP, McNutt T, Escott E, Everson GT, Tyler KL. Naturally-Acquired West Nile Virus Encephalomyelitis in Transplant Recipients: Clinical, Laboratory, Diagnostic, and Neuropathological Features. Ach Neurol 2004 Aug; 61 (8):1210-20.

147. Robinson TN, Stiegmann GV, Everson GT. Laparoscopic Palliation of Polycystic Liver Disease. Surg Endosc 2005 Jan; 19(1):130-2.

148. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE. Evolution of the HALT-C Trial Pegylated Interferon as Maintenance Therapy for Chronic Hepatitis C in Previous Interferon Nonresponders. Controlled Clinical Trials 2004. 25(5):472-92.

149. Everson GT, Taylor MR, Doctor RB. Polycystic Disease of the Liver. Hepatology 2004 Oct 40 (4): 774-782.

150. Brown RS, Everson GT. What You Should Know About Living Donor Liver Transplantation. Patient Care, December 2004:26-33.

151. Everson GT, Taylor MR. Management of Polycystic Liver Disease. Current Gastroenterology Reports; 2005 Feb; 7(1):19-25.

152. Everson, GT. Hepatitis C Therapy With Pegylated Interferon. Literature Review, June 2004.

39

153. Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, DiBisceglie AM, Lindsay KL, Malet PF, Chang M, Gretch DR, Sullivan DG, Bhan AK, Wright EC, Koziel MJ, and the HALT C Trial Group. Associations Among Clinical, Immunological, and Viral Quasispecies Measurements in Advanced Chronic Hepatitis C. Hepatology 2005;41(3):617-25.

154. Morishima C, Ray R, Polyak SJ, Sullivan DG, Di Bisceglie AM, Malet PF, Bonkovsky HL, Bhan AK, Gretch DR, Doherty MC, Rothmann AL, Koziel MJ, Lindsay KL, and the HALT-C Trail Group. HCV-specific Immunity in Advanced Disease is Associated with Non-response to Antiviral Therapy. Submitted to Publications Committee, NIDDK, and Roche

155. Di Bisceglie AM, Sterling R, Chung R, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok ASF, Lee WM, Morgan TR, Ghany MG, Gretch DR, and the HALT-C Trial Group. Serum Alpha-Fetoprotein Levels in Patients with Advanced Hepatitis C: Results from the HALT-C Trial. J Hepatol 2005 Sep; 43(3):434-41.

156. Robinson RN, Stiegmann GV, Everson, GT. Laparoscopic palliation of polycystic liver disease. Surgical Endoscopy (2005) 19:130-132.

157. Everson GT. Management of cirrhosis due to chronic hepatitis C. Journal of Hepatology 42 (2005) S65-S74.

158. Everson GT. Should we treat patients with chronic hepatitis C on the waiting list? Journal of Hepatology 2005; April 42(4):456-62.

159. Everson GT. Antiviral Therapy in the Liver Transplant Candidate and Recipient. Current Hepatitis Report 2005; 4:75-82.

160. Polyak SJ, Sullivan DG, Austin MA, Dai JY, Shuhart MC, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morishima C, Gretch DR, and the HALT-C Trial Group. Comparison of Amplification Enzymes for Hepatitis C Virus Quasispecies Analysis. Virol J 2005; 2(1):41.

161. Everson GT. Treatment of Hepatitis C in the Patient with Decompensated Cirrhosis. Clin Gastroenterol Hepatol, 2005;3:S106-S112.

162. Trotter J, Pieramici E, Everson GT. Chronic Albumin Infusions to Achieve Diuresis in Patients with Ascites Who Are Not Candidates for Transjugular Intrahepatic Portosystemic Shunt (TIPS). Digestive Dis and Sciences 2005 Jul; 50(7):1356-60.

163. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey, B, Ray C. Treatment of Advanced Hepatitis C with a Low Accelerating Dosage Regimen (LADR) Of Antiviral Therapy. Hepatology 2005, 42(2):255-262.

164. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C, the HALT-C Trial Group. Predicting cirrhosis in Patients with Hepatitis C Based on Standard Laboratory Tests: Results of the HALT-C Cohort. Hepatology 2005, 42(2):282-292.

40

165. Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Kronfol Z, Lok AS, Padmanabhan L, the HALT-C Trail Group. Cognitive Function in Hepatitis C Patients with Advanced Fibrosis Enrolled in the HALT-C Trial. J of Hepatology 2005; 43:614-622.

166. Everson GT. Treatment of Hepatitis C in Patients who have Decompensated Cirrhosis. Clinics in Liver Disease 2005, Aug; 9(3):473-86.

167. Everson GT, Balart L, Lee SS, Reindollar RW, Shiffman ML, Minuk GY, Pockros PJ, Govindarajan S, Lopez-Talavera JC, Heathcote EJ. Histologic benefits of Peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or cirrhosis. Submitted J Hepatology, October 2005.

168. Swize L, Everson GT. Chronic Hepatitis C: Reasons to Treat Besides the Liver. Submitted, July 2005.

169. Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Garcia A, Moore PA, Yu R, Subramanian GM. Modulation of interferon Specific Gene Expression by Albumin-interferon-Alpha-Experienced Patients with Chronic Hepatitis C. Antivir Ther, 2006; 11(7):901-8.

170. McHutchison JG, Patel K, Schiff ER, GItlin N, Mur RE, Everson GT, Carithers RL, Davis GL, Marcellin P, Shiffman ML, Harvey J, Albrecht JK. Interferon Alfa-2b Continuous Long-Term Therapy Versus Repeated 24-Week Cycles for Retreating Chronic Hepatitis C. Submitted to Hepatology, 2005.

171. Sieja KS, Everson GT. De Novo Hepatocellular Carcinoma in a Patient with Chronic Hepatitis C 5 years after Sustained Virologic Response to Interferon/Ribavirin Therapy. Dig Dis Sci, 2006 Mar;51(3):600-2.

172. Fontana RJ, Sanyal AJ, Mehta S, Doherty MC, Neuschwander-Tetri BA, Everson GT, Kahn JA, Malet PF, Sheikh MY, Chung RT, Ghany MG, Gretch DR, and the HALT-C Trial Group. Portal Hypertensive Gastropathy in Chronic Hepatitis C Patients with Bridging Fibrosis and Compensated Cirrhosis: Results from the HALT-C Trial. Am J Gastroenterol 2006; 101(5):983-92.

173. Kulig CC, Beresford TP, Everson GT. Rapid, Accurate, and Sensitive Fatty Acid Ethyl Ester Determination by Gas Chromatography-Mass Spectometry. J Lab Clin Med. 2006 Mar;147(3):133-8.

174. Sanyal AJ, Fontana RJ, Di Bisceglie AM, Everhart JE, Doherty MC, Everson GT, Donovan JA, Malet PF, Mehta S, Sheikh MY, Reid AE, Ghany MG, Gretch DR and the HALT-C Trial Group. The Prevalence and Risk Factors Associated with Esophageal Varices in Subjects with Hepatitis C and Advanced Fibrosis. Gastrointest Endosc 2006;64:855-64.

175. Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Post AB, Redfield RR, Davis GL, Neumann AU, Osborn BL, Freimuth WW, Subramanian GM. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C

41

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Freimuth+WW%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Freimuth+WW%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Osborn+BL%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Neumann+AU%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Davis+GL%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&%20cmd=Search&itool=pubmed_Abstract&term=%22Redfield+RR%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Post+AB%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Dickson+RC%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Wiesner+RH%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Lambiase+LR%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Everson+GT%22%5B%20Author%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Sulkowski+MS%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Nelson+DR%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Balan+V%22%5BAuthor%5D

patients who have failed previous interferon-alpha-based therapy. Antivir Ther. 2006;11(1):35-45.

176. Schlenker C, Trotter JF, Shah RJ, Everson G, Chen YK, Antillon D, Antillon MR. Endoscopic gallbladder stent placement for treatment of symptomatic cholelithiasis in patients with end-stage liver disease. Am J Gastroenterol. 2006 Feb;101(2):278-83.

177. Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie Am, Malet PF, Bonkovsky HL, Sullivan DG, Gretch DR, Rothman AL, Koziel MJ, Lindsay KL, and the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial Group. Hepatitis C Virus-Specific Immune Responses and the Quasi-Species Variability at Baseline are Associated with Nonresponse to Antiviral Therapy during Advanced Hepatitis C. J Infect Dis 2006; 193(7):931-40.

178. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok ASF, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR, and the HALT-C Trial Group. HCV RNA Detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) Trial. Hepatology, 2006; 44:360-367.

179. Arrazola L, Moonka D, Gish RG, Everson GT. Model for End-Stage Liver Disease (MELD) Exception for Polycystic Liver Disease. Liver Transplantation 2006;12:S110-S111.

180. Bonkovsky HL , Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, Fontana RJ, DiBisceglie AM, Ghany MG, Morishima C, and the HALT-C Trial Group. Roles of Iron and HFE Mutations on Severity and Response to Therapy during Retreatment of Advanced Chronic Hepatitis C. Gastroenterology 2006;131:1440-1451.

181. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok ASF, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C, and the HALT-C Trial Group. Impact of Disease Severity on Outcome of Antiviral Therapy for Chronic Hepatitis C: Lessons from the HALT-C Trial. Hepatology 2006;44:1675-1684.

182. Trotter JF, Campsen J, Bak T, Wachs M, Forman L, Everson G, Kam I. Outcomes of donor evaluations for adult-to-adult right hepatic lobe living donor liver transplantation. Am J Transplant 2006; Aug;6(8):1882-9.

183. Everson GT, Kulig CC. Antiviral Therapy for Hepatitis C in the Setting of Liver Transplantation. Current Treatment Options in Gastro 2006;9:520-529.

184. Everson GT. Everolimus and mTOR Inhibitors in Liver Transplantation: Opening the “Box.” Liver Transplantation 2006;12:1571-1573.

185. Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, Lok ASF, Bonkovsky HL, Lee WM, Morgan TR, Ghany MG, and the HALT C Trial Group. Systemic Factors Associated with Virologic Nonresponse to Peginterferon/Ribavirin Retreatment of Choronic Hepatitis C. Submitted to J Hepatology, December 2006.

42

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Antillon+MR%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Antillon+D%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Chen+YK%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Everson+G%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Shah+RJ%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Trotter+JF%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Schlenker+C%22%5BAuthor%5D

186. Everson GT, Shiffman ML, Morgan TR, Hoefs JC, Sterling RK, Wagner DA, Kugelmas M, Doherty MC, Wright EC, and the HALT-C Trial Group. Quantitation of Liver Function in Patients with Fibrosis and Compensated Cirrhosis due to Chronic Hepatitis C: Results from the HALT-C Trial. In preparation, 2006.

187. Bieliauskas LA, Back-Madruga C, Lindsay KL, Wright EC, Kronfol Z, Lok ASF, Fontana RJ, and the HALT-C Trial Group. Cognitive Reserve and Neuropsychological Functioning in Patients Infected with Hepatitis C. Submitted to Journal of International Neuropsychological Society, May 2006.

188. Fontana RJ, Sanyal AJ, Mehta S, Doherty MC, Neuschwander-Tetri BA, Everson GT, Kahn JA, Malet PF, Sheikh MY, Chung RT, Ghany MG, Gretch DR; HALT-C Trial Group. Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial.Am J Gastroenterol. 2006 May;101(5):983-92.

189. Morfin JP, Kulig C, Everson GT, Beresford T. Controlling for Serum Albumin Improves the Correlations Between Serum-Fatty Acid Ethyl Esters and Blood Ethanol Level. Alcohol Clin Exp Res 2007;31(2):265-8.

190. Terrault NA, Shiffman ML, Lok AS, Saab S, Tong L, Brown RS, Everson GT, Reddy KR, Farr JH, Kulik LM, Pruett TL, Seeff LB. Outcomes in Hepatitis C Virus Infected Recipients of Living Donor Versus Deceased Donor Liver Transplantation. Liver Transpl 2007;13(1):122-129.

191. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok ASF, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR, and the HALT-C Trial Group. Impact of reducing peginterferon alfa-2a and ribavirin dose on virologic response in patients with chronic hepatitis C. Gastroenterology 2007;132(1):103-12.

192. Lok AS, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG, Morishima C; HALT-C Trial Group. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol. 2007 Feb;5(2):245-54.

193. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RJ, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Everhart JE, Ghany MG, Gretch DR and the HALT C Trial Group. Health-Related Quality of Life in Patients with Chronic Hepatitis C and Advanced Fibrosis. J Hepatology 2007; 46(3):420-31.

194. Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Garcia A, Moore PA, Yu R, Subramanian GM. Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C. Antivir Ther 2006;11(7):901-8.

195. Everson GT, Martucci MA, Shiffman ML, Sterling RK, Morgan TR, Hoefs JC, The HALT-C Trial Group. Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt. Aliment Pharmacol Ther, 2007 Aug 1:26(3):401-10.

43

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Subramanian%20GM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Yu%20R%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Moore%20PA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Garcia%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Dickson%20RC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wiesner%20RH%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lambiase%20LR%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Everson%20GT%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sulkowski%20MS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Nelson%20DR%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Balan%20V%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22HALT-C%20Trial%20Group%22%5BCorporate%20Author%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Morishima%20C%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ghany%20MG%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Morgan%20TR%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lee%20WM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Di%20Bisceglie%20AM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bonkovsky%20HL%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lindsay%20KL%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1


http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Shiffman%20ML%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Greenson%20JK%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Padmanabhan%20L%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Chung%20RT%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Everhart%20JE%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lok%20AS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1



http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Gretch%20DR%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ghany%20MG%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Chung%20RT%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sheikh%20MY%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Malet%20PF%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Kahn%20JA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1


http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Neuschwander-Tetri%20BA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Doherty%20MC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mehta%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sanyal%20AJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Fontana%20RJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

196. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C; HALT-C Trial Group. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006 Dec;44(6):1675-84.

197. Sanyal AJ, Fontana RJ, Di Bisceglie AM, Everhart JE, Doherty MC, Everson GT, Donovan JA, Malet PF, Mehta S, Sheikh MY, Reid AE, Ghany MG, Gretch DR, Halt-C Trial Group. The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc. 2006 Dec;64(6):855-64.

198. Everson GT, Shiffman ML, Morgan TR, Hoefs JC, Sterling RK, Wagner DA, Kugelmas M, Curto T, Wright EC, and the HALT-C Trial Group. The Spectrum of Hepatic Functional Impairment in Patients with Fibrosis and Compensated Cirrhosis Due to Chronic Hepatitis C: Results from the HALT-C Trial. Aliment Pharmacol Ther. 2008 May;27(9):798-809.

199. Fontana RJ, Bieliauskas LA, Lindsay KL, Back-Madruga C, Wright EC, Snow KK, Lok ASF, Kronfol Z, Padmanabhan L, and the HALT-C Trial Group. Cognitive function does not worsen during peginterferon and ribavirin treatment of chronic hepatitis C. Accepted by JINS, 2007.

200. McHutchison J, Everson GT. Interferon Alfa-2b Continuous Long-term Therapy Versus Repeated 24-Week Cycles for Retreating Chronic Hepatitis C. Submitted to Antiviral Therapy, January 2007.

201. Hoevenaren IA, Wester R, Schrier RW, McFann K, Doctor RB, Drenth JPH, Everson GT. Polycystic liver: Clinical characteristics of patients with isolated polycystic liver disease compared to patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver International, 2008 Feb;28(2):264-70.

202. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL, the HALT-C Trial Group. Prolonged therapy of advanced chronic hepatitis C with low-dose Peginterferon. N Engl J Med. 2008 Dec 4;359(23):2429-41. PMID: 19052125

203. McHutchison JG, Patel K, Schiff ER, Gitlin N, Mur RE, Everson GT, Carithers RL Jr, Davis GL, Marcellin P, Shiffman ML, Harvey J, Albrecht JK; International Hepatitis Interventional Therapy Group. Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C. Aliment Pharmacol Ther. 2008 Mar 1;27(5):422-32.

204. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, DiBisceglie AM, Lee WM, Ghany MG, HALT-C Trial Group. Herbal product use by person enrolled in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology, 2007 Dec 21:47(2): 605-612.

205. Everson GT, Balart L, Lee SS, Reindollar RW, Shiffman ML, Minuk GY, Pockros PJ, Govindarajan S, Lentz E, Heathcote EJ. Histologic benefits of virologic response to

44

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22International%20Hepatitis%20Interventional%20Therapy%20Group%22%5BCorporate%20Author%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22International%20Hepatitis%20Interventional%20Therapy%20Group%22%5BCorporate%20Author%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Albrecht%20JK%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Harvey%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Shiffman%20ML%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Marcellin%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Davis%20GL%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Carithers%20RL%20Jr%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1


http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mur%20RE%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Gitlin%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Schiff%20ER%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Patel%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22McHutchison%20JG%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Halt-C%20Trial%20Group%20%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Halt-C%20Trial%20Group%20%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Gretch%20DR%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ghany%20MG%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Reid%20AE%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sheikh%20MY%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mehta%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Malet%20PF%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Donovan%20JA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Everson%20GT%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Doherty%20MC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Everhart%20JE%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Di%20Bisceglie%20AM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Fontana%20RJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sanyal%20AJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22HALT-C%20Trial%20Group%22%5BCorporate%20Author%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus


http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Morishima%20C%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus


http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Dienstag%20JL%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lee%20WM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus


http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lok%20AS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Kahn%20JA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Kahn%20JA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Shiffman%20ML%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Naishadham%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bonkovsky%20HL%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Seeff%20LB%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Hoefs%20JC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus


peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther. Apr 1;27(7):542-51.

206. Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, Lock AS, Bonkovsky HL, Lee WM, Morgan TR, Ghany MG, HALT C Trial. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol. 2008 Feb;6(2):234-41.

207. Everson GT. Is early steroid withdrawal after liver transplantation feasible with tacrolimus monotherapy? Nat Clin Pract Gastroenterol Hepatol. 2008 Apr;5(4):194-5.

208. Everson GT, Helmke SM, Doctor B. Advances in management of polycystic liver disease. Expert Rev Gastroenterol Hepatology. 2008 Aug ;2(4):563-76. PMID: 19072404

209. Hoffenberg AS, Kulig C, Everson G, Brimhall B, Beresford T. Validation characteristics of fatty acid ethyl ester (FAEE) concentrations in alcohol misuse. In preparation, May 2008.

210. Pockros PJ, Nelson D, Godofsky E, Rodriguez-Torres M, Everson GT, Fried MW, Ghalib R, Harrison S, Nyberg L, Shiffman ML, Najera I, Chan A, Hill G. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008 Aug;48(2):385-97.

211. Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR, Shiffman ML, Everson GT, Lindsay KL, Lee WM, Lok AS, Dienstag JL, Ghany MG, Curto TM; HALT-C Trial Group. Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology 2008 Nov;48(5):1412-9.

212. Pockros P, Nelson D, Godofsky E, Rodriguez-Torres M, Everson GT, Fried MW, Ghalib R, Harrison S, Nyberg L, Shiffman ML, Chan A, Hill G. High relapse rate seen at week 72 for patients treated with R1626 combination therapy. Hepatology 2008 Oct;48(4):1349-50.

213. Nelson DR, Davis GL, Jacobson I, Everson GT, Fried MW, Harrison SA, Hassanein T, Jensen DM, Lindsay KL, Terrault N, Zein N. Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol. 2009 Apr;7(4):397-414; quiz 366. PMID: 19114127

214. Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Desanto JL, Curto TM, Wright EC; HALT-C Trial Group. Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial. Aliment Pharmacol Ther. 2009 Mar 1;29(5):589-601. PMID: 19053983

215. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD; HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009 Jan;136(1):138-48. PMID: 18848939

45

216. Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C; HALT-C Trial Group. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology. 2009 Jun;49(6):1828-37. PMID: 19291787

217. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009 Apr 30;360(18):1827-38. PMID: 19403902

218. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR; HALT-C Trial Group. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2009 Jun;49(6):1847-58. PMID: 19434718

219. Burton JR Jr, Everson GT. HCV NS5B polymerase inhibitors. Clin Liver Dis. 2009 Aug;13(3):453-65. PMID: 19628161.

220. Ghany MG , Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL; HALT-C Trial Group. Predicting Clinical and Histological Outcomes Based on Standard Laboratory Tests In Advanced Chronic Hepatitis C. Gastroenterology. 2009 Sep 17. PMID: 19766643

221. Heller JC, Prochazka AV, Everson GT, Forman LM. Long-term management after liver transplantation: primary care physician versus hepatologist. Liver Transpl. 2009 Oct;15(10):1330-5. PMID: 19790168

222. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R; HALT-C Trial Group. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009 Nov;50(5):1360-9. PMID: 19676128

223. Shiffman ML , Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG; HALT-C Trial Group. Effect of HCV RNA Suppression During Peginterferon Alfa-2A Maintenance Therapy on Clinical Outcomes in the HALT-C Trial. Gastroenterology. 2009 Dec;137(6):1986-94. PMID: 19747918

224. Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, Wright EC, Brunt EM, Kleiner DE, Shiffman ML, Everson GT, Lindsay KL, Dienstag JL, Morishima C; HALT-C Trial Group. Fibrosis progression in chronic hepatitis C:

46







http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Naishadham%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wright%20EC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus


http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Hoefs%20JC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lindsay%20KL%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus



http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Shiffman%20ML%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus



http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Morgan%20TR%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Morgan%20TR%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus




http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sterling%20RK%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Stoddard%20AM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wright%20EC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Curto%20TM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus



http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Everhart%20JE%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus



morphometric image analysis in the HALT-C trial. Hepatology. 2009 Dec;50(6):1738-49. PMID: 19824074

225. Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE, Naishadham D, Everson GT, Kahn JA, Di Bisceglie AM, Szabo G, Morgan TR, Everhart JE; HALT-C Trial Group. Factors that Determine the Development and Progression of Gastroesophageal Varices in Patients with Chronic Hepatitis C. Gastroenterology. 2010; 138:2321-2331. PMID: 20211180.

226. Pierucci-Lagha A, Covault J, Bonkovsky HL, Feinn R, Abreu C, Sterling RK, Fontana RJ, Kranzler HR; HALT-C Trial Group. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics. 2010 Mar;51(2):137-48. PMID: 20332289

227. Merion RM, Shearon TH, Berg CL, Everhart JE, Abecassis MM, Shaked A, Fisher RA, Trotter JF, Brown RS Jr, Terrault NA, Hayashi PH, Hong JC; A2ALL Study Group. Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation. Ann Surg. 2010 Mar;251(3):542-9. PMID: 20130466.

228. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, Di Bisceglie AM, Bonkovsky HL, Dienstag JL; HALT-C Trial Group. Complication Rate of Percutaneous Liver Biopsies among Persons with Advanced Chronic Liver Disease in the HALT-C Trial. Clin Gastroenterol Hepatol. 2010; 8:877-883. PMID: 20362695.

229. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010 Apr 8;362(14):1292-303. PMID: 20375406.

230. Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Flisiak R, Rasenack JW, Kryczka W, Lee CM, Bain VG, Pianko S, Patel K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG; ACHIEVE-2/3 Study Team. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 2010 Oct;139(4):1267-76. PMID: 20600017

231. Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, Grigorescu M, Tice AD, Lurie Y, Cianciara J, Muir AJ, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG; ACHIEVE-1 Study Team. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology. 2010 Oct;139(4):1257-66. PMID: 20600013

232. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31;364(13):1195-206. PMID: 21449783

47

http://www.ncbi.nlm.nih.gov/pubmed/21449783


233. Dibaise JK, Richmond BK, Ziessman HH, Everson GT, Fanelli RD, Maurer A, Ouyang A, Shamamian P, Simons RJ, Wall LA, Weida TJ, Tulchinsky M. Cholecystokinin-Cholescintigraphy in Adults: Consensus Recommendations of an Interdisciplinary Panel. Clin Gastroenterol Hepatol. 2011 Feb 17. PMID: 21334459

234. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR; HALT-C Trial Group. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011 Mar;140(3):840-849. PMID: 21129375

235. Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR, the PHOENIX Study Group. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 17:528-538, 2011. PMID: 21506241

236. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink H, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F, the ILLUMINATE Study Team. Duration of Initial Telaprevir Treatment for HCV Infection. Accepted for publication, N Engl J Med. 2011.

237. Trotter JF, Gillespie BW, Terrault NA, Abecassis MM, Merion RM, Brown RS Jr, Olthoff KM, Hayashi PH, Berg CL, Fisher RA, Everhart JE; Adult-to-Adult Living Donor Liver Transplantation Cohort Study Group. Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl. 2011 Apr;17(4):409-17. doi: 10.1002/lt.22246. PMID: 21445924

238. Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima C, Morgan TR, Bonkovsky HL; HALT-C Trial Group. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology. 2011 May;140(5):1490-500.e3. Epub 2011 Feb 15. PMID: 21335007

239. Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG; HALT-C Trial Group. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011 Apr;53(4):1100-8. doi: 10.1002/hep.24169. PMID: 21480316

240. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; for the HALT-C Trial Group. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011 Apr 21. PMID: 21520194

241. Berg CL, Merion RM, Shearon TH, Olthoff KM, Brown RS Jr, Baker TB, Everson GT, Hong JC, Terrault N, Hayashi PH, Fisher RA, Everhart JE. Liver transplant recipient survival benefit with living donation in the MELD allocation era. Hepatology. 2011 Jun 17. PMID:21688284

48





242. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011 Jun 23;364(25):2405-16. PMID:21696307.

243. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011 Jun 23;364(25):2417-28. PMID: 21696308

244. Olthoff KM, Abecassis MM, Emond JC, Kam I, Merion RM, Gillespie BW, Tong L; Adult-to-Adult Living Donor Liver Transplantation Cohort Study Group. Outcomes of adult living donor liver transplantation: comparison of the Adult-to-adult Living Donor Liver Transplantation Cohort Study and the national experience. Liver Transpl. 2011 Jul;17(7):789-97. PMID: 21360649

245. Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR; HALT-C Trial Group. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011 Aug;54(2):434-42. PMID: 21374690

246. Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE; HALT-C TRIAL GROUP.Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology. 2011 Jun;140(7):1961-9. PMID: 21376050

247. Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT; HALT-C Trial Group. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology. 2011 Jul;141(1):141-9. PMID: 21440548

248. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F; ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011 Sep 15;365(11):1014-24. PMID: 21916639

249. O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM; HALT-C Trial Group. An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One. 2011;6(7):e20904. PMID:21760886

250. Everson GT , Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Lauriski S, Curto TM, Stoddard A, Wright EC; The HALT-C Trial Group. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the HALT-C trial. Hepatology. 2011 Oct 26. PMID: 22030902

49

http://www.ncbi.nlm.nih.gov/pubmed/22030902#%23

http://www.ncbi.nlm.nih.gov/pubmed?term=%22The%20HALT-C%20Trial%20Group%22%5BCorporate%20Author%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Wright%20EC%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Stoddard%20A%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Curto%20TM%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lauriski%20S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lauriski%20S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Wagner%20DA%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sterling%20RK%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Morgan%20TR%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hoefs%20JC%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Shiffman%20ML%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Everson%20GT%22%5BAuthor%5D



http://www.ncbi.nlm.nih.gov/pubmed?term=%22HALT-C%20Trial%20Group%22%5BCorporate%20Author%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Pfeiffer%20RM%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bonkovsky%20HL%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sninsky%20JJ%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dotrang%20M%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Shiffman%20ML%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Shao%20Y%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Chung%20RT%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lok%20AS%22%5BAuthor%5D


http://www.ncbi.nlm.nih.gov/pubmed?term=%22Everhart%20JE%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22O'Brien%20TR%22%5BAuthor%5D


http://www.ncbi.nlm.nih.gov/pubmed?term=%22ILLUMINATE%20Study%20Team%22%5BCorporate%20Author%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Poordad%20F%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Wright%20CI%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22George%20S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kauffman%20RS%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Adda%20N%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sankoh%20AJ%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Martin%20M%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Reesink%20HW%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Adler%20M%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Fried%20MW%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Fried%20MW%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Everson%20GT%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sulkowski%20MS%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nelson%20DR%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Afdhal%20NH%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Flamm%20SL%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sherman%20KE%22%5BAuthor%5D



http://www.ncbi.nlm.nih.gov/pubmed?term=%22Chung%20RT%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Tanabe%20KK%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dienstag%20JL%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22O'Brien%20TR%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sninsky%20JJ%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yamada%20S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Karl%20DL%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Fuchs%20BC%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yang%20M%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Abu%20Dayyeh%20BK%22%5BAuthor%5D


http://www.ncbi.nlm.nih.gov/pubmed?term=%22HALT-C%20TRIAL%20GROUP%22%5BCorporate%20Author%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22HALT-C%20TRIAL%20GROUP%22%5BCorporate%20Author%5D


http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sinha%20R%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Wright%20EC%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lindsay%20KL%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Curto%20TM%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Freedman%20ND%22%5BAuthor%5D





http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hussain%20M%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kim%20HY%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Di%20Bisceglie%20AM%22%5BAuthor%5D


http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lok%20AS%22%5BAuthor%5D


http://www.ncbi.nlm.nih.gov/pubmed?term=%22Adult-to-Adult%20Living%20Donor%20Liver%20Transplantation%20Cohort%20Study%20Group%22%5BCorporate%20Author%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Tong%20L%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gillespie%20BW%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Merion%20RM%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kam%20I%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Emond%20JC%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Abecassis%20MM%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Olthoff%20KM%22%5BAuthor%5D

251. Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P; Terlipressin Study Group. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl. 2011 Nov;17(11):1328-32. PMID: 21837734

252. Curto TM, Lagier RJ, Lok AS, Everhart JE, Rowland CM, Sninsky JJ; HALT-C Trial group. Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7). Pharmacogenet Genomics. 2011 Dec;21(12):851-60. PMID: 21946897

253. Ghany MG, Kim HY, Stoddard A, Wright EC, Seeff LB, Lok AS; HALT-C Trial Group. Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology. 2011 Nov;54(5):1527-37. PMID: 22045670

254. DiBaise JK, Richmond BK, Ziessman HA, Everson GT, Fanelli RD, Maurer AH, Ouyang A, Shamamian P, Simons RJ, Wall LA, Weida TJ, Tulchinsky M. Cholecystokinin-cholescintigraphy in adults: consensus recommendations of an interdisciplinary panel. Clin Nucl Med. 2012 Jan;37(1):63-70. PMID: 22157031

255. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012 Jan 19;366(3):216-24. PMID: 22256805

256. Rowan SE, Levi ME, Youngwerth JM, Brauer B, Everson GT, Johnson SC. The variable presentations and broadening geographic distribution of fascioliasis. Clin Gastroenterol Hepatol. 2012 Feb 25 (epub ahead of print). PMID: 22373727

257. Corey KE, Zheng H, Mendez-Navarro J, Delgado-Borrego A, Dienstag JL, Chung RT; HALT-C Trial Group. Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS One. 2012;7(2):e27144. doi: 10.1371/journal.pone.0027144. Epub 2012 Feb 16. PMID: 22359532

258. Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Lauriski S, Curto TM, Stoddard A, Wrights EC, the HALT-C Trial Group. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2012 April; 55(4): 1019-1029.

259. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012 May; 55(5):1620-8. PMID: 22331658

260. Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol. 2012 Jun 12. doi: 10.1038/ajg.2012.137. PMID: 22688849PMID: 22688849

50
















261. Rowan SE, Levi ME, Youngwerth JM, Brauer B, Everson GT, Johnson SC. The variable presentations and broadening geographic distribution of hepatic fascioliasis. Clin Gastroenterol Hepatol. 2012 Jun;10(6):598-602. doi: 10.1016/j.cgh.2012.02.013. Epub 2012 Feb 25. PMID: 22373727

262. Everson GT, Terrault NA, Lok AS, Rodrigo DR, Brown RS Jr, Saab S, Shiffman ML, Al-Osaimi AM, Kulik LM, Gillespie BW, Everhart JE; and the Adult-to-Adult Living Donor Liver Transplantation Cohort Study. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology. 2012 Jul 23. doi: 10.1002/hep.25976. PMID: 22821361

263. Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, McHutchison J, Chen PJ, Han KH, Campbell F, Hyde D, Brainsky A, Theodore D; ELEVATE Study Group. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012 Aug 23;367(8):716-24. Doi: 10.1056/NEJMoa1110709. PMID: 22913681

264. Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, Hézode C, Lim JK, Bronowicki JP, Abrams GA, Bräu N, Morris DW, Thuluvath PJ, Reindollar RW, Yin PD, Diva U, Hindes R, McPhee F, Hernandez D, Wind-Rotolo M, Hughes EA, Schnittman S. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis. 2012 Sep;12(9):671-7. doi: 10.1016/S1473-3099(12)70138-X. Epub 2012 Jun 18. PMID: 22714001

265. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012 Sep;143(3):608-18.e1-5. Doi: 10.1053/j.gastro.2012.05.011. Epub 2012 May 21. PMID: 22626609

266. Nelson DR, Jensen DM, Sulkowski MS, Everson G, Fried MW, Gordon SC, Jacobson I, Reau NS, Sherman K, Terrault N, Thomas D. Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy. Hepatitis Research and Treatment. 2012 October; Hindawi Publishing Corp:doi:10.1155/2012/138302

267. Kulik LM, Fisher RA, Rodrigo DR, Brown RS Jr, Freise CE, Shaked A, Everhart JE, Everson GT, Hong JC, Hayashi PH, Berg CL, Lok AS; A2ALL Study Group. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant. 2012 Nov;12(11):2997-3007. doi: 10.1111/j.1600-6143.2012.04272.x. Epub 2012 Sep 20. PMID: 22994906

268. Everson GT, Hoefs JC, Niemann CU, Olthoff KM, Dupuis R, Lauriski S, Herman A, Milne N, Gillespie BW, Goodrich NP, Everhart JE. Functional elements associated with hepatic regeneration in living donors after right hepatic lobectomy. Liver Transpl. 2013 19(3):292-304. PMID:23239552. PMCID:3600052

269. Biggins SW, Trotter J, Gralla J, Burton J, Bambha KM, Dodge J, Brocato M, Cheng L, McQueen M, Forman L, Chang M, Kam I, Everson G, Spritz RA, Klintmalm G, Rosen HR. Differential Effects of Donor and Recipient IL28B and DDX58 SNPs on Severity

51






http://www.hindawi.com/39518369/
















of HCV after Liver Transplantation. J Hepatol. 2013 Jan 15. doi:pii: S0168-8278(13)00015-9.10.1016/j.jhep.2012.12.027. PMID: 23333445

270. Burton JR Jr, Everson GT. Management of the transplant recipient with chronic hepatitis C. Clin Liver Dis. 2013 Feb;17(1):73-91. doi: 10.1016/j.cld.2012.09.013. PMID: 23177284

271. Everson GT, Terrault NA, Lok AS, Rodrigo DR, Brown RS Jr., Saab S, Shiffman ML, Al-Osaimi AM, Kulik LM, Gillespie BW, Everhart JE; and the A2ALL Study group. A Randomized Controlled Trial of Pretransplant Antiviral Therapy to Prevent Recurrence of Hepatitis C after Liver Transplantation. Hepatology 57: 1752-1762, 2013.

272. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM; AI444040 Study Group.

273. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski MS, Xie W, Pilot-Matias T, Liossis G, Larsen L, Khatri A, Podsadecki T, Bernstein B. N Engl J Med. 2014 Jan 16;370(3):222-32. doi: 10.1056/NEJMoa1306227.

274. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.Lok AS, Gardiner DF, Hézode C, Lawitz EJ, Bourlière M, Everson GT, Marcellin P, Rodriguez-Torres M, Pol S, Serfaty L, Eley T, Huang SP, Li J, Wind-Rotolo M, Yu F, McPhee F, Grasela DM, Pasquinelli C. J Hepatol. 2014 Mar;60(3):490-9. doi: 10.1016/j.jhep.2013.10.019. Epub 2013 Oct 26.

275. DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4.Everson G, Cooper C, Hézode C, Shiffman ML, Yoshida E, Beltran-Jaramillo T, Andreone P, Bruno S, Ferenci P, Zeuzem S, Brunda M, Le Pogam S, Nájera I, Zhou J, Navarro MT, Voulgari A, Shulman NS, Yetzer ES.Liver Int. 2014 Jan 19. doi: 10.1111/liv.12471.

276. Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study.Terrault NA, Stravitz RT, Lok AS, Everson GT, Brown RS Jr, Kulik LM, Olthoff KM, Saab S, Adeyi O, Argo CK, Everhart JE, Rodrigo del R; A2ALL Study Group.Hepatology. 2014 Apr;59(4):1311-9. doi: 10.1002/hep.26920. Epub 2014 Mar 1.

277. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW; ION-3 Investigators.

52


N Engl J Med. 2014 May 15;370(20):1879-88. doi: 10.1056/NEJMoa1402355.

278. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators.N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11.

279. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators.N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11.

280. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.Burton JR Jr, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS Jr, Terrault NA.J Hepatol. 2014 Sep;61(3):508-14. doi: 10.1016/j.jhep.2014.04.037. Epub 2014 May 5.

281. A Randomized Phase 2b Study of Peginterferon Lambda-1a for the Treatment of Chronic HCV Infection.Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S; for the EMERGE study group.J Hepatol. 2014 Jul 23. pii: S0168-8278(14)00521-2. doi: 10.1016/j.jhep.2014.07.022

282. Liver regeneration after living donor transplant: Adult to adult living donor liver transplantation cohort (A2ALL) study.Olthoff KM, Emond JC, Shearon TH, Everson G, Baker TB, Fisher RA, Freise CE, Gillespie BW, Everhart JE. Liver Transpl. 2014 Jul 28. doi: 10.1002/lt.23966.

283. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S; on behalf of the HALLMARK-DUAL Study Team.Lancet. 2014 Jul 26. pii: S0140-6736(14)61059-X. doi: 10.1016/S0140-6736(14)61059-X.

284. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

53

Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S.Gut. 2014 Jul 30. pii: gutjnl-2014-307498. doi: 10.1136/gutjnl-2014-307498.

285. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: a randomised trial. Gregory T. Everson, MD; William J. Towner, MD; Mitchell N. Davis, DO; David L. Wyles, MD; Ronald G. Nahass, MD; Paul J. Thuluvath, MD; Kyle Etzkorn, MD; Federico Hinestrosa, MD; Myron Tong, MD, PhD; Mordechai Rabinovitz, MD; John McNally, PhD; Diana M. Brainard, MD; Lingling Han, PhD; Brian Doehle, PhD; John G. McHutchison, MD; Timothy Morgan, MD; Raymond T. Chung, MD; and Tram T. Tran, MDAnnals of Internal Medicine. 2015; 163:818-826. doi: 10.7326/M15-1000

BOOK CHAPTERS

1. Everson GT, Kern F Jr. Bile acid metabolism. In Advances in Hepatology. IT MacSween, Editor. Churchill Livingstone, London, pp. 171-189, 1983.

2. Everson GT. Liver diseases. In Medical Therapeutics. RW Schrier, Editor. Raven Press, New York, Ch. 12, pp. 264-278, 1984.

3. Everson GT. Dual isotope techniques for measuring bile acid kinetics in healthy man: Stable isotopes and serum sampling. In Enterohepatic Circulation of Bile Acids and Sterol Metabolism. MTP Press Ltd., Falcon Press, Lancaster, England, Ch. 34, pp 259-261, 1985.

4. Everson GT. Diseases of the small intestine. In Decision Making in Gastroenterology. JS Levine, Editor. BC Decker, Inc., Toronto, pp. 200-236, 1985.

5. Everson GT. Diseases of the biliary tree. In Decision Making in Gastroenterology. JS Levine, Editor. BC Decker, Inc., Toronto, pp. 236-258, 1985.

6. Everson GT, Kern F Jr. Effects of female sex hormones on bile acids. In Trends in Hepatology. L Bianchi, Gerok, and H Popper, Editors. MTP Press Ltd., Falcon Press, Lancaster, England, pp. 67-70, 1985.

7. Everson GT. Bile acid synthesis by liver cell hybrids (rat): Studies of the regulation of bile acid synthesis by dexamethasone. In Bile Acids and the Liver. G Baumgartner, A Stiehl, and W Gerok, Editors. MTP Press Ltd., Ch. 9, pp. 61-63, 1987.

8. Everson GT. Disorders of motility of the biliary system. In Principles and Practice of Gastroenterology and Hepatology. G Gitnick, Editor. John Elsevier, pp. 872-893, 1988.

9. Everson GT. Liver and biliary tract disease. In Current Medical Therapy, Second Edition. R Schrier, Editor. Raven Press, New York, pp. 303-323, 1989.

54

10. Everson GT. Characteristics of hepatic cysts. In Advances in the Pathogenesis of Polycystic Kidney Disease. Carone and JW Dobbie, editors. Baxter Healthcare Corporation/TP&T, Inc., Chicago, IL, pp. 77-78, 1990.

11. Everson GT. Section of: Diseases of the biliary tree. In Decision Making in Gastroen-terology. JS Levine, Editor. JS Levine, Editor. BC Decker, Inc., Toronto, 2nd Edition, pp. 318-341, 1992. Chapters include: Cholelithiasis: Ultrasonography vs. oral cholecystography, Asymptomatic cholelithiasis, Symptomatic cholelithiasis, Acute cholecystitis, Postcholecystectomy syndrome, Retained common duct stones, Acute cholangitis, Sclerosing cholangitis, Cancer of the gallbladder and bile ducts, Biliary stricture, Cystic lesions of the liver, Cystic lesions of the extrahepatic biliary tree.

12. Everson GT. Diseases of the liver. In Decision Making in Gastroenterology JS Levine, Editor. BC Decker, Inc., Toronto, 2nd Edition, pp. 414-475, 1992. Chapters included: Surgical risk in the patient with liver disease, Acute viral hepatitis, Viral hepatitis during Pregnancy, Chronic hepatitis: diagnosis, Chronic hepatitis: therapy, hepatoxic drug reactions, Fulminant hepatic failure, Granulomatous hepatitis, Hepatic consequences of circulatory failure, Fatty liver (Steatosis), Alcoholic liver disease, Primary biliary cirrhosis, Ascites in liver disease, Hepatic encephalopathy, Coagulopathy in liver disease, Hepatorenal syndrome, spontaneous bacterial peritonitis, Variceal hemorrhage, Hemochromatosis, Wilson's disease, Alpha1-antitrypsin deficiency, The Porphyrias, Congenital hyperbilirubinemias, Hepatic vein thrombosis, Portal vein thrombosis, Hepatic abscess, Benign hepatic tumors, Hepatocellular carcinoma, Hepatocellular carcinoma, Hepatic transplantation: selection of patients, Hepatic transplantation: postoperative management, Hepatic transplantation: abnormal liver tests post-transplantation.

13. Everson GT. Disorders of motility of the biliary system. In Principles and Practice of Gastroenterology and Hepatology, Editor Gary Gitnick, Daniel Hollander, I. Michael Samloff, Leslie Schoenfield, and John M. Vierling, 2nd Edition, pp 873-893.

14. Everson GT, Kam I. Liver Transplantation: Current Status and Controversies. In Advances in Internal Medicine, Editor Robert Schrier, vol. 42, pp. 505-553.

15. Bilir BM, Everson GT. Liver Transplantation. In GI/Liver Secrets, Editor Peter R. McNally; Pub: Hanley & Belfus, Inc: Philadelphia; 1996, pp. 187-196.

16. Shrestha R, Everson GT. Gallbladder Disease. In GI/Liver Secrets, Editor Peter R. McNally; Pub. Hanley & Belfus, Inc: Philadelphia; 1996, pp. 237-245.

17. Everson GT, Shrestha R,: Hepatic Encephalopathy, Editor Lawrence Brandt; Pub. Current Medicine: Philadelphia; 1997, pp 14-29.

18. Everson GT, Shrestha R. Management of Fibrocystic Disease of the Liver. Medical Management of Liver Disease. Ed. Krawitt, Marcel Dekker, Inc., 1999, chapter 32, pp 445-462.

19. Everson GT, Shrestha R. Cystic Disorders of the Liver and Biliary Tree. Diseases of the Liver. Ed. Bisceglie, Bacon. 1999.

20. Kam I, Everson T, Trouillot, Wachs M. Post-operative care: Immediate, Lippincott,

55

Williams and Wilkins. Transplantation of the Liver. Submitted June, 1999.

21. Sandhu I, Jarvis C, Everson GT. Total Parenteral Nutrition and Cholestasis. Clinics in Liver Disease, August 1999: 3:3; 489-508.

22. Everson GT. Management of Hepatic Failure, Upper Gastrointestinal Bleeding, and Lower Gastrointestinal Bleeding in the Intensive Care Unit. Editors David J. Dries, M.S.E., M.D., FCCP, FCCM, Richard K. Albert, M.D., F.C.O.P., Society of Critical Care Medicine and American College of Chest Physicians. ACCP-SCCM Combined Critical Care Course, August, 1999. ISBN 0-916609-16-2.

23. Everson GT, Shrestha R. Hepatic Encephalopathy. Clinical Practice of Gastroenterology. Ed Brandt. Pennsylvania: Current Medicine, Inc. Vol. 2 999-1009, 1999.

24. Everson GT, Kam I. Postoperative Care: Immediate. Transplantation of the Liver, Maddrey, Sorrell and Shiff editors. In Press, September, 2000.

25. Everson GT. Biliary and Cholestatic Diseases. Comprehensive Clinical Hepatology, In Press, May 2000.

26. Trotter J, Everson GT. Benign Focal Lesions of the Liver. Clinics in Liver Disease. Ed. Gaitlin and DiBisceglie. Philadelphia, WB Saunders Company, February 2001;5(1): 17- 42.

27. Everson GT, Kam I. Immediate Postoperative Care. Transplantation of the Liver, 3rd

Edition. Ed. Maddrey, Schiff, Sorrell. Philadelphia: Lippincott Williams & Wilkins. 2001. Chapter 10: 131-162.

28. Everson GT. Maintenance Immunosuppression for Liver Transplantation. Primer on Transplantation. Ed. Norman and Turka. New Jersey: American Society of Transplantation. 2001. Section VII, 591-596.

29. Everson GT. Natural History of Hepatitis C. Clinical Gastroenterology Diagnosis and Therapeutics, Chapter 4:9-94, August, 2001.

30. Everson GT. Upper Gastrointestinal Bleeding, Lower Gastrointestinal Bleeding, and Hepatic Failure. Ed. Wilhite. Illinois: Society of Critical Care Medicine/American College of Chest Physicians. 2002. Chapter, 327- 342; Combined Critical Care Course, 2002.

31. Everson GT. Treatment Options for Those whose Initial treatment Failed to Clear the Hepatitis C Virus. Hepatitis C Choices. Ed. Sandt and St. John. Hepatitis C Caring Ambassadors Program. 2002: Chapter 8:104-114.

32. Everson GT. Natural History of Hepatitis C. Chronic Viral Hepatitis: Diagnosis and Therapeutics. Ed. Koff and Wu. New Jersey: Humana Press. 2002, Chapter 4: 59-94.

33. Everson GT, Trotter JF. Transplantation of the Liver. Disease of the Liver, Volume 2. Ed. Schiff, Sorrell, Maddrey. Pennsylvania: Lippincott, Williams, & Wilkins. 2003. Chapter 62:15851614.

56

34. Everson GT. Upper Gastrointestinal Bleeding, Lower Gastrointestinal Bleeding, and Hepatic Failure, Chapter, 289-302; American College of Chest Physicians, Critical Care Board Review Course, 2003.

35. Everson GT. Upper Gastrointestinal Bleeding, Lower Gastrointestinal Bleeding, and Hepatic Failure, Chapter, American College of Chest Physicians, Critical Care Board Review Course, 2004.

36. Everson GT, Membreno F. Biliary Diseases, Gallstones and Cystic Disease, Chapter 28:435-450; Comprehensive Clinical Hepatology, 2nd Edition. Ed. Bacon, O’Grady, DiBisceglie, Lake. Elsevier Mosby. Section IV: Chapter 28: 435-451 July 2005.

37. Everson GT. Upper Gastrointestinal Bleeding, Lower Gastrointestinal Bleeding, and Hepatic Failure, Chapter, 315-328; American College of Chest Physicians, Critical Care Board Review Course, Northbrook, IL USA copyright 2005.

38. Everson GT. Hepatic Encephalopathy. Textbook of Critical Care, Fifth Edition. Ed. Fink, Abraham, Vincent, Kochnek. Pennsylvania: Elsevier Saunders. 2005. Chapter 119: 991-1002.

39. Everson GT. Treatment of Hepatitis C in Patients who have Decompensated Cirrhosis. Clinics in Liver Disease. Ed. Keeffe, Gitlin. Pennsylvania: Elsevier Saunders. 2005. Volume 9, number 3:473-486.

40. Everson GT, Membreno FE. Liver Transplantation: Indications, Contraindications and Results. Chapter 25.2; Textbook of Hepatology: From Basic Science to Clinical Practice, 2006.

41. Doctor RB, Nash Sr, Nichols MT, Everson GT. Fibrocystic Diesaeses of the Liver. Zakim and Boyer’s Hepatology: A Textbook of Liver Disease, 5 th Edition. Ed. Boyer, Wright, Manns. Pennsylvania: Elsevier Saunders. 2006. Chapter 70:1329-1353.

42. Everson GT. Treatment of Chronic Hepatitis C in Patients with Cirrhosis. Hot Topics in Viral Hepatitis. Difficult-to-treat patients with chronic hepatitis C (part two), Editor-in-chief: Francesco Negro. Italy: FB Communications. 2006. Pages 13-18.

43. Everson GT. Upper Gastrointestinal Bleeding, Lower Gastrointestinal Bleeding, and Hepatic Failure, Chapter, 159-172; American College of Chest Physicians, Critical Care Board Review Course, Northbrook, IL USA copyright 2006.

44. Everson GT. Treatment of Patients with Compensated and Decompensated Cirrhosis, Chaper. In 100 Key Questions on Hepatitis C. Spain: Permanyer Publications, copyright 2008, pages 55-67.

45. Everson, GT. HCV in patients with advanced disease: do you treat them and do you have any caveats? Clinical Dilemmas in Viral Liver Disease, Ed. Foster, Reddy. Blackwell Publishing, Ltd. 2010. Chapter 25: 115-122.

BOOKS1. Everson GT, Weinberg H. Living with Hepatitis C: A Survivor’s Guide. Pub:

57

Hatherleigh Press, Inc., New York, NY, 1998.

2. Everson GT, Weinberg H. Living with Hepatitis C: A Survivor’s Guide, 2nd Edition. Pub: Hatherleigh Press, Inc., New York, NY 1999.

3. Weinberg, H, Shump S, Everson GT. My Mom Has Hepatitis C. Pub: Hatherleigh Press, Inc. New York, NY, 2000.

4. Everson GT, Weinberg H. Living with Hepatitis B: S Survivor’s Guide. Pub: Hatherleigh Press, Inc. New York, NY, 2001.

5. Everson GT, Weinberg H. Living with Hemochromatosis, Expert Answers to Your Questions About Iron Overload. Pub: Hatherleigh Press, Inc. New York, NY, 2003.

6. Everson GT, Weinberg H. Living with Hepatitis C: A Survivor’s Guide, 3 rd Edition. Pub: Hatherleigh Press, Inc., New York, NY 2002.

7. Everson GT, Weinberg H. Living with Hepatitis C: A Survivor’s Guide, 4th Edition. Pub: Hatherleigh Press, Inc., New York, NY 2006.

8. Everson GT, Trotter JF-Editors. Liver Transplantation. Challenging Controversies and Topics. Humana Press, Totowa, NJ, 2009.

9. Everson GT, Weinberg H. Living with Hepatitis C: A Survivor’s Guide, 5 th edition. Hatherleigh Press, Inc., Long Island City, NY 2009.

10. Positive organ donor: risks, benefits and strategies. Continuing Medical Education Newsletter, Release date 1/5/08. University of Kentucky Colleges of Pharmacy and Medicine and CTI Clinical Trial and Consulting Services, Publishers.

11. Everson GT, Pruett TL - Faculty Editors. Utilization of Hepatitis B core antibody positive organ donor: risks, benefits and strategies. Continuing Medical Education Newsletter, Release date 11/9/09. University of Kentucky Colleges of Pharmacy and Medicine and CTI Clinical Trial and Consulting Services, Publishers.

ABSTRACTS1. Everson GT, Kern F Jr. Validation and comparison of two methods for measuring rate

constants of gallbladder emptying in control and pregnant subjects. Clin Res, 28(2):275A, 1980.

2. Everson GT, Johnson M, Kern F Jr. Gallbladder function in pregnancy: Increased retention of bile from 8 am until midnight. Gastroenterology, 78(5 Pt 2):1162, 1980.

3. Everson GT, McKinley C, Showalter R, Johnson M, DeMark B, Szczepanik-Van-Leeuwen P, Klein P, Kern F. Bile acid (BA) kinetics and gallbladder (GB) function in pregnancy: The apparent regulatory role of the gallbladder. Gastroenterology, 78(5 Pt 2):1162, 1980.

4. Kern F, DeMark B, Szczepanik-VanLeeuwen P, Everson GT, Braverman D, McKinley C, Showalter R, Klein P. Effects of contraceptive steroids (CS) on biliary lipids and bile acid (BA) kinetics. Clin Res, 28(2):545A, 1980.

58

5. Everson GT, Kern F Jr, McKinley C, Showalter R, DeMark B, Szczepanik-Van-Leeuwen P, Klein P. A new technique for measuring storage and concentration of bile acid in the gallbladder in intact subjects. Gastroenterology, 80(5 Pt 2):1144, 1981.

6. Everson GT, DeMark B, Klein P, Showalter R, McKinley C, Kern F Jr. Measurement of cholic acid (CA) kinetics with 13C-CA using serum: Validation of method. Gastro-enterology, 80(5 Pt 2):1144, 1981.

7. Everson GT, Lawson M, McKinley C, Showalter R, Kern F Jr. Differential effects of liquid formula (F) and amino acid (AA) solutions on gallbladder (GB) emptying, small bowel transit and biliary lipid secretion. Gastroenterology, 80(5 Pt 2):1145, 1981.

8. Everson GT, Hachey D, Klein P, Showalter R, McKinley C, Kern F Jr. Simultaneous serum and biliary henodeoxycholic (CDC) kinetics using 13C-CDC. Gastroenterology, 82(5 Pt 2):1051, 1982.

9. Everson GT, Lawson M, McKinley C, Kern F Jr. Diminished gallbladder (GB) concentrating ability in benign recurrent intrahepatic cholestasis (BRIC): A possible clue to the underlying defect. Gastroenterology, 82(5 Pt 2):1051, 1982.

10. Lawson M, Everson GT, McKinley C, Konterski E, Klingensmith W, Taylor I, Kern F Jr. Relations of gastric emptying, gallbladder (GB) emptying and refilling, gastrointestinal transit (GIT) and serum pancreatic polypeptide (PP). Clin Res, 30(1):36A, 1982.

11. Lawson M, Everson GT, McKinley C, Konterski E, Klingensmith W, Taylor I, Kern F Jr. Relations of gastric emptying, gallbladder (GB) emptying and refilling, gastrointestinal transit (GIT) and serum pancreatic polypeptide (PP). Gastroenterology, 82(5 Pt 2):1112, 1982.

12. Everson GT, Lawson M, McKinley C, Kern F Jr. Small bowel transit time (SBTT) in pregnancy. Clin Res, 31(1):30A, 1983.

13. Everson GT, Lawson M, McKinley C, Kern F Jr. Small bowel transit time (SBTT) in pregnancy. Gastroenterology, 84(5 Pt 2):1146, 1983.

14. Everson GT. Failure of short-term intravenous S-adenosylmethionine (SAMe) to reverse cholestasis in benign recurrent intrahepatic cholestasis (BRIC). Clin Res, 32(1):75A, 1984.

15. Everson GT. Steady-state chenodeoxycholic (CDCA) turnover (FTR) measured from a single serum sample: Evaluation of a double stable isotope technique. Clin Res, 32(1):75A, 1984.

16. Everson GT, Fennessey P. A significant advance in the measurement of cheno-deoxycholic acid (CDCA) kinetics in healthy man: A double label stable isotope technique using serum. Gastroenterology, 86(5 Pt 2):1071, 1984.

17. Everson GT, Fausel C, Lawson M, Kern F Jr. Chronic premarin administration does not alter gallbladder function, bile acid kinetics, or biliary lipid secretion in postmenopausal women. Hepatology, 4(5):1069, 1984.

59

18. Everson GT, Polokoff M. Quantitation of bile acid synthesis in hybridomas by gas chromatography/mass spectrometry/stable isotope radiometry (GC/MS/IR): Suppression of cholic acid synthesis by dexamethasone plus insulin. Hepatology, 4(5):1066, 1984.

19. Everson GT, Krawitt E. S-adenosylmethionine (SAMe) may be deleterious in familial forms of Intrahepatic cholestasis (FIC). Hepatology, 4(5):1066, 1984.

20. Everson GT, Miles B, Farrell R. Oral contraceptive steroids (CS) depress the synthesis of chenodeoxycholic acid (CDCA) in healthy women. Gastroenterology, 88(5 Pt 2):1657, 1985.

21. Everson GT, Polokoff M, Nemeth A. Bile acid synthesis in the human hepatoma cell line, HepG2: Studies of the conversion of deuterium-labeled and isomers of 7-OH cholesterol to chenodeoxycholic (CDCA) and cholic acid (CA). Gastroenterology, 88(5 Pt 2):1657, 1985.

22. Everson GT, Polokoff MA. HepG2: A cell line exhibiting defects in bile acid synthesis. Hepatology, 5(5):1022, 1985.

23. Kern F Jr, Everson GT, Showalter R, McKinley C, Fausel C. Contraceptive steroids (CS) alter the regulatory mechanisms of cholesterol homeostasis and biliary lipid secretion in healthy young women. Gastroenterology, 88(5 Pt 2):1670, 1985.

24. Everson GT, Nemeth A, Kourieran. A facile method for measuring carbon monoxide (CO) production rates in intact man. Clin Res, 34(1):28A, 1986.

25. Everson GT, Polokoff M. Effect of dexamethasone on bile acid synthesis by cultured cells: Studies of rat hepatocyte X rat hepatoma hybrids. Clin Res, 34(1):28A, 1986.

26. Everson GT, Polokoff MA. HepG2: A cell line exhibiting defects in bile acid synthesis. Clin Res, 34(1):29A, 1986.

27. Everson GT, Polokoff MA. Effect of dexamethasone on bile acid synthesis by cultured cells: Studies of rat hepatocyte X rat hepatoma hybrids. Gastroenterology, 90(1 Pt 2):1724, 1986.

28. Everson GT, Nemeth A, Kourourian S. A method for measuring carbon monoxide (CO) production rates in intact man. Gastroenterology, 90(1 Pt 2):1724, 1986.

29. Stiegmann GV, Everson GT, Sun J. Variceal size appears independent of shunt fraction in a canine esophageal varices model. Hepatology, 6(5):1138, 1986.

30. Kern F Jr, Everson GT. Chronic premarin administration increases biliary cholesterol (CH) secretion and decreases chenodeoxycholic acid (CDCA) pool and synthesis. Gastroenterology, 90(5 Pt 2):1738, 1986.

31. Everson GT, Morse L, Stiegmann G, Schmelter R. Determination of nutrient portal shunt fraction using stable isotope labeled-bile acids: Validation studies. Clin Res, 35(1):184A, 1987.

60

32. Everson GT, Scherzinger A, Berger-Leff N, Manco-Johnson M, Gabow P. Polycystic liver disease (PKD): Validation of a method for measuring liver and cyst volume. Clin Res, 35(1):184A, 1987.

33. Everson GT, Leff N, Dixon D, Githens J, Pretorius D, Manco-Johnson M. Gallbladder function is altered in sickle hemoglobinopathies (SH): Potential role in gallstone formation. Gastroenterology, 92:1731, 1987.

34. Everson GT, Fennessey P, Kern F Jr. Contraceptive steroids alter the steady-state kinetics of bile acids. Hepatology, 7(5):1109, 1987.

35. Everson GT, Scherzinger A, Leff N, Lee E, Seibert J, Manco-Johnson M. Liver cell, liver cyst and kidney volumes in subjects with autosomal dominant polycystic kidney disease with liver cysts (ADPKD + LC). Hepatology, 7(5):1100, 1987.

36. Everson GT, Fennessey P, Kern F Jr. Contraceptive steroids alter the steady-state kinetics of bile acids. Presented at Aspen Conference on Hepatic Lipoprotein and Cholesterol Metabolism, 1987.

37. Kern F, Everson GT. Mechanisms of effects of contraceptive steroids (CS) on biliary cholesterol secretion. Gastroenterology, 92:1743, May 1987.

38. Junker L, Straka M, Zogg D, Everson GT, Davis R. Regulation of rat liver cholesterol 7-alpha hydroxylase by microsomal free cholesterol. Hepatology, 7(5):1108, 1987.

39. Junker L, Straka MS, Zogg DL, Everson GT, Davis RA. Regulation of cholesterol 7-alpha hydroxylase by microsomal free cholesterol. Presented at Aspen Conference on Hepatic Lipoprotein and Cholesterol Metabolism, 1987.

40. Everson GT, Leff N, Zogg D, Reichen J, Gabow P. Polycystic liver disease: Quantitative assessment of hepatic and cyst function. Gastroenterology, 94(5 Pt 2):A538, 1988.

41. Everson GT, Kern F Jr. Mechanisms of gallstone formation in post-menopausal women taking conjugated estrogens (Premarin). Gastroenterology, 94:A538, 1988.

42. Everson GT, Leff N, Brown WR, Emmett M. Characteristics of hepatic cysts in autosomal dominant polycystic kidney disease (ADPKD). Hepatology, 8(5):1341, 1988.

43. Kern F Jr, Everson GT. Female sex steroid hormones and the pathogenesis of cholesterol gallstones. Gastroenterology, 94(5 Pt 2):A554, 1988.

44. Kern F Jr, Everson GT. The effects of female sex steroid hormones on cholesterol and bile acid metabolism. Presented at the Bengt Borgstrom Symposium, Falsterbo, Sweden, May/June 1988.

45. Everson GT, Butler E, Trombley C. Effects of female steroid hormones on bile acid synthesis by HepG2 cells. Clin Res, 37(1):111A, 1989.

61

46. Everson GT, McKinley C, Showalter R, Kern F Jr. Influence of dietary cholesterol on biliary lipid metabolism in women taking conjugated estrogens. Clin Res, 37(1):111A, 1989.

47. Everson GT, McKinley C, Showalter R, Kern F Jr. Influence of dietary cholesterol on biliary lipid metabolism in women taking either conjugated estrogens (PremarinR) or medroxyprogesterone (ProveraR). Gastroenterology, 96(5 Pt 2):A596, 1989.

48. Everson GT, Johnson A, Kaehny W, Duley I, Manco-Johnson M, Gabow P. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease (ADPKD). Gastroenterology, 96(5 Pt 2):A144, 1989.

49. Zaccaro L, Sutherland E, Iwahashi M, Burnett R, Everson GT. Acute cholestasis with taurolithocholate is due to direct reversible non-competitive inhibition of sodium-dependent taurocholate uptake. Gastroenterology, 6(2):A675, May 1989.

50. Rector WG, DeRoche G, Everson GT. The relationship of portal-systemic shunting and liver function to sodium retention in patients with alcoholic liver disease. Hepatology, 10(4):587, 1989.

51. Everson GT. Bile acid synthesis by HepG2 is regulated by insulin and dexamethasone. Gastroenterology, 98(5 Pt 2):A585, May 1990.

52. Everson GT, Malik R, McKinley C. Effects of synthetic progestin (norethindrone) on the enterohepatic circulation and metabolism of bile acids. Hepatology, 12(4):1005, 1990.

53. Everson GT, Valdivieso V, Covarrubias C, Espinosa R, Trombley C, Smith P. Intrahepatic cholestasis of pregnancy: Effects on bile acid metabolism. Hepatology, 12(4 Pt 2):898, 1990.

54. Lewis F, Everson GT, White C, Adair O, Hossack K, Rector W. Plasma glucagon concentration is related to liver function but not portal-systemic shunting, systemic vascular resistance or urinary sodium excretion in patients with cirrhosis. Hepatology, 12(4):855, 1990.

55. Everson GT, Ahnen D, Harper PC, Krawitt EL. Benign recurrent intrahepatic cholestasis: Failure of S-adenosylmethionine therapy. Hepatology Elsewhere, 12(2):367, Aug 1990.

56. Everson GT, Malik R, McKinley C. Effects of synthetic progestin (norethindrone) on gallbladder motility, intestinal transit, and the kinetics of bile acids. Clin Res, 36(1):95A, 1991.

57. Everson GT, Malik R, McKinley C. Effects of norethindrone on bile acid metabolism in healthy subjects and subjects post-cholecystectomy. Gastroenterology, 100:A739, May 1991.

58. Everson GT, Daggy BP, McKinley C, Story JA. Study of mechanisms of the hypocholesterolemic effect of psyllium in man. Circulation, 84(4 Suppl): II601, Oct 1991.

62

59. Everson GT, Daggy BP, McKinley C, Story JA. Dietary fiber (psyllium) lowers LDL cholesterol by stimulating bile acid synthesis in man. Hepatology, 14(4 Pt 2):148A, 1991.

60. Pinto PC, Everson GT, Rector WG Jr. Does progressive reduction in hepatic metabolic capacity signal sodium retention in alcoholic cirrhosis? Hepatology, 14(4 Pt 2):86A, 1991.

61. Suleymanlar I, Suleymanlar G, Chan L, Everson GT, Karrer F, Schroter G, Kam I. Early postoperative renal failure predicts survival after orthotopic liver transplantation (OLTX). Hepatology, 14(4 Pt 2):288A, 1991.

62. Everson GT, Butler E, Showalter R, Trombley C. Glucocorticoid regulation of human bile acid metabolism. Clin Res, 40(1):27A, 1992.

63. Lindsey KL, Davis GL, Schiff E, Bodenheimer H, Balart L, Dienstag R, Perrillo R, Goff J, Everson GT, Tamburro C, Albrecht J, Sanghvi B. Long-term Response to Higher Doses of Interferon (IFN) Alfa- 2b Treatment of Patients with Chronic Hepatitis C: A Randomized Multicenter Trial. Hepatology, 18(4 Pt 2):106, 1993.

64. Everson GT, Lezotte DL, Clark A, Kam I. Biochemical Profile in The First 21 Days After Hepatic Transplantation: The Uncomplicated Course. Hepatology, 18(4 Pt 2):329, 1993.

65. Everson GT, McKinley C, Kam I. Quantitative Tests (QLFT) of Hepatic Function: Assessment of Patients Prior to Hepatic Transplantation (OLTx). Hepatology, 18(4 Pt 2):330, 1993.

66. Everson GT, McKinley C, Showalter R, Shrestha R, Mills M. Characterizatio of Hepatic Lipid Metabolism in Obese Subjects Entering a Weight Loss Treatment Program. Hepatology, 18(4 Pt 2):310, 1993.

67. Stegall M, Everson GT, Karrer F, Schroter G, Kam I. Metabolic Complications After Liver Transplantation: Diabetes and Hypercholesterolemia. ASTS Meeting, 1994.

68. Slater J, Chan L, Kam I, Schroter G, Karrer F, Bilir B, Howell C, Coll J, Everson GT. Predictors of Dialysis in Liver Transplantation. ASTS Meeting, 1994.

69. Slater J, Chan L, Kam I, Schroter G, Karrer F, Bilir B, Howell C, Coll J, Everson GT. Renal Failure and Dialysis as Predictors of Outcome in Liver Transplant Patients. ASTS Meeting, 1994.

70. Everson GT, Stegall M, Karrer F, Schroter G, Howell C, Bilir B, Kam I., The Clinical Characteristics of Adult Patients Who Develop Hypercholesterolemia After Liver Transplantation. ASTS Meeting, 1994.

71. Everson GT, McKinley C, Mills M, Cippola T, Showalter R, Peterson F. The Metabolic Basis for Cholesterol Gallstone Formation In Obese Women During Weight Loss. Clinical Research, 42(1):75A, 1994.

63

72. Shrestha R, McKinley C, Russ P, Scherzinger A, Bonner R, Showalter R, Everson GT. Estrogens Inhibit the Metabolism of Antipyrine in Postmenopausal Women with Autosomal Dominant Polycystic Disease (ADPD). Clinical Research, 42(1):75A, 1994.

73. Everson GT, Shrestha R, McKinley C, Smith P. Complete Response to Interferon is Associated with Improvement in Hepatic Function. Gastroenterology, 106(4):A889, 1994.

74. Shrestha R, McKinley C, Russ, P, Scherzinger A, Bonner R, Showalter R, Everson G. Estrogens Inhibit the Metabolism of Antipyrine in Postmenopausal Women with Autosomal Dominant Polycystic Disease (ADPD). Gastroenterology, 106(4):A985, 1994.

75. Mills MR, Butler E, Trombley C, Everson GT. Characterization of Insulin-Induced Inhibition of Bile Acid Synthesis by Cultured Human Hepatoblastoma Cells (Hep G2). Gastroenterology, 106(4):A943, 1994.

76. Everson GT, McKinley C, Mills M, Cippola T, Showalter R, Peterson F. Weight Loss in Obese Women Markedly Inhibits Bile Acid Synthesis. The Metabolic Basis for Cholesterol Gallstone Formation? Gastroenterology, 106(4):A889, 1994.

77. Everson GT, Cippola T, McKinley C, Showalter R. Hepatic Lipid Metabolism During Severe Cholestasis: Lessons Learned from the Comprehensive Study of a Single Patient. Gastroenterology, 106(4):A877, 1994.

78. Lindsay KL, Spencer G, Nicoloff J, Milestein S, Davis GL, Schiff E, Bodenheimer H, Balart L, Dienstag J, Perrillo R, Tamburro C, Everson GT, Sanghvi B, Albrecht J. Thyroid Peroxidase Antibody-A Potential Predictor of IFN-Associated Thyroid Disease. Hepatology, 20 (4 Pt.2):168A, October 1994.

79. Everson GT, Bilir BM, Kam I, Karrer F, Mandell S, Katz J, Stegall M, Schroter G, Steinberg T. Influence of Age on Patient Outcome and Graft Survival After Liver Transplantation. Hepatology, 20 (4 Pt. 2):346A, October, 1994.

80. Shrestha R, McKinley C, Showalter R, Everson GT. Quantitative Liver Function Tests (QLFTs) Define the Functional Severity of Liver Disease In Early Stage Cirrhosis. Hepatology, 20 (4 Pt. 2):119A, October 1994.

81. Shrestha R, Bilir BM, Steinberg SE, Lee RE, Showalter RB, Kumpe DA, Everson GT. CA 19-9 Is A Constituent of Normal Human Bile and Its Biliary Concentration Does Not Correlate With Hepatobiliary Malignancy. Hepatology, 20 (4 Pt. 2):399A, October 1994.

82. Lawrence SP, Lezotte DC, Durham JD, Everson GT, Bilir BM. The Course of Thrombocytopenia of Cirrhosis After Transjugular Intrahepatic Portosystemic Shunts. Hepatology, 20 (4 Pt. 2):368A, October 1994.

83. Sokol RJ, McKim JM, Devereaux MW, Everson GT. Vitamin E Reduces Oxidant Injury to Hepatic Mitochondria Caused by Intravenous Taurochenodeoxycholic Acid in the Rat. Hepatology, 20 (4 Pt. 2):178A, October 1994.

64

84. Lee WM, Everson GT. Hepatitis Study Group. Does Hepatitis C Viral (HCV) Genotype or Initial HCV RNA Titer Predict Induction of Response to Interferon Alfa 2a in Chronic Hepatitis C? Hepatology 1995; 22(4):176A.

85. Bilir BM, Durham JD, Kumpe DA, Karrer F, Hanks T, Ostrowska A, Kam I, Trujillo N, Lear J, Trouillot T, Shrestha R, Everson GT. Critical Analysis of Intra-Splenic Transplantation of Cryopreserved Human Hepatocytes in a Patient with Acute Liver Failure. Hepatology 1995; 22(4):203A.

86. Katz JJ, Mandell MS, Barton B, House RM, Bilir BM, Everson GT, Zamudio S. Preservation of CO2-Dependent Regulation of Cerebral Arterial Blood Flow Velocity in End Stage Liver Disease. Hepatology 1995; 22(4):260A.

87. Bennet J, Bilir BM, Shrestha R, Kam I, Stegall M, Karrer F, Katz J, Mandell S, Everson GT. Recovery from Central Pontine Myelinolysis in Patients with Hepatic Failure and Orthotopic Liver Transplantation. Hepatology 1995; 22(4):394A.

88. Trouillot T, McKinley C, Showalter R, Everson GT. The Effect of Gender on Gallbladder Motility in Obese and Non-Obese Subjects. Hepatology 1995; 22(4):502A.

89. Shrestha R, Durham JD, Kumpe DA, Bilir BM, DeRoche G, Showalter R, Rector W, Everson GT. Outcome after Transjugular Intrahepatic Portal-Systemic Shunt for Refractory Ascites in Patients with Advanced Cirrhosis. Hepatology 1995; 2(4):165A.

90. Shrestha R, Bilir BM, Everson GT, Steinberg SE. Endoscopic Stenting of Gallbladder for Symptomatic Cholelithiasis in Patients with End Stage Liver Disease Awaiting Orthotopic Liver Transplantation. Hepatology 1995; 22(4):490A.

91. Gordon SC, Everson GT, McHutchison JG, Reinus J, Regenstein F, Kaplan MM, Koff RS, Fedorczyk D , Plasse T. Natural Alfa Interferon (Alferon N) Treatment of Chronic Hepatitis C in Patients Refractory to Recombinant Interferon Alfa 2B. Hepatology 1995; 22(4):117A.

92. Simon DM, Gordon SC, Kaplan MM, Koff RS, Regenstein F, Everson GT, Weiner F, Plasse T, Fedorczyk D, Einstein A. Natural Alfa Interferon (Alferon N) Treatment of Chronic Hepatitis C in Previously Untreated Patients. Hepatology 1995; 22(4):151A.

93. Hollinger FB, Tong MJ, Reddy KR, Lee WM, Pockros PJ, Heols JC, Keeffe E, Heathcote JL, White H, Foust RT, Hensen DM, Krawitt EL, Fromm H, Black M, Klein M, Lubina J, Manyak C, Blatt LM, and the Consensus Interferon Study Group*, Baylor College of Medicine, The Consensus Interferon Study Sites and Amgen Inc. A Phase 3 Study for the Treatment of Patients with Chronic Hepatitis C (HCV) Infection with Consensus Interferon(CIFN).Hepatology Meeting, Rome, Italy.

94. Wilner KD, Foulds GH, Hansen RA, Everson GT, McClain CJ. Multiple Dose Pharmacokinetics of Sertraline in Subjects with Varying Degrees of Hepatic Impairment. CINP Meeting, Melbourne, Australia, June 1996.

95. Bharadhwaj G, Everson GT, Bilir B, Shrestha R, Kam I, Karrer F, Wachs M, Stegall M, Schroter G, Steinberg T, Ford C, Beresford T. Relapse to Alcohol Consumption in

65

Liver Transplant Recipients Followed for More Than One Year: Early Analysis of a Comprehensive Psychosocial Evaluation. American Society of Transplant Physicians Meeting, May 1996.

96. Trouillot T, Stegall M, Bilir B, Shrestha R, Kam I, Schroter G, Karrer F, Wachs M, Ford C, Steinberg T, Everson GT. Successful Steroid Withdrawal after Orthotopic Liver Transplantation in Patients with Autoimmune Chronic Active Hepatitis. American Society of Transplant Physicians Meeting, May 1996.

97. Taylor S, Shrestha R, Bilir B, Wachs M, Karrer F, Kam I, Stegall M, Ford C, Steinberg T, Schroter G, Everson GT. Internalized Biliary Stenting Reduces the Incidence of Biliary Tract Complications after Liver Transplantation. American Society of Transplant Physicians Meeting, May 1996.

98. Shrestha R, Durham JD, Kumpe DA, Bilir BM, DeRoche G, Showalter R, Rector W, Everson GT. Outcome after transjugular intrahepatic portal-systemic shunt for refractory ascites in patients with advanced cirrhosis. AASLD Single Topic Symposium Conference, Reston, VA, June 1996.

99. Stegall MD, Everson GT, Wachs M, Schroter G, Karrer F, Bilir B, Shrestha R, Kam I. Prednisone withdrawal 14 days after adult liver transplantation with mycophenolate mofetil (MM). Hepatology 1996; 24(4):174A.

100. Pockros PJ, Tong MJ, Lee WM, Van Leeuwen DJ, Keeffe E, Bala K, Killenberg PG, Foust RT, Rosenblate HJ, Payne KM, Fromm H, Lesesne HR, Black M, Snyder R, Gerrard T, Conrad A, Blatt LM, and the Consensus Interferon Study Group*. Relationship between biochemical and virological response to type 1 interferon therapy of chronic HCV infection. Hepatology 1996; 24(4): 155A.

101. Bilir B, Durham JD, Krystal J, Karrer F, Kumpe D, Ostrowska A, Guenette D, Trouillot T, Shrestha R, Taylor S, Kam I, Everson GT. Transjugular intra-portal transplantation of cryopreserved human hepatocytes in a patient with acute liver failure. Hepatology 1996; 24(4):308A.

102. Bharadwaj G, Everson GT, Bilir B, Shrestha R, Kam I, Karrer F, Wachs M, Stegall M, Schroter G, Steinberg T, Ford C, Beresford T. Relapse to alcohol consumption in liver transplant recipients followed for more than one year: early analysis of a comprehensive psychoscocial evaluation. Hepatology 1996; 24(4):244A.

103. Shrestha R, McKinley C, Showalter R, Marsano L, Vivian B, Everson GT. Quantitative liver function tests (QLFTs) define functional severity and predice decompensation of liver disease in early stage cirrhosis. Hepatology 1996; 24(4):300A.

104. Colton J, Chapman A, Everson GT. Augmentation of the diuretic response to furosemide by albumin in cirrhotic patients with ascites. Hepatology 1996; 24(4):446A.

105. Shrestha R, McKinley C, Showalter R, Bilir B, Durham J, Kumpe D, Krysl J, Everson GT. Transjugular intrahepatic portosystemic shunts (TIPS) for ascites: the prognostic and predictive value of quantitative liver function tests (QLFTs). Hepatology 1996; 24(4):449A.

66

106. Sokol RJ, Devereaux MW, Straka MS, Everson GT. Melatonin attenuates hydrophobic bile acid toxicity to isolated rat hepatocytes. Hepatology 1996; 24(4):338A.

107. Jensen DM, Blatt LM, Tong MJ, Lee WM, Mullen K, Hoefs JC, Keeffe E, Hollinger FB, Heathcote EJL, White H, Foust RT, Krawitt EL, Fromm H, Black M, Albert D, Gerrard T, and Consensus Interferon Study Group*. Treatment of high viral titer chronic HCV patients with consensus interferon (CIFN) results in a significantly greater number of sustained HCV RNA responders as compared to treatment with interferon -2b. Hepatology 1996; 24(4):275A.

108. Keeffe E, Blatt LM, Dusheiko G, Tong MJ, Hollinger FB, James S, Mullen K, Everson GT, Pimstone N, Heathcote EJL, Donovan J, Conrad A, Schmid P, Albert D, Gerrard T, and Consensus Interferon Study Group*. Differential response to treatment with consensus interferon (CIFN) and IFN -2b in chronic HCV patients infected with different HCV serotypes. Hepatology 1996; 24)4):275A.

109. Bilir BM, Durham JD, Shrestha R, Karrer FM, Everson GT. Percutaneous hepatocyte transplantation in acute liver failure. J Investigative Med 1997; 45:161A.

110. Trouillot TE, Stegall M, Bilir B, Shrestha R, Kam I, Schroter G, Karrer F, Wachs M, Ford C, Steinberg T, Everson GT. Successful prednisone withdrawal after liver transplantation in patients with autoimmune chronic active hepatitis. 1997 ASTP Program and Abstracts issue, 16 Annual Meeting, 237A.

111. Everson GT, Bharadhwaj G, House R, Talamantes M, Bilir B, Shrestha R, Kam I, Wachs M, Karrer F, Fey B, Ray C, Steinberg T, Morgan C, Beresford T. Liver transplantation for alcoholic liver disease: long-term results. 1997 ASTP Program and Abstracts issue, 16 Annual Meeting, 261A.

112. Shrestha R, Bilir B, Trouillot T, Stegall M, Wachs M, Steinberg T, Morgan C, Kam I, Everson GT. Outcome of liver transplantation in chronic hepatitis B, eAg negative patients using OKT3 induction and maintenance immunosuppression without prednisone. 1997 ASTP Program and Abstracts issue, 16 Annual Meeting

113. Beresford TP, Bharadhwaj G, Everson GT. Alcohol dependent liver graft recipients: a controlled three year follow-up. 1997 ASTP Program and Abstracts issue, 16 Annual Meeting, 262A.

114. Stegall MD, Wachs ME, Kam I, Bilir B, Shrestha R, Karrer F, Everson GT. Prednisone withdrawal 14 days after liver transplantation with mycophenolate : A prospective trial of cyclosporine and tacrolimus. 1997 ASTP Program and Abstracts issue, 16 Annual Meeting, 40A.

115. Craig JR, Bain VG, Ehrinpreis M, Doust R, Lee W, Smith CI, VanLeeuwen DJ, and the Consensus Interferon Study Group*. Liver histology improves in both cirrhotic and non-cirrhotic patients with chronic HCV infection following consensus interferon (CIFN) therapy. Gastroenterology 1997; 112(4):A1248.

116. Jensen D, Shafritz D, Craig JR, Krawitt E, and the CIFN Study Group*. Non-responders to CIFN show clinically relevant improvements in liver histology. Gastroenterology 1997; 112(4):A1294.

67

117. Lee WM, Reddy KR, van Leeuwen DJ, Hollinger FB, and the Consensus Interferon Study Group*. Undetectable HCV RNA concentrations at early time points predict sustained virological responses after treatment with consensus interferon (CIFN). Gastroenterology 1997; 112(4):A1317.

118. Pockros P, Bain V, Hunter E, Conrad A, Balart LA, Hollinger FB, and the Consensus Interferon Study Group*. Rt-PCR and BDNA assays for hepatitis C virus correlate at high but not low viral titers. Gastroenterology 1997; 112(4):A1360.

119. Heathcote J, Keeffe E, Lee S, Feinman S, Tong M, and the Consensus Interferon Study Group*. Retreatment of chronic HCV infection with a higher dose (15 g) of consensus interferon (CIFN) produces sustained responses in non-responders and relapsers. Gastroenterology 1997; 112(4):A1280.

120. Keeffe EB, Hollinger FB, and the Consensus Interferon Study Group*. Consensus interferon trials. Submitted to NIH Consensus Development Conference on the Management of Hepatitis C.

121. Trouillot TE, Stegall M, Bilir B, Shrestha R, Kam I, Schroter G, Karrer F, Wachs M, Ford C, Steinberg T, Everson GT. Successful prednisone withdrawal after liver transplantation in patients with autoimmune chronic active hepatitis. ILTS Meeting, October 1997.

122. Beresford TP, Bharadhwaj G, Everson GT. Alcohol dependent liver graft recipients: a controlled three year follow-up. ILTS Meeting, October 1997.

123. Everson GT, Bharadhwaj G, House R, Talamantes M, Bilir B, Shrestha R, Kam I, Wachs M, Karrer F, Fey B, Ray C, Steinberg T, Morgan C, Beresford T. Liver transplantation for alcoholic liver disease: long-term results. ILTS Meeting, October 1997.

124. Shrestha R, Bilir B, Trouillot T, Stegall M, Wachs M, Steinberg T, Morgan C, Kam I, Everson GT. Outcome of liver transplantation in chronic hepatitis B, eAg negative patients using OKT3 induction and maintenance immunosuppression without prednisone. ILTS Meeting, October 1997.

125. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C, Shiffman M, Zeuzem S, Craxi A, Raffanel C, Reindollar R, Rizzetto M, and the International Hepatitis Interventional Therapy Group (IHIT). Retreatment of relapse after interferon therapy for chronic hepatitis C: An international randomized controlled trial of interferon plus ribavirin vs. interferon alone. Hepatology 1997; 26(4): 247A.

126. Amponsah A, Everson GT, Stephens J, Tannenbaum M, Shrestha R, Trouillot T, Bilir B, Wachs M, Kam I, Steinberg T, Morgan C, Fey B, Ray C, Beresford T. Relapse to drinking after liver transplantation: failure of explant histology to predict relapse. Hepatology 1997; 26(4): 472A.

127. Amponsah A, Shrestha R, Trouillot T, Bilir B, Wachs M, Kam I, Steinberg T, Morgan C, Fey B, Ray C, Everson GT. Do first-week post-transplant plasma levels of cyclosporine (neoral) or tacrolimus predict early rejection within first 30 days?

68

Hepatology 1997; 26(4): 236A.

128. Amponsah A, Everson GT, Stephens J, Tannenbaum M, Shrestha R, Trouillot T, Bilir B, Wachs M, Kam I, Steinberg T, Morgan C, Fey B, Ray C, Beresford T. Correlation of explant histology with pre-transplant alcohol dependence (DSM IV). Hepatology 1997; 26(4): 472A.

129. Trouillot TE, McKinley CL, Showalter RB, Everson GT. Gallbladder motility in obese subjects after diet-induced weight loss relative to gallstone formation. Hepatology 1997; 26(4): 399A.

130. Trouillot TE, Eckel RH, McKinley CL, Showalter RB, Yost TJ, Everson GT. The link between weight loss, gallstones, and insulin action: a pathophysiologic study in humans. Hepatology 1997; 26(4): 399A.

131. Trouillot TE, Eckel RH, McKinley CL, Showalter RB, Yost TJ, Everson GT. Hepatic and total body insulin sensitivities are disassociated in obese subjects after diet-induced weight loss followed by isocaloric weight maintenance. Hepatology 1997; 26(4): 380A.

132. Shrestha R, Wachs M, Kam I, Karrer F, Steinberg T, Morgan C, Bilir B, Trouillot T, Everson GT. Endoscopic management of biliary anastomotic strictures after orthotopic liver transplantation. Hepatology 1997; 26(4): 598A.

133. Bilir BM, Guenette D, Ostrowska A, Durham J, Kumpe D, Krysl J, Shrestha R, Trouillot T, Teitelbaum I, Everson GT. Percutaneous hepatocyte transplantation (PHT) in liver failure. Hepatology 1997; 26(4): 252A.

134. Everson G, Craig JR, Jensen D, van Leeuwen DJ, and the Consensus Interferon Study Group*. Cirrhotic patients demonstrate similar response pattern compared to noncirrhotic patients when treated with consensus interferon. Hepatology 1997; 26(4): 422A.

135. Stephens JK, Everson GT, McCune C, Kam I, Shrestha R, Bilir B, Wachs M, Haney J, Franklin WA. Transmission of fatal malignant melanoma from a single donor to multiple allograft recipients. United States and Canadian Academy of Pathology Conference.

136. Stephens JK, Frost M, Everson GT, Steinberg T, and the University of Colorado Liver Transplant Group. Post-transplant (OLT) liver pathology after rapid steroid withdrawal (14 days): effects of immunosuppression and hepatitis C (HCV). United States and Canadian Academy of Pathology Conference; ILTS Program

137. Sandhu IS, Stephens J, Krysl J, Durham JD, Kumpe DA, Shrestha R, Trouillot TE, Everson GT, Bilir BM. Utility of Transjugular Liver Biopsy Using Liver Access Biopsy Automated Needle. Gastroenterology 1998: 114(4): A1332.

138. Bilir BM, Kumpe D, Krysl J, Guenette D, Ostrowska A, Everson GT, Shrestha R, Lin TC, Cole W, Lear J, Durham JD. Hepatocyte Transplantation (HT) in Patients with Liver Cirrhosis. Gastroenterology 1998; 114(4):A1212.

139. JS Goff, RF Hamman, FS Wamboldt, Everson GT, Shrestha R, Kam I, Wachs M,

69

Lezotte DC, Steinberg T, Talamantes M, Bilir BM. Quality of life after liver transplantation in patients with hepatitis C. Gastroenterology 1998; 114(4):A1247.

140. Shrestha R, Wachs M, Kam I, Bilir B, Trouillot T, Everson GT. Endoscopic stenting of the gallbladder for symptomatic cholelithiasis in patients with end-stage liver disease awaiting orthotopic liver transplantation. American Society of Transplant Physicians Meeting, May, 1998. (Not accepted/not published)

141. Shrestha R, Ryu R, Durham J, Krysl J, Kam I, Wachs M, Bilir B, Trouillot T, Everson GT. Use of transjugular intrahepatic portosystemic shunt as a bridge to transplantation in Budd-Chiari syndrome. Transplantation 1998; 65(12):S54.

142. Shrestha R, Wachs M, Kam I, Karrer F, Steinberg T, Morgan C, Bilir B, Trouillot T, Everson GT. Endoscopic management of biliary anastomotic strictures after orthotopic liver transplantation. American Society of Transplant Physicians Meeting, May, 1998. (Not accepted/not published)

143. Stephens JK, Everson GT, McCune C, Kam I, Shrestha R, Bilir B, Wachs M, Haney J, Franklin WA. DNA analysis by polymerase chain reaction assay (PCR) establishes the donor origin of post-transplantation malignancy. American Society of Transplant Physicians Meeting, May, 1998. (Not accepted/not published)

144. Talamantes M, Everson GT, Shrestha R, Trouillot T, Bilir B, Wachs M, Kam I, Steinberg T, Morgan C, House R, Mandell S. Katz J, Fey B, Ray C. Successful outcome after liver transplantation of patients with a high-risk at pre-transplant psychosocial evaluation. Transplantation 1998; 65 (12): S52.

145. Everson GT, Stephens J, Tannenbaum T, Amponsah A, Shrestha R, Trouillot T, Bilir B, Wachs M, Kam I, Steinberg T, Morgan C, Fey B, Ray C, Mandell S, Katz J, Beresford T. A controlled study of explant histology in liver transplant recipients with pre-transplant alcohol dependence. American Society of Transplant Physicians Meeting, May, 1998. (Not accepted/not published)

146. Everson GT, Shrestha R, Wachs M, KAM I, Bilir B, Trouillot T, Nold K, Mandell S, Katz J, Fey B, Ray C, Steinberg T, Morgan C. Components of care responsible for the rising costs incurred during the pre-transplant period in liver transplant recipients. Transplantation 1998; 65 (12): S25.

147. Everson GT, Shrestha R, Trouillot T, Bilir B, Amponsah A, Wachs M, Stegall M, Mandell S, Katz J, Steinberg T, Morgan C, Fey B, Ray C, Kam I. Costs of cyclosporine (Neoral) and tacroliums (Prograf) in the first year after liver transplantation (OLT). Transplantation 1998; 65 (12): S51.

148. Everson GT, Stephens J, Tannenbaum M, Amponsah A, Shrestha R, Trouillot T, Bilir B, Wachs M, Kam I, Steinberg T, Morgan C, Fey B, Ray C, Mandell S, Katz J, Beresford T. Explant histology suggesting ongoing alcohol-induced injury fails to predict relapse to drinking after liver transplantation. American Society of Transplant Physicians Meeting, May, 1998. (Not accepted/not published).

149. Shivaram K, Winklhofer-Roob B, Straka M, Devereaux M, Everson GT, Mierau G, Sokol R. The effect of idebenone, a coenzyme Q analogue, on hydrophobic bile acid toxicity to isolated rat hepatocytes and hepatic mitochondria. Free Biology &

70

Medicine, March 1998; 25 (4/5):480-492.

150. Everson GT, Folan R, Goff J, Richman L, Ansel C, Trouillot T, Shrestha R, McKinley C. The Colorado Hepatitis Treatment Group: Early results of the use of combination interferon-alfa-2B (intron A) plus ribavirin (rebetrol) in the treatment of non-responders. Hepatology October 1998, 476A.

151. Stephens JK, Kam I, Wachs M, Trouillot T, Thompson H, Frost M, Everson GT, UCHSC Liver Transplant Group, Departments of Pathology, Medicine, Anesthesiology and Surgery. Post-transplant (OLT) liver pathology after rapid steroid withdrawal (14 days): effect of immunosuppression and hepatitis C (HCV). AASLD November 1999; Liver Transplantation and Surgery, October, 1999.

152. Everson GT, Trouillot T, Wachs M, Bak T, Kam I, Nedrow A, Stephens JK, UCHSC Liver Transplant Group, Departments of Medicine, Surgery, Pathology and Tumor Registry. Increased incidence of HCV-related hepatocellular (HCC) from 1988 to 1997 in the state of Colorado: Implications for liver transplantation (LTx). AST May, 1999; Liver Transplantation and Surgery, October, 1999; ILTS Program Abstracts.

153. Bak T, Everson GT, Wachs M, Trouillot T, Kam I, Departments of Surgery and Hepatology. Living-donor liver transplantation for adults with fulimant hepatic failure (FHF): an under-utilized resource? AST May, 1999; Liver Transplantation and Surgery, October, 1999; ILTS Program Abstracts.

154. Sato S, Everson GT, Trouillot TE, Chen M, Steinberg T, Bak T, Wachs ME, Kam I, Departments of Surgery and Medicine. Effect of hepatitis C on survival in orthotopic liver transplant recipients undergoing rapid steroid withdrawal. AST May 1999; Liver Transplantation and Surgery, October, 1999; ILTS Program Abstract.

155. Trouillot T, Wachs M, Kam I, Everson GT, Depts of Medicine and Surgery. Steady-state serum cholesterol levels after liver transplantation: effects of cyclosporine (CSA) and tacrolimus (TAC) monotherapy. ILTS Program Abstracts, October, 1999.

156. Trouillot T, Steinberg T, Bak T, Talamantes M, Wachs M, Kam I, Everson GT. Quality of life (QOL) after liver transplantation external validation of the NIDDK QOL instrument. AST, International Hep C Conference, May, June, 1999; Liver Transplantation and Surgery, October, 1999 and ILTS Program Abstracts.

157. Davis, GL, Schiff E, Marcellin P, Esteban Mur R, Goodman Z, Harvey J, Albrecht JK, S Fang JW, University of Florida College of Medicine, Gainesville, University of Miami Hospital, Miami, Hospital Beacon , FR; Hospital Valie Hebron, Spain; Armed Forces Institute. Long-term continuous recombinant interferon alfa-2b (intron A) versus repeated 24-week cycles for disease suppression in IFN-Relapsers with chronic hepatitis C. AASLD Annual Meeting, Dallas, TX November, 1999.

158. Hann HW, Wright T, Baker A, Everson GT, Schiff E, Riely C, Riker-Hopkins M, Harnedani A, Brown N. Lamivudine treatment for decompensated cirrhosis due to hepatitis B: A multicenter longitudinal study. Submitted to DDW, 1999.

159. Fontana R, Hie-Won L Hann, Wright T, Everson GT, Baker A, Schiff E, Reily C, Riker-

71

Hopkins M, Harnedani A, Brown N, University of Michigan, Ann Arbor, MI, Jefferson Medical College, Philadelphia, PA, United States Veterans Affairs Medical Center, San Francisco, CA, University of Colorado Health Sciences Center, Denver, CO University of Chicago, Chicago, IL, University of Miami, Miami, FL, University of Tennessee, Memphis, TN, Glaxo Wellcome, RTP, NC. Lamivudine treatment of hepatitis B following liver transplantation: a multi-center U.S. study. AST Transplant 2000 Joint Meeting.

160. Trotter JF, Wachs M, Nold K, Trouillot TE, Bak T, Steinberg T, Everson GT, Kam I, University of Colorado Health Sciences Division of Gastroenterology/Hepatology/ Transplant Surgery/Office of Clinical Practice, Denver, CO. A comparison of charges for organ acquisition: adult cadaveric vs. adult living donor transplantation. AST Transplant 2000 Joint Meeting.

161. Trotter JF, Wachs M, Trouillot TE, Bak T, Steinberg T, Everson GT, Kam I, University of Colorado Health Sciences Division of Gastroenterology/Hepatology/Transplant Surgery, Denver, CO. The evaluation of one-hundred potential recipients for liver donor liver transplantation. AST Transplant 2000 Joint Meeting.

162. Sim S, Wachs M, Kam I, Everson GT, Trouillot T, Steinberg T, Foraged E, Lin T, Chen Y, Division of Gastroenterology & Hepatology, Transplant Surgery, University of Colorado Health Sciences Center, Denver, CO. Liver transplant-related biliary complications in the post T-tube era. AST Transplant 2000 Joint Meeting.

163. Trouillot TE, Eckel R, Wachs M, Kam I, Bak T, Trotter JF, Everson GT, University of Colorado Health Sciences Transplant Surgery, Denver, CO. Patterns of dyslipidemia in patients on cyclosporine and tacrolimus monotherapy after liver transplantation. AST Transplant 2000 Joint Meeting, 1999.

164. DiBisceglie A, Bonkovsky H, Dienstag J, Everson GT, Lindsay K, Gretch D, Hoefs J, Lee W, Lok A, Tralka T, Shiffman M, Wright T. Design of the HALT-C trial (hepatitis C antiviral long term treatment to prevent cirrhosis). Submitted to DDW 2000; In Press Gastroenterology, May, 2000.

165. Wachs M, Bak T, Everson GT, Trotter JF, Trouillot TE, Steinberg T, Kam I, Division of Transplant Surgery, UCHSC, Denver, CO. Adult to Adult Living Donor Liver Transplants Using a Right Hepatic Lobe. AST 2000 Joint Meeting, May, 2000.

166. Everson GT, Trouillot T, Trotter J, Skilbred J, Tomasi C, McKinley C, Halprin A, Fey B, Ray C, Epp J. Treatment of Decompensated Cirrhotics with a Low-Accelerating Dose Regimen of Interferon alfa-2b and Ribavirin (LADR): Safety and Efficacy. AASLD Annual Meeting, October, 2000.

167. Trotter J, Wachs M, Bak T, Trouillot T, Everson GT, Kam I, Division of Gastroenterology and Hepatology, Division of Transplant Surgery, University of Colorado Health Sciences Center, Denver, CO. Liver Transplantation with Using Sirolimus and Three-Day Corticosteroid Taper. AASLD Annual Meeting, October, 2000.

168. Trotter J, Wachs M, Trouillot T, Bak T, Everson GT, Kam I, Division of Gastroenterology and Hepatology, Division of Transplant Surgery, University of

72

Colorado Health Sciences Center. The Effect of Living Donor Liver Transplantation (LDLT) on Median Waiting Times for UNOS Status IIB Cadaveric Recipients at One Center. AASLD Annual Meeting, October, 2000.

169. Stolpman N, Kam I, Wachs M, Bak T, Trouillot T, Trotter J, Steinberg T, Stephens J, Everson GT. Mycophenolate Mofetil Does Not Lower the Incidence or Cost of Rejection, Use of OKT3, or Improve Survival After Liver Transplantation and Rapid (14d) Steroid Withdrawal. AASLD Annual Meeting, October, 2000.

170. Everson GT, Folan R, Goff J, Richman L, Anselm C, Trouillot T, Shrestha R, McKinley C, University of Colorado School of Medicine and General Clinical Research Center, Denver, CO. The Colorado Hepatitis Treatment Group: Interferon-Alfa 2b (Intron A ) Plus Ribavirin (Rebetol) is Efficacious in Non-responders to Prior Interferon Monotherapy. AASLD Annual Meeting October 2000.

171. Heimbach J, Wachs M, Bak T, Steinberg T, Stolpman N, Calkins C, Everson GT, Kam I, Trotter J, University of Colorado Health Sciences Center, Denver, CO. OKT-3 Does Not Increase the Incidence of Lymphoprolifeative Disease After Adult Liver Transplantation. AASLD Annual Meeting, October, 2000.

172. Trouillot T, Stolpman N, Wachs M, Bak T, Trotter J, Kam I, Everson GT, Division of Gastroenterology and Hepatology, Division of Transplant Surgery, University of Colorado Health Sciences Center, Denver, CO. Mycophenolate Mofetil-Based Immunosuppression Does Not Increase the Risk of Cytomegalovirus Disease in Patients Treated with Rapid (14d) Steroid Withdrawal After Liver Transplantation. AASLD Annual Meeting, October, 2000.

173. Stolpman N, Stephens J, Trouillot T, Trotter J, Kugelmas M, Wachs M, Bak T, Steinberg T, Kam I, Everson GT. Apparent Slowing of Hepatitis C Recurrence and Progression after Liver Transplantation Using Very Early (14d) Steroid Withdrawal. AST Transplant 2001 Meeting, May, 2001.

174. Everson GT, Halprin A, Trouillot T, Trotter J, Kugelmas M, Skilbred J, Tomasi C, McKinley C, Fey B, Ray C, Epp J, Department of Medicine, University of Colorado School of Medicine, Denver, CO. Treatment of Decompensated Cirrhotics May Reduce Recurrence of Hepatitis C After Liver Transplantation. AST Transplant 2001 Meeting, May, 2001.

175. Zeuzem S, Manns M, Rustgi V, Aurora S, Smith C, Shiffman M, Reddy R, Reindollar R, Slaker D, Rai R, Keeffe E, International Interferon alfacon-1 Study Group. Daily Interferon Alfazon-1 (Infergen) Therapy: Interim Results from an Ongoing International Clinical Trial to Compare Daily Interferon Alfacon-1 Therapy (9 mcg) for Treatment of Chronic Hepatitis C Virus. European Association for the Study of the Liver Annual Conference, 2001.

176. Trotter J, Schiano T, Wachs M, Kim-Schluger L, Bak T, Kugelmas M, Trouillot T, Everson GT, Miller C, Kam I. Living Donor Liver Transplantation in Hepatitis C Patients: Short-Term Results Compared to Cadaveric Transplantation. AST Transplant 2001 Meeting, May, 2001.

177. Talamantes M, Trotter J, McClure M, Wachs M, Bak T, Trouillot T, Kugelmas M,

73

Steinberg T, Everson GT, Kam I. Assessment of the Impact of Living Donor Liver Transplantation on Quality of Life in Donors. AST Transplant 2001 Meeting, May, 2001.

178. Wachs M, Bak T, Everson GT, Trotter J, Trouillot T, Kugelmas M, Steinberg T, McClure M, Brackett T, Kam I, Division of Transplant Surgery. Adult Living Donor Liver Transplant: The University of Colorado Experience. AST Transplant 2001, May, 2001.

179. Trotter J, Wachs M, Trouillot T, Bak T, Kugelmas M, Everson GT, Kam I. Sirolimus is Not Associated with Hypercholesterolemia in the Absence of Prednisone in Liver Transplant Recipients. AST Transplant 2001, May, 2001.

180. Shiffman M, Everson GT, Lindsay K, DiBisceglie A, Lok A, Bonkovsky H, Everhart J, Dienstag J, Seeff L, Lee W, Wright L, Chihiro M, Ghany M, Morgan T, Hoofnagel J. Retreatment of Interferon and Interferon-Ribavirin Non-Responders with Peg-interferon-Alpha 2A and Ribavirin: Initial Results from the Lead-In Phase of the HALT-C Trial. Hepatology 2001; 34(4):243A.

181. Halprin A, Trotter J, Everson GT, Wachs M, Bak T, Kugelmas M, Kam I. Post-Transplant Eradication of Hepatitis C by Pre-Transplant Treatment in Living Donor Liver Transplant Recipients. AASLD, 2001.

182. Pauls T, Trotter J, Wachs M, Bak T, Kugelmas M, Kam I, Everson GT. Increased Immunosuppressant Levels in Hepatitis C Liver Transplant Recipients Receiving Sirolimus. AASLD, 2001.

183. Dunkelberg J, Trotter J, Steinberg T, Wachs M, Bak T, Kugelmas M, Everson GT, Kam I. Sirolimus is Not Associated with a Higher Incidence of Wound or Hepatic Artery Complications in Liver Transplant Recipients. AASLD, 2001.

184. Trotter J, Bock SA, Wachs M, Kam I, Everson GT. Transference of Peanut Allergy Through Liver Transplantation. AASLD, 2001.

185. Stevens A, Busuttil R, Han S, Baquerizo A, Fair J, Shrestha R, Johnson M, Bloomer J, McGuire B, Rosenthal P, Ascher N, Freise V, Watanabe F, Rogiers X, Schulte J, Nyberg S, Wiesner RH, Broelsch C, Malago M, Kribben A, Lerut J, Laterre P, Salizzoni M, Lavezzo B, Brown R, Emond J, Lobritto S, De Hemptinne B, Colardyn F, Hoste E, Fagan E, McChesney L, Muraca M, Mas Ordeig A, Salmeron G, Rabkin J, Pratt D, de la Mata M, Montero J, Pozo J, Metselaar H, Everson GT, Pitkin Z, Mullon C, Solomon B, Demetriou A. In Interim Analysis of Phase II.III Prospective Randomized, Multicenter, Controlled Trial of the Hepatassist Bioartificial Liver Support System for the Treatment of Fulminant Hepatic Failure. AASLD, 2001

186. Trotter J, Stolpman N, Wachs M, Bak T, Kugelmas M, Kam I, Everson GT. Living Donor Liver Transplant Recipients Achieve Higher Immunosuppressive Levels than Cadaveric Recipients. AASLD, 2001

187. Fontana RJ, Kronfol Z, Wright E, Lindsay K, Seeff L, Shiffman M, DiBisceglie A, Bonkovsky H, Everson G, Lok ASF, Lee WM, Deinstag J, Morgan T, Morishima C,

74

Ghany M for the HALT-C Study Group. There is a High Lifetime Incidence of Substance Abuse but not Mood Disorders in Hepatitis C Non-Responders with Advanced Fibrosis: Results from the HALT-C Trial. Gastroenterol 2002;122:A-164.

188. Shiffman M, HALT-C Trial Investigators. Retreatment of HCV Non-Responders with Peginterferon and Ribavirin: Results from the Lead-In Phase of the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 2002; 336(4):295A.

189. Lok AS, Everhart JE, Everson G, Wright EC, Sterling R, Ghany M, Goodman Z, HALT-C Trail Investigators. Clinical Model to Predict Cirrhosis in Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 21002;36(4):315A.

190. Trotter J, Pearson M, Ferrell B, Everson GT, Shrestha R. The Effect of Altitude on the Prevalence and Severity of Pulmonary Hypertension in End-Stage Liver Disease. Accepted, Ninth Meeting of ILTS, 13th Meeting of the LICAGE, Barcelona Spain, 2003.

191. Stolpman N, Kam I, Wachs M, Bak T, Trotter J, Everson GT, Department of Medicince, Surgery and Pharmacy, UCHSC. Pharmacoeconomic Analysis of Four Maintenance Immunosuppressive Regimes Used in Liver Transplantation. Ninth Meeting of ILTS, 13th Meeting of the LICAGE, Barcelona Spain, 2003.

192. Hayashi P, Steinberg T, Forman L, Kugelmas M, Trotter J, Wachs M, Bak T, Kam I, Everson GT, Hepatology Division, Transplant Surgery, UCHSC. Impact of Pretransplant Diagnosis of Hepatocellular Carcinoma on Cadaveric Liver Allocation in the Era of MELD. Ninth Meeting of ILTS, 13th Meeting of the LICAGE, Barcelona Spain, 2003.

193. Kulig CC, Trotter JF, Everson GT. Treatment of lamivudine-resistant chronic hepatitis B with tenofovir. Gastroenterol 2003; 124(4, Suppl 1). Abstract M2029, p A-763. DDW, Orlando, FL, 2003.

194. Osborne JC, Heller MA, Forman L, Kugelmas M, Everson GT, Bak T, Wachs M, Kam I, Trotter JF. Tacrolimus level/dose ratio is significantly higher in hepatitis C liver transplant recipients: impact on cost. Hepatology 2003, 38(4). Abstract 150, p. 228A. AASLD, Boston, MA, 2003.

195. Balan V, Sulkowski M, Nelson D, Everson GT, Bambury J, Recta J, Zhong H, Mesghali J, Murray B, Osborn L, Novello W, Freimuth G, Subramanian G. A Phase ½ Study to Evaluate the Pharmacokinetics, Safety, Tolerability, Immungenicity and Pharmacodynamics of Albuferon in Treatment Experienced Subject with Chronic Hepatitis C. Hepatology 2003,38(4). Abstract 313, 307A. AASLD Boston,MA, 2003.

196. Everson GT, Lauriski S, DeSanto J, Kugelmas M, Shiffman ML, Hofmann C, Sterlling R, Morgan T, Hoefs J, Miline N, Rietker W, Wagner D. Quantitative Tests (QLFTs) Detect Impaired Hepatic Function in a High Proportion of Chronic Hepatitis C Patients with Fibrosis or Compensated Cirrhosis and May Predict Risk of Cirrhosis, Splenomegaly, and Varices. Hepatology 2003,38(4). Abstract 309, p.304A. AASLD, Boston, MA, 2003.

75

197. Osgood MJ, Forman L, Kugelmas M, Everson GT, Bak T, Wachs M, Kam I, Trotter JF. Preliminary analysis: graft loss from recurrent hepatitis C is not increased in patients receiving sirolimus as primary immunosuppression. Hepatology 2003, 38(4). Abstract 764, p. 529A. AASLD, Boston, MA, 2003.

198. Osgood M, Hayashi PH, Ludkowski M, Johnson S, Durham J, Brackett T, Steinberg T, Forman L, Kugelmas M, Trotter J, Bak T, Wachs M, Kam I, Everson GT. Hepatic artery chemoembolization for hepatocellular carcinoma: an intentino-t9=transplant analysis. Hepatology 2003, 38(4). Abstract 1259, p. 766A. AASLD, Boston, MA, 2003.

199. Taniguchi M, Wachs M, Bak T, Trotter J, Kugelmas M, Everson G, Kam I. Hepatitis C recurrence in living donor liver transplantation (abstract). Am J Transplantation, 2(suppl 2): 138, 2002.

200. Robinson TN, Stiegmann GV, Everson GT. Laparoscopic Palliation of Polycystic Liver Disease. SAGES Conference.

201. Forman L, Kam I, Everson GT. Maintenance of excellent patients survival after liver transplantation for chronic hepatitis C in a single center during three eras of immunosuppression characterized by wide variation in use of OKT3. Am J of Transplant 2004; 4(8). Abstract 722, p. 355. ATC Conference, Boston, MA, 2004.

202. Everson GT, Marder B, Levi M, Laird SP, McNutt T, Pape WJ, Forman L, Kleinschmidt-DeMaster, BK, Tyler KL. Community-Acquired West Nile Virus Encephalomyelitis in Solid Organ and Bone Marrow Transplant Recipients: Clinical, Diagnostic, and Neuropathological Features. Am J of Transplant 2004; 4(8). Abstract 974, p. 424. ATC conference, Boston, MA, 2004.

203. Stolpman NM, Valuck R, Lezotte D, Glazner J, Everson GT. A PHarmacoeconomic Assessment of the Benefits and Costs of Managing Immhnosuppression in Post-Liver Transplant Patients: A University Hospital Perspective. ISPOR 9th Annual International Meeting.

204. Everson GT. Shiffman ML, Hoefs JC, Kugelmas M, Sterling RK, Morgan TR, DeSanto J, McKinley C, Hofmann C, Smith P, Rietkerk W, Lauriski S, Milne N, Wagner D, Doherty MC, Wright EC. Quantitative Liver Function Tests Predict Sustained Virologic Response to Retreatment with Peginterferon alfa-2a plus Ribavirin: Results of the Lead-In Phase of the HALT-C trial. Hepatology, Vol. 40, No.4, Suppl. 1, 2004, page 113a.

205. Everson GT, Hoefs JC, Malet P, The HALTC Trial Group. Impaired Virologic Response in Patients with Advanced Liver Disease due to Chronic Hepatitis C is Independently Linked to Severity of Disease: Results from the HALT C Trial. Hepatology, Vol. 40, No.4, Suppl. 1, 2004, page 180-181a.

206. Shiffman ML, Morgan TR, Ghany MG, Wright EC, the HALT-C Trial Group. The Impact of Peginterferon (PEGIFN) and Ribavirin (RBV) Dosing on Sustained Virologic Response (SVR) in Patients with Chronic Hepatitis C Virus (HCV) Undergoing Retreatment in the HALT-C Trial. Hepatology, Vol. 40, No.4, Suppl. 1, 2004, page 314a.

76

207. Lok AS, Everhart JE, Chung RT, Padmanabhan L, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG, Morishima C, for the HALT-C Trial Investigators. Prevalence of insulin resistance (IR) and impact on treatment in chronic hepatitis C (CHC). Hepatology, Vol. 40, No.4, Suppl. 1, 2004, page 314a-315a.

208. Talamanes M, McClure M, Bak T, Wachs M, Kam I, Foreman L, Everson GT, Trotter J. Impact of Right Hepatic Lobe Donation on Donor Quality-of-Life: Long-Term Follow-Up of The University of Colorado Cohort. Hepatology, Vol. 40, No.4, Suppl. 1, 2004.

209. Balan V, Sulkowski M, Nelson D, Everson GT, Lambiase L, Post A, Redfield R, Wiesner, R, Davis G, Neumann A, Rectal J, Moore P, Osborn B, Novello L, Freimuth W, Sumramanian M. Albuferon – A Novel Therapeutic Agent for Hepatitis C: Results of a Phase ½ Study In Treatment Experienced Subjects with Chronic Hepatits C. Hepatology, Vol. 40, No. 4, Suppl 1, 2004.

210. Everson G, Heathcote J, Pappas SC, Govindarajan S, Lentz E, Lopez-Talavera JC, Hoffman F. Histological Beneit of Pegintergeron Alfa-2A (40KD) (Pegasys ®) Monotherapy in Patients with Advanced Fibrosis or Cirrhosis Due to Chronic Hepatitis C. Hepatology, Vol. 40, No. 4, Suppl 1, 2004.

211. Robinson TN, Stiegmann GV, Everson GT. Laparoscopic palliation of polycystic liver disease. Surgical Endoscopy November 11, 2004.

212. Braddock AL, Kulig CC, Morfin JP, Beresford TP, Everson GT. Fatty Acid Ethyl Esters and Blood Alcohol Level: Intoxication, Tolerance, and Influence of Gender and Age. W2005, Category: Gastroenterology and Hepatology, Category Number: 8, Affiliations: WSMR,WSCI.

213. Everson GT, Bangaru S. Portal-Systemic Shunting and Fractional Turnover of Bile Acids in Polycystic Liver Disease: Implications for Pre- and Post-transplant Management. Liver Transpl 2005, 11(7):C-24, abstract 94.

214. Everson. Treatment of Patients with Decompensated Cirrhosis due to Chronic Hepatitis C: Results with a Low Accelerating Dose Regimen (LADR) of Antiviral Therapy. Liver Transpl 2005, 11(7):C-37, abstract 145.

215. Terrault NA, Shiffman ML, Lok ASF, Saab S, Gillespie BW, Seeff LB, and the A2ALL Study Group. Transplant Center Experience Explains Differences in the Risk of Graft Failure between Hepatitis C Virus (HCV)-Infected Recipients of Living donor (LDLT) and Decreased donor (DDLT) Liver Transplant Recipients. Hepatol Vol 42, No 4, Suppl 1, 2005; abstract 7, p 198A.

216. Campsen J, Wachs M, Bak T, Kam I, Forman L, Everson G, Trotter JF. Outcomes of donor candidates evaluated fro adult-to-adult right hepatic lobe living donor liver transplantation from a single center. Hepatol Vol 42, No 4, Suppl 1, 2005; abstract 644, p 450A.

77

217. Campsen J, Wachs M, Bak T, Forman L, Everson G, Kam I, Trotter JF. Is liver biopsy mandatory for all donors for adult-to-adult right hepatic lobe living donor liver transplantation? Hepatol Vol 42, No 4, Suppl 1, 2005; abstract 653, p 454A.

218. Bonkovsky HL, Di Bisceglie AM, Morishima C, Chung RT, Everosn GT, Ghany MC, Hoofnagle JH, Lindsay KL, Hoefs JC, Lee WM, Lok, As, Shiffman ML, Wright EC. Iron and HFE gene mutations in advance chronic hepatitis C (CHC): results from the lead-in phase of the HALT-C Trial. Hepatol Vol 42, No 4, Suppl 1, 2005; abstract 894, p 548A.

219. Forman L, Everson G. Nonalcoholic fatty liver disease hospitalizations in the United States in 202: characteristics and comparison to chronic hepatitis C. Hepatol Vol 42, No 4, Suppl 1, 2005; abstract 1083, p 622A.

220. Everson GT, Shiffman ML, Sterling Rk, Hoefs JC, Morgan T, DeSanto J, Lauriski S, Shea S, Hofmann C, Rietker W, Milne N, Wright E, Doherty M. Hepatic function improves after sustained virologic response in hepatitis C paitents with advanced fibrosis and cirrhosis: Results of the lead-in phase of the HALT-C Trial. Hepatol Vol 42, No 4, Suppl 1, 2005; abstract 1265, p 697A.

221. McHutchison JG, Patel K, Schiff ER, GItlin N, Mur RE, Everson GT, Carithers RL, Davis GL, Marcellin P, Shiffman ML, Harvey J, Albrecht JK. Five-Year long term follow up of sustained viologic responders to interferon-alfa-2b +/- ribavirin therapy. Submitted to EASL, Vienna, April 2006.

222. McHutchison JG, Patel K, Schiff ER, GItlin N, Mur RE, Everson GT, Carithers RL, Davis GL, Marcellin P, Shiffman ML, Harvey J, Albrecht JK. Sustained virologic response (SVR) to interferon-alfa-2b +/- ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5-year follow up. Submitted to EASL, Vienna, April 2006.

223. McHutchison JG, Patel K, Schiff ER, GItlin N, Mur RE, Everson GT, Carithers RL, Davis GL, Marcellin P, Shiffman ML, Harvey J, Albrecht JK. Five-Year long term follow up of sustained viologic responders to interferon-alfa-2b +/- ribavirin therapy. Submitted to DDW, May 2006.

224. McHutchison JG, Patel K, Schiff ER, GItlin N, Mur RE, Everson GT, Carithers RL, Davis GL, Marcellin P, Shiffman ML, Harvey J, Albrecht JK. Sustained virologic response (SVR) to interferon-alfa-2b +/- ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5-year follow up. Submitted to DDW, May 2006.

225. Everson GT, Kulig CC, Shiffman ML, Sterling RK, Morgan TR, Hoefs JC, Curto TM, Everhart JE, Wagner D, DeSanto J, McKinley C, Hofmann C, Smith P, Rietkerk W, Lauriski S, Milne N. Altered Hepatic Metabolic Function in Patients with Chronic Hepatitis C is Associated with Obesity, Insulin Resistance, or Hepatic Steatosis, Independent of Cirrhosis: Results from the HALT-C Trial. Poster Presentation, AASLD 2006.

226. Hoefs, JC, Everson GT, Shiffman ML, Morgan TR, Naishadham D, Wright EC. Enhanced Quantitative Liver Spleen Scan (QLSS) Prediction of Liver Disease Severity in Baseline HALT-C Patients with Moderate Fibrosis or Cirrhosis. Poster Presentation, AASLD 2006.

78

227. Seeff L, Herbal and Milk Thistle Use in the HALT-C Trial of Advanced Chronic Hepatitis C. Poster Presentation, DDW 2007.

228. Everson GT, Jacobson IM, Gordon SC, McHutchison JG, Kaufman R, McNair L, Muir A. Prove 1: Results from a Phase 2 Study of Telaprevir with Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Subjects with Hepatitis C. Gastroenterology 2008;134:A-758 (AASLD 2008 abstract number 223).

229. Poordad F, Everson GT, Gordon SC, Jacobson IM, Kauffman R, Mcnair L, Muid A, McHutchinson JG. Results from a planned interim analysis of a phase 2 study of telaprevir (PROVE 1) with peginterferon alfa-2a and ribavirin in treatment-naïve subjects with Hepatitis C. Hepatol Int 2008(2):S230 (APASL abstract number FP025)

230. Nelson D, Pockros PJ, Godofsky E, Rodriguez-Torres M, Everson GT, Fried M, Ghalib R, Harrison S, Nyberg L, Shiffman M, Chan A, Hill G. High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2a (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa-2a and ribavirin. J. Hepatol 2008(48): S2 S371 (EASL abstract 993)

231. McHutchinson JG, Everson GT, Gordon SC, Jacobson I, Kauffman R, McNair L, Muir A. PROVE 1: results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naïve subjects with Hepatitis C. J. Hepatol 2008(48):S2 S4 (EASL abstract 4)

232. Lalezari J, Gane E, Rodriguez-Torres M, De Jesus E, Nelson D, Everson GT, Jacobson I, Reddy R, Hill GZ, Beard A, Symonds WT, Berrey MM, McHutchinson JG. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500mg BID for 28 days. J. Hepatol 2008(48):S2 S29 (EASL abstract number 66)

233. Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR. PHOENIX: A randomized controlled trial of peginterferon alfa-2a/ribavirin prophylactic treatment after liver transplant for Hepatitis. Liver Transplant 2010(16):S1 S118 (ILTS abstract number O-162)

234. Lawitz EJ, Boyer TD, Everson GT, Jacobson IM, Lee W, McHutchinson JG, Pockros PJ, Shiffman ML, Vierling JM, Cruickshank S, Rodell TC, Apelian D. GI-5005 immunotherapy plus PEG-IFN/ribavirin versus PEG-IFN/ribavirin in genotype 1 chronic HCV subjects; preliminary phase 2 EVR analyses. J. Hepatol 2009(50): S1 S230-S231 (EASL abstract number 627)

235. Everson GT, Terrault N, Lok AS, Brown RS, Saab S, Shiffman ML, Al-Osaimi AM, Kulik LM, Gillespie BW, Everhart JE. Interim analysis of a controlled trial of pre-transplant peginterferon alfa-2B/ribavirin (PEG/RBV) to prevent recurrent hepatitis c virus (HCV) infection after liver transplantation (LT) in the adult-to-adult liver transplantation (A2ALL) study. Hepatology 2009(50):4 302A (AASLD 2009 abstract number 1).

236. Berg CL, Merion RM, Shearon TH, Olthoff KM, Brown RS, Baker TB, Everson GT, Hong JC, Terrault N, Hayashi PH, Fisher RA, Everhart JE. Benefit of living donor liver transplantation according to MELD score and diagnosis of hepatocellular carcinoma. Hepatology 2009(50):4 339A (AASLD 2009 abstract number 75).

79

237. Bzowej NH, Nelson D, Terrault N, Everson GT, Teng LL, Prabhakar A, Charlton M. A Randomized controlled trial of the efficacy, tolerability, and safety of prophylactic treatment with peginterferon alfa-2a plus ribavirin after orthotopic liver transplantation (OLT) for Hepatology c: the PHOENIX study. Hepatology 2009(50):4 547A (AASLD 2009 abstract number 506).

238. Everson GT, Dusheiko GM, Gerenci P, Alves K, Bengtsson L, McNair L, McHutchinson JG, Muir A, Pawlotsky J-M, Zeuzem S. Telaprevir, peginterferon alfa-2a and ribavirn improved rates of sustained virologic response (SVR) in “difficult-to-cure” patients with chronic hepatitis C (CHC): a pooled analysis from the PROVE1 and PROVE 2 Trials. Hepatology 2009(50):4 1025A (AASLD abstract number 1565.

239. Everson GT, Hoefs JC, Shiffman ML, Morgan TR, Sterling RK, Curto TM, Wagner D, Wright EC, Everhart JE. Hepatic Impairment measured by quantitative tests of liver function (QLFTs) predicts clinical outcome in patients with advanced fibrosis: results from the Hepatitis C Antriviral Long-Term Treatment Against Cirrhosis (HALT-C) trials. Hepatology 2009(50): 4 1057A (AASLD abstract number 1627)

240. Kulik L, Fisher RA, Lok AS, Rodrigo DR, Brown RS, Freise CE, Shaked A, Everson GT, Hong JC, Hayashi PH, Berg CL. HCC recurrence and survival in living donor liver transplant (LDLT) compared to deceased donor liver transplant (DDLT): results of the Adult to Adult Living Donor Transplant (A2ALL) cohort. Hepatology 2010(52):4 371A (AASLD Abstract number 103)

241. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Kleber K, Martin M, Sankoh AJ, Kauffman RS, George S, Wright CI, Poordad F. Telaprevir in combination with peginterferon alfa-2a and ribavirin for 24 or 28 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study. Hepatology 2010(52):4 401A (AASLD Abstract number LB-2)

242. Pockros P, Jacobson I, Boyer TD, Schiff ER, Everson GT, Lee WM, Vierling JM, Lawitz E, Kugelmas M, Tsai N, Shiffman ML, Brown RS, Armstrong BR, Mattson A, Rodell TC, Apelian D. GI-5005 therapeutic vaccine plus peg-ifn/ribavirin improves sustained virologic response versus peg-ifn/ribavirin in prior non-reponders with genotype 1 chronic HCV infection. Hepatology 2010(52):4 404A (AASLD abstract number LB-6)

243. Ladner D, Butt Z, Gillespie BW, Tong L, Brown RS, Freise CE, Hayashi PH, Hong JC, Ashworth A, Berg CL, Everson GT, Shaked A. Long-term health related quality of life (HRQOL) after liver donation (LD) in the Adult to Adult Living Donor Liver Transplantation cohort (A2ALL) study. Hepatology 2010(52):4 567A (AASLD abstract number 497)

244. Everson GT, Hoefs JC, Niemann CU, Olthoff KM, Dupuis R, Milne N, Herman A, Lauriski S, Gillespie BW, Lok AS, Baisden K, Everhart JE. Functional elements associated with hepatic regeneration in living donors after right lobectomy – a sub-study of the Adult to Adult Living Donor Liver Transplant cohort (A2ALL) study. Hepatology 2010(52): 4 569A (AASLD abstract number 500)

245. Muir AJ, Lawitz E, Ghalib RH, Sussman NL, Anderson F, Everson GT, Jacobson IM, Lopez-Talavera JC, Hillson JL, Gray TE, Fontana D, Ramos EL, Rodriguez-Torres M.

80

Pegylated interferon lambda (PEG-IFNλ) phase 2 dose-ranging, active-controlled study in combination with ribavirin (RBV) for treatment-naïve HCV patients (genotypes 1, 2, 3 or 4): safety, viral response, and impact of IL-28B host genotype through week 12. Hepatology 2010(52): 4 715A (AASLD 2010 abstract number 821)

246. Pol S, Everson GT, Ghalib R, Rustgi V, Martorell C, Tatum HA, Lim J, Hezode C, Diva U, Yin PD, Hindes R. Once-daily NS5A inhibitor (BMS-790052) plus peginterferon-alpha-2A and ribavirin produces high rates of extended rapid virologic response in treatment-naïve HCV-genotype 1 subjects: phase 2A trial. J. Hepatol 2010(52): S1 S462 (EASL 2010 abstract number 1189)

247. McHutchinson JG, Goodman ZD, Everson GT, Jacobson IM, Boyer TD, Schiff ER, Lee WM, Chasen RM, Vierling JM, Lawitz EJ, Kugelmas M, Tsai NC, Buynak RJ, Sheikh AM, Armstrong B, Rodell TC, Apelian D. GI-5005 therapeutic vaccine plus PEG-IFN/Ribavirin improves biopsy necro-inflammatory scores and ALT normalization at 48 weeks versus PEG-IFN/ribavirin in genotype 1 chronic HCV patients. J. Hepatol 2010(52):S1 S116 (EASL 2010 abstract number 277)

248. Jacobson IM, McHutchinson JG, Boyer TD, Schiff ER, Everson GT, Pockros PJ, Chasen RM, Vierling JM, Lawitz EJ, Kugelmas M, Tsai NC, Shiffman ML, Buynak RJ, Sheikh AM, Armstrong B, Rodell TC, Apelian D. GI-5005 therapeutic vaccine plus PEG-IFN/ribavirin significantly improves virologic response and ALT normalization at end-of-treatment and improves SVT24 compared to PEG-IFN/ribavirin in genotype-1 chronic HCV patients. J. Hepatol 2010(52): S1 S465-S466 (EASL 2010 abstract number 2006)

249. McHutchinson JG, Thompson AJ, Jacobson IM, Boyer TD, Schiff ER, Everson GT, Vierling JM, Shiffman ML, Brown RS, Di Bisceglie AM, Gordon SC, Lee WM, Guo Z, King TH, Armstrong B, Rodell TC, Apelian D. Pharmacogenomic analysis reveals improved virologic response in all IL-28B genotypes in naïve genotype 1 chronic HCV patients trated with GI-5005 therapetuic vaccine plus PEG-IFN/ribavirin. J. Hepatol 2010(52):S1 S457 (EASL 2010 abstract number 1181)

250. Pockros PJ, Gordon SC, McCullough A, Charlton M, Bzowej N, Vierling J, Bansal M, Yoffe B, Everson GT, Huyghe M, Fox A, Mento S, Bohm O, Plouffe B, Cross R, Shiffman M. Randomized, placebo-controlled, double-blind, dose response (RPCDBDR) trial of CTS-1027, an inhibitor of matrix metalloproteases (MMPS) in patients with HCV who had failed prior therapies. J. Hepatol 2010(52): S1 S297-S298 (EASL 2010 abstract number 765)

251. Hezode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat GE, Lawitz E, Rustgi VK, Pol S, Weis N, Pockros P, Bourliere M, Serfaty L, Vierling JM, Fried MW, Weiland O, Burnetto, MR, Everson GT, Zeuzem S, Kwo PY, Sulkowsku MS, Yin PD, Diva UA, Hughes EA, Wind-Rotolo M, Schnittman SM. BMS-790052, A NS5A replication complex inhibitor, combined with peginterferon alfa-2A and ribivirin in treatment-naïve HCV-genotyle 1 or 4 patients: phase 2B AI444010 study interim week 12 results. Hepatology 2011(54): S1 474A (AASLD 2011 abstract number 227)

252. Hoefs JC, Everson GT, Shiffman ML, Morgan T, Chen W-P, Gillen D. Non-invasive measurement of hepatic fibrosis form the quantitative liver-spleen scan (QLSS): HALT-

81

C trial results. Hepatology 2011(54): S1 569A (AASLD 2011 abstract number 423)

253. Hoefs JC, Shiffman ML, Everson GT, Morgan T, Gillen D, Chen W-P. Effective detection of cirrhosis from the quantitiative liver-spleen scan (QLSS): HALT-C trial results. Hepatology 2011(54): S1 575A (AASLD 2011 abstract number 436)

254. Hoefs JC, Everson GT, Shiffman ML, Morgan T, Chen W-P, Gillen D. Is the platelet count determined by hepatic function or hyperslenism: results of the HALT-C trial? Hepatology 2011(54): S1 582A (AASLD 2011 abstract number 451)

255. Biggins S, Brocato MA, Trotter JF, Chang MF, Burton JR, Forman L, Bambha K, Riccardi S, Everson GT, Kam I, Klintmalm G, Rosen HR. IL28B and IFN-gamma polymorphisms in HCV-infected liver transplant recipients: a large multicenter matched case-control analysis. Hepatology 2011(54): S1 618A (AASLD 2011 abstract number 524)

256. Fortune BE, Martinez-Camacho A, Kreidler S, Gralla J, Everson GT. Outcomes of liver transplantation for Hepatitic C: non-proportional hazard analysis of the impact of HCV RNA status at transplantation on graft and patient survival. Hepatology 2011(54): S1 624A (AASLD 2011 abstract number 538)

257. Kiser JJ, Burton JR, Robert JL, Baouchi F, Wolfe P, Ray M, Bushman L, Levine JS, Everson GT. Intracellular ribavirin pharmacokinetics at first done and steady state in persons with chronic HCV undergoing treatment with peginterferon alfa-2a and ribavirin. Hepatology 2011(54): S1 820A (AASLD 2011 abstract number 977)

258. Everson GT, Gray TE, Hillson JL, Horga M, Xu D, Fontana D, Freeman JA, Lopez-Talavera JC. Pegylated interferon lambda ameliorates ribavirin (RBV)-induced anemia in HCV patients by maintaining compensatory erythropoiesis: analysis of EMERGE phase 2B results through week 12. Hepatology 2011(54): S1 993A (AASLD 2011 abstract number 1343)

259. Helmke SM, Kulig CC, Lauriski S, Herman S, Dudekula A, Everson GT. Significant alteration of the portal circulation in over half of the chronic HCV patients with Ishak fibrosis stage F0-F2. Hepatology 2011(54): S1 1328A (AASLD 2011 abstract number 2063)

260. Marcellin P, Sullivan J, Fried MW, Kieffer TL, Dusheiko GM, Martin EC, Nelson DR, Di Bisceglie AM, Wright CL, George S, BEngtsson L, Bartels DJ, Everson GT, Adda N. Sustained virologic response rates and viral resistance profiles were similar in patients treated with a telaprevir-based regimen regardless of liver fibrosis stage. Hepatology 2011(54): S1 1348A (AALSD 2011 abstract number 2105)

261. Rodriguez-Torres M, Lawitz E, Ghalib R, Sussman N, Anderson F, Everson GT, Jacobson I, Lopez-Talavera JC, Horga MA, Hillson J, Gray T, Fontana D, Ramos E, Muir AJ. Phase 2 study of pegylated interferon lambda for HCV: safety, viral response, and impact of host genotype through week 12. Hepatol Int 2011(5):3-558 258 (APASL 2011 abstract number PP13-64)

262. Gardiner DF, Lok A, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, Wendelburg P, Zhu K, Shah V, Sherman D, McPhee F, Wind-Rotolo M, Bifano M,

82

Eley T, Guo T, Persson A, Hindes R, Grasela D, Pasquinelli C. Combination BMS-790052, BMS 650032 and PegIFN/RBV provides undetectable HCV RNA through 12 weeks fot herapy in HCV genotype 1 null responders. Hepatol Int 2011 (5):3-558 262 (APASL 2011 abstract number PP13-76)

263. Afdhal NH, Nelson DR, Everson GT, Sulkowski MS, Fried MW, Flamm SL, Poordad F, Kleber K, Martin M, Sankoh AJ, Kauffman RS, George S, Wright C, Sherman KE, ILLUMINATE Study Team. Telaprevir in combination with peginterferon alfa-2a/ribavirin in treatment-naïve genotype 1 HCV patients; final results of phase 3 ILLUMINATE study. Hepatol Int 2011 (5):3-558 266 (APASL 2011 abstract number PP13-89)

264. Zeuzem S, Arora S, Bacon B, Box T, Charlton M, Diago M, Dieterich D, Esteban Mur R, Everson GT, Fallon M, Ferenci P, Flisiak R, George J, Ghalib R, Gitlin N, Gladysz A, Gordon S, Greenbloom S, Hassanein T, Jacobson I, Jeffers L, Kowdley K, Lawitz E, Lee S, Leggett B, Lueth S, Nelson D, Pockros P, Rodriguez-Torres M, Rustgi V, Serfaty L, Sherman M, Shiffman M, Sola R, Sulkowski M, Vargas H, Vierling J, Yoffe B, Ishak L, Fontana D, Xu D, Lester J, Gray T, Horga A, Hillson J, Ramos E, Lopez-Talavera JC, Muir A, EMERGE Study Group. Pegylated interferon-lambda (PEGIFN-λ) shows superior viral response with improved safety and tolerability versus PEGIFNά-2A in HCV patients (GI/2/3/4): EMERGE phase IIB through week 12. J. Hepatol 2011(54): S1 S538-S539 (EASL 2011 abstract number 1360)

265. Everson GT, Dusheiko G, Pol S, Nelson D, Muir A, Andreone P, Kauffman R, Adda N, Wright C, Bengtsson L, Martin M, Sankoh A, George S, Sherman K, Jacobson I, Zeuzem S. Telaprevir in combination with peginterferon alfa-2a and ribavirin increased sustained virologic response in genotype 1 chronic HCV and allowed for shorter treatment duration in treatment-naïve and prior relapse patients. Am J Gastro 2011(106):S2 S113 (ATC meeting abstract number 288)

266. Chojkier M, Everson GT, Muir A, Bacon B, Rodriguez-Torres M, Bennett M, Fried M, Gordon S, Gross J, Nelson D, Balart L, Jonas M, Szabo G, Bloomer J, McCullough A, Nyberg L, Smith C, Bohm O, Fox AW, Castelloe E, Huyghe M, Mento S, Spada A. 24-week treatment with CTS-1027 I combination with ribavirin reduces HCV-RNA in treatment naïve genotype-1 patients. J. Hepatol 2011(54): S1 S165 (EASL 2011 abstract number 410)

267. Lok A, Gardiner D, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, McPhee F, Wind-Rotolo M, Persson A, Zhu K, dimitrova D. Eley T, Guo T, Grasela D, Pasquinelli C. Quadruple therapy with BMS-790052, BMs-650032 and PEG-IFN/RBV for 24 weeks results in 100% SCR12 in HCV genotype 1 null responders. J. Hepatol 2011(54):S1 S536 (EASL 2011 abstract number 1356)

268. Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, Hezode C, Lim JK, Bronowicki J-P, Abrams GA, Brau N, Morris DW, Thuluvath P, Reindollar R, Yin PD, Diva U, Hindes R, McPhee F, Gao M, Thiry A, Schnittman S, Hughes EA. First report of SVR12 for a NS5A replication complex inhibitor BMS-790052 in combination with PEG-IFNa-2A and RBV: phase 2A trial in treatment naïve HCV-genotype-1 subject. J. Hepatol 2011(54): S1 S544-S545 (EASL 2011 abstract number 1373)

269. Rodriguez-Torres M, Bacon B, Gordon S, Rubin R, Box T, Kugelmas M, Vierling J,

83

Yoffe B, Pockros P, Everson GT, Jonas M, Balart L, Bohm O, Castelloe E, Huyghe MR, Mento S, Spada A, Fox AW, Chojkier M. Unique pattern of virologic response in patients with genotype-1 HCV: a phase II study of CTS-1027 in combination with peginterferon/ribavirin (SOC) in null responders. J. Hepatol 2011(54): S1 S191 (EASL 2011 abstract number 268

270. Everson GT, Cooper C, Hezode C, Shiffman ML, Yoshida E, Beltran-Jaramillo T, Ferenci P, Zeuzem S, Brunda M, Shulman N. Navarro M, Voulgari A, Najera I, Le Pogam S. Yetzer ES. Rapid and sustained achievement of undetectable HCR RNA during treatment with ritonavir-boosted danoprevir/PEF-INFa-2A/RBV in HCV genotype 1 or 4 patients: DAUPHINE week 12 interim analysis. J. Hepatol 2012(56):S2 S466 (EASL 2012 abstract number 1177)

271. Lok A, Gardiner D, Hezode C, Lawitz E, Bourliere M, Everson GT, Marcellin P, Rodriguez-Torres M, Pol S, Serfaty L, Eley T, Huang S-P, Wind-Rotolo M, McPhee F, Grasela D, Pasquinelli C. Confirmation that quadruple therapy with daclatasvir (NS5A inhibitor), asunaprevir (NS3 inhibitor) and peginterferon/ribavirin results in high rate of SVR4 in HCV genotype 1 null responders. J. Hepatol 2012(56):S2 S557 (EASL 2012 abstract number 1415)

272. Ratziu V, Gadano A, Pol S. Hezode C, Ramji A, Cheng W, Sulkowski M, Everson GT, Diva U, McPhee F, Wind-Rotolo M, Hughes EA, Yin PD, Schnittman S. Triple therapy with daclatasvir (DCV; BMS-790052), peginterferon alfa-2a and ribavirin in HCV-infected prior null and partial responders: 12-week results of phase 2B COMMAND-2 trials. J. Hepatol 2012(56):S2 S478-S479 (EASL 2012 abstract number 1207)

273. Zeuzem S, Arora S, Bacon B, Box T, Charlton M, Diago M, Dieterich D, Mur RE, Everson GT, Fallon M, Ferenci P, Rlisaik R, George J, Ghalib R, Gitlin N, Gladysz A, Gordon S, Greenbloom S, Hassanein T, Jacobson I, Jeffers L, Kowdley K, Lawitz E, Lee SS, Leggett B, Lueth S, Neldon D, Pockros P, Rodriguez-Torres M, Rustgi V, Serfaty L, Sherman M, Shiffman M, Sola R, Sulkowski M, Vargas H, Vierling J, Yoffe B, Ishak L, Fontana D, Xu D, Gray T, Horga A, Hillson J, Lopez-Talavera JC, Muir A, EMERGE Study Group. Peginterferon lambda-1a (lambda) compared to peginterferon alfa-2a (alfa) in treatment-naïve patients with HCV genotypes (G) 2 or 3: first SVR24 retuls from EMERGE phase IIB. J. Hepatol 2012(56):S2 S5-S6 (EASL 2012 abstract number 10)

274. Poordad F, Lawitz E, Kowdley KV, Everson GT, Freilich B, Cohen D, Siggelkow S, Heckaman M, Menon R, Pilot-Matias T, Podsadecki T, Bernstein B. 12-week interferon-free regimen of ABT-450/R +ABT-333 +ribavirin achieved SVR12 in more than 90% of treatment-naïve HCV genotype-1-infected subjects and 47% of previous non-responders. J. Hepatol 2012(56):S2 S549-S550 (EASL 2012 abstract number 1399)

275. Regalia K, Fortune BE, Smolkin MJ, Czwornog J, Austin G, Everson GT. Sa1021 The use of Noninvasive Indices of Hepatic Fibrosis to Detect Clinically Significant Portal Hypertension. Gastroenterology 2012: 142(5) S-948.

276. Wallack A, Helmke SM, Herman A, Isberg H, Lauriski S, Everson GT. 375 Non-Invasive Measurement of the Portal Circulation Using Cholates Quantifies Disease Severity in Primary Sclerosing Cholangitis. Gastroenterology 2012: 142(5) S-911.

84

277. Helmke SM, Wallack A, Herman A, Lauriski S, Everson GT. Non-invasive measurements of the portal circulation using cholates quantifies disease severity in waiting list patients with primary sclerosing cholangitis. Liver Transplant 2012(18): S233 (ILTS abstract number LB65)

278. Everson GT, Gray T, Hillson J, Horga A, Xu D, Fontana D, Freeman J, Lopez-Talavera JC. Peginterferon lambda-1a (Lambda) ameliorates ribavirin (RBV)-induced anemia in HCV paitents by maintaining compensatory erythropoiesis: analysis of EMERGE phase 2b results through week 12. Hepatol Int 2012(6):67-309, 181 (APASL 2012 abstract number PP13-076)

279. Marcellin P, Sullivan JC, Fried MW, Kieffer TL, Dusheiko GM, Martin EC, Nelson DR, Di Bisceglie AM, Everson GT, Adda N. Sustained virologic response rates and ciral resistance profiles were similar in paitents treated with a telaprevir-based regimen regardless of liver fibrosis stage. Hepatol Int 2012(6):67-309, 192 (APASL 2012 abstract number PP13-117)

280. Terrault NA, Stravitz RT, Lok AS, Everson GT, Brown RS, Kulik LB, Olthoff KM, Saab S, rubinas T, Argo CK, Everhart JE, Rodrigo DR. Long-term Hepatitis C (HCV) graft loss and fibrosis severity is unrelated to donor type: results from the Adult to Adult Living Donor Liver Transplantation (A2ALL) study. Am J Transplant 2012(12):s3 105 (ACT abstract number 270)

281. Burton JR, Everson GT. Initial experience with telaprevir for treating Hepatitis C virus in liver recipients: virologic response, safety, and tolerability. Am J Transplant 2012(12):s3 186 (ACT abstract number LB01)

282. Lok AS, Gardiner DF, Hezode C, Lawitz E, Bourliere M, Everson GT, Marcellin P, Rodriguez-Torres M, Pol S, Serfaty L, Eley T, Huang S0P, Wind-Rotolo M, McPhee F, GraselaDM, Pasquinelli C. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV: NS5A inhibitor) and asunaprevir (ASV: NS3 inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV). Hepatology (2012)56(4) 230A (Abstract number 79)

283. Emond JC, Fisher RA, Everson GT, Samstein B, Pomposelli J, Zhao B, Forney SA, Olthoff KM, Baker TB, Gillespie BW, Merion RM. Changes in liver and spleen volumes after living liver donation are correlated with persistent laboratory abnormalities in the adult-to-adult living donor liver transplantation cohort study (A2ALL). Hepatology (2012)56(4) 239AA (Abstract number 94)

284. Burton JR, O’Leary JG, Verna EC, Lai JC, Everson GT, Trotter JF, Brown RS, Stravitz R, Terrault N. A multicenter study of protease inhibitor-triple therapy in HCV-invected liver transplant recipients: Report from the CRUSH-C Group. Hepatology (2012)56(4) 297A (Abstract number 211)

285. Emond JC, Zhao B, Pomposelli J, Forney SA, Fisher RA, Everson GT, Olthoff KM, Baker TB, Gillespie BW, Merion RM, Hill-Callahan MM. Variability in image-based volumetry for livng liver donation: Results from the adult-to-adult living donor liver transplantation cohort study (A2ALL). Hepatology (2012)56(4) 521A (Abstract number 688)

85

286. Everson GT, Cooper C, Hezode C,Shiffman ML, Yoshida EM, Beltran-Jaramillo T, Andreone P, Bruno S, Ferenci P, Zeuzem S, Brunda M, Shulman N, Le Pogam S, Najera I, Chi B, Navarro MT, Voulgari A, Yetzer ES. High SVR24 rates with ritonavir-boosted danoprevir plus Peg-IFNα-2a (40KD)/RBV in HCV genotype 1 or 4 patients in the DAUPHINE study. Hepatology (2012)56(4) 552A (Abstract number 754)

287. Hezode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat GE, Lawitz E, Rustgi VK, Pol S, Weis N, Pockros P, Bourliere M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, ZeuzemS, Kwo PK, Sulkowski MS, Brau N, Wind-Rotolo M, Liu Z, Hughes EA, Schnittman SM, Yin PD. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 subjects: Phase 2b COMMAND-1 SVR 12 results. Hepatology (2012)56(4) 553A (Abstract number 755)

288. Hezode C,Shiffman ML, Cooper C, Everson GT, Marcellin P, Rodriguez-Torres M, Bourliere M, Pol S, Richardson D, Navarro MT, Voulgari A, Shulman N, Yetzer ES. Ritonavir-boosted danoprevir plus Peg-IFNα-2a/ribavirin (P/R) demonstrates up to 100% SVR24 with 12 or 24 weeks of total treatment in treatment-naïve patients with HCV genotype 4 infection in the DAUPHINE study. Hepatology (2012)56(4) 557A (Abstract number 760)

289. Everson GT, Lawitz E, Thompson AJ, Sulkowski MS, Zhu Y, BrainardDM, Mendelson L, McHutchison JG, Pang PS, Yang JC, Marcellin P, Afdhal N. The NS5A inhibitor GS-5885 is safe and well-tolerated iin over 1000 patients treated in Phase 2 studies. Hepatology (2012)56(4) 572A (Abstract number 783)

290. Helmke SM, DeSanto J, Herman A, Lauriski S, Everson GT. Alteration of the portal circulation across the entire spectrum of fibrosis in patients with chronic hepatits-C as measured by dual cholate clearances. Hepatology (2012)56(4) 678A (Abstract number 1005)

291. Afdhal N, Giannini EG, Sigal S, Gordon SC, Everson GT, Al-Osaimi AM, Dusheiko GM, Casanovas T, Brau N, Vasey SY, Iyengar M, Forssen U, Campbell FM, Theodore D. Albumin and MELD score predict decompensation in patients with HCV cirrhosis and thrombocytopenia on interferon therapy: Analysis from the ENABLE studies. Hepatology (2012)56(4) 738A (Abstract number 1138)

292. Helmke SM, Wallack A, Herman A,Isberg H, Lauriski S, Everson GT. Slow, moderate, and rapid progressors: Three distinct categories of patients with primary sclerosing cholangitis detected by functional assessment using cholate testing. Hepatology (2012)56(4) 1133A (Abstract number 2027)

293. Helmke SM, Desanto JL, Herman A, Lauriski S, Everson GT. A Disease Severity Index Based on Dual Cholate Clearances and Shunt Outperforms Biopsy at Predicting Clinical Outcomes in Chronic Hepatitis C Gastroenterology. 2013;144 (5):S951-2.

294. Helmke SM, Wallack A, Isberg H, Bhatt A, Cookson M, Lauriski S, Everson GT. A Disease Severity Index Based on Dual Cholate Clearances and Shunt Identifies PSC Patients at Risk for Clinical Complications. American Journal of Transplantation.

86

2013;13(S5):513.

295. Helmke SM, Wallack A, Herman A, Isberg H, Brocato M, Bhatt A, Lauriski S, Everson GT. Cholate Testing is Superior to MELD in Assessing Disease Severity in Patients with Primary Sclerosing Cholangitis Liver Transplantation. 2013;19:S97-98.

296. Helmke SM, Wallack A, Herman A, Isberg H, Brocato M, Bhatt A, Lauriski S, Everson GT. Serial Cholate Testing is Better than ∆MELD in Assessing Disease Progression in Waiting List Patients with Primary Sclerosing Cholangitis Liver Transplantation. 2013;19:S294.

297. Rachel Gomel, Ricky Safer, Jesse A. King, Estella M. Geraghty, Gregory T. Everson, Keith D. Lindor, Christopher L. Bowlus Characterization Of A Patient Driven International Registry For Primary Sclerosing Cholangitis. Hepatology (2015)62(S1) 522A (Abstract number 630)

298. Nezam H. Afdhal, Gregory T. Everson, José Luís Calleja, Geoff McCaughan, Tarik Asselah, Robert P. Myers, Raul E. Aguilar Schall, Jill M. Denning, Diana M. Brainard, Mani Subramanian, John G. McHutchison, Michael R. Charlton, Edward J. Gane, Xavier Forns, Jaime Bosch. Serum lysyl oxidase-like-2 (sLOXL2) is correlated with the hepatic venous pressure gradient (HVPG) in patients with cirrhosis due to hepatitis C. Hepatology (2015)62(S1) 582A (Abstract number 746)

87

299. Tania M. Welzel, K. Rajender Reddy, Michael P. Manns, Steven L. Flamm, David J. Mutimer, Edward J. Gane, Bernard E. Willems, Christian Trautwein, Robert H. Hyland, Sarah Arterburn, Phillip S. Pang, John G. McHutchison, Philip Wong, Didier Samuel, Michael R. Charlton, Xavier Forns, Gregory T. Everson, Stefan Zeuzem, Michael P. Curry. Effect of Different Immunosuppressant Regimens on Viral Kinetics and SVR12 in Liver Transplant Recipients Treated with LDV/SOF in the SOLAR Trials. Hepatology (2015)62(S1) 720A (Abstract number 1045)

300. Edward J. Gane, Michael P. Manns, Geoff McCaughan, Michael P. Curry, Markus Peck-Radosavljevic, Hans Van Vlierberghe, Jill M. Denning, Sarah Arterburn, Phillip S. Pang, Diana M. Brainard, John G. McHutchison, Princy N. Kumar, Eric M. Yoshida, Massimo Colombo, Bart van Hoek, Jean-Francois Dufour, Charles S. Landis, Robert Brown, David J. Mutimer, Steven L. Flamm, Michael R. Charlton, K. Rajender Reddy, Didier Samuel, Gregory T. Everson, Xavier Forns. High efficacy of ledipasvir/sofosbuvir with ribavirin in patients with decompensated cirrhosis or liver transplantation and HCV infection: combined efficacy from the SOLAR-1 and SOLAR-2 trials. Hepatology (2015)62(S1) 722A (Abstract number 1049)

301. Nancy Reau, Fred Poordad, Jeffrey Enejosa, Asma Siddique, Humberto I. Aguilar, Jacob P. Lalezari, Franco Felizarta, Peter J. Ruane, Peter Varunok, David Bernstein, Douglas Dieterich, Gregory T. Everson, Yiran Hu, Greg Ball, Tami Pilot-Matias, Nancy Shulman, Sanjeev Arora. Preliminary Safety and Efficacy Results from TOPAZ-II: A Phase 3b Study Evaluating Long-Term Clinical Out comes in HCV Genotype 1 -infected Patients Receiving Ombitasvir/Paritaprevir/r and Dasabuvir +/-Ribavirin. Hepatology (2015)62(S1) 732A (Abstract number 1065)

302. Tania M. Welzel, K. Rajender Reddy, Michael P. Manns, Steven L. Flamm, David J. Mutimer, Edward J. Gane, Robert H. Hyland, Ming Lin, Phillip S. Pang, John G. McHutchison, Didier Samuel, Michael R. Charlton, Xavier Forns, Gregory T. Everson, Stefan Zeuzem, Nezam H. Afdhal. On-treatment HCV RNA Decline in Pre-and Post-Liver Transplant Patients with Different Degrees of Fibrosis and Cirrhosis: a combined analysis of the SOLAR trials. Hepatology (2015)62(S1) 766A (Abstract number 1130)

303. Steve M. Helmke, Jennifer DeSanto, Shannon Lauriski, Gregory T. Everson. A New Simple Quantitative Liver Function Test, HepQuant-STAT, Correlates with all Chronic HCV Ishak Fibrosis Stages, but Outperforms Fibrosis at Predicting the Risk of Future Clinical Outcomes. Hepatology (2015)62(S1) 1111A (Abstract number 1849)

PRESENTATIONS AT SCIENTIFIC MEETINGS

1. Everson GT, Johnson M, Kern F Jr. Gallbladder function in pregnancy: Increased retention of bile from 8 am until midnight. Gastroenterology, 78(5 Pt 2):1162, 1980.

2. Everson GT, McKinley C, Showalter R, Johnson M, DeMark B, Szczepanik-Van-Leeuwen P, Klein P, Kern F. Bile acid (BA) kinetics and gallbladder (GB) function in pregnancy: The apparent regulatory role of the gallbladder. Gastroenterology, 78(5 Pt 2):1162, 1980.

88

3. Kern F, DeMark B, Szczepanik-VanLeeuwen P, Everson GT, Braverman D, McKinley C, Showalter R, Klein P. Effects of contraceptive steroids (CS) on biliary lipids and bile acid (BA) kinetics. Clin Res, 28(2):545A, 1980.

4. Everson GT, Lawson M, McKinley C, Showalter R, Kern F Jr. Differential effects of liquid formula (F) and amino acid (AA) solutions on gallbladder (GB) emptying, small bowel transit and biliary lipid secretion. Gastroenterology, 80(5 Pt 2):1145, 1981.

5. Everson GT, Hachey D, Klein P, Showalter R, McKinley C, Kern F Jr. Simultaneous serum and biliary chenodeoxycholic (CDC) kinetics using 13C-CDC. Gastroenterol-ogy, 82(5 Pt 2):1051, 1982.

6. Lawson M, Everson GT, McKinley C, Konterski E, Klingensmith W, Taylor I, Kern F Jr. Relations of gastric emptying, gallbladder (GB) emptying and refilling, gastrointestinal transit (GIT) and serum pancreatic polypeptide (PP). Clin Res, 30(1):36A, 1982.

7. Lawson M, Everson GT, McKinley C, Konterski E, Klingensmith W, Taylor I, Kern F Jr. Relations of gastric emptying, gallbladder (GB) emptying and refilling, gastrointestinal transit (GIT) and serum pancreatic polypeptide (PP). Gastroenterology, 82(5 Pt 2):1112, 1982.

8. Everson GT, Lawson M, McKinley C, Kern F Jr. Small bowel transit time (SBTT) in pregnancy. Clin Res,1(1):30A, 1983.

9. Everson GT, Lawson M, McKinley C, Kern F Jr. Small bowel transit time (SBTT) in pregnancy. Gastroenterology, 84(5 Pt 2):1146, 1983.

10. Everson GT, Polokoff M, Nemeth A. Bile acid synthesis in the human hepatoma cell line, HepG2: Studies of the conversion of deuterium-labeled and isomers of 7-OH cholesterol to chenodeoxycholic (CDCA) and cholic acid (CA). Gastroenterology, 88(5 Pt 2):1657, 1985.

11. Everson GT, Polokoff MA. HepG2: A cell line exhibiting defects in bile acid synthesis. Hepatology, 5(5):1022, 1985.

12. Kern F Jr, Everson GT, Showalter R, McKinley C, Fausel C. Contraceptive steroids (CS) alter the regulatory mechanisms of cholesterol homeostasis and biliary lipid secretion in healthy young women. Gastroenterology, 88(5 Pt 2):1670, 1985.

13. Everson GT, Polokoff M. Effect of dexamethasone on bile acid synthesis by cultured cells: Studies of rat hepatocyte X rat hepatoma hybrids. Clin Res, 34(1):28A, 1986.

14. Everson GT, Polokoff MA. HepG2: A cell line exhibiting defects in bile acid synthesis. Clin Res, 34(1):29A, 1986.

15. Everson GT, Polokoff MA. Effect of dexamethasone on bile acid synthesis by cultured cells: Studies of rat hepatocyte X rat hepatoma hybrids. Gastroenterology, 90(1 Pt 2):1724, 1986.

16. Kern F Jr, Everson GT. Chronic premarin administration increases biliary cholesterol (CH) secretion and decreases chenodeoxycholic acid (CDCA) pool and synthesis.

89

Gastroenterology, 90(5 Pt 2):1738, 1986.

17. Everson GT, Leff N, Dixon D, Githens J, Pretorius D, Manco-Johnson M. Gallbladder function is altered in sickle hemoglobinopathies (SH): Potential role in gallstone formation. Gastroenterology, 92:1731, 1987.

18. Everson GT, Fennessey P, Kern F Jr. Contraceptive steroids alter the steady-state kinetics of bile acids. Hepatology, 7(5):1109, 1987.

19. Everson GT, Scherzinger A, Leff N, Lee E, Seibert J, Manco-Johnson M. Liver cell, liver cyst and kidney volumes in subjects with autosomal dominant polycystic kidney disease with liver cysts (ADPKD + LC). Hepatology, 7(5):1100, 1987.

20. Everson GT, Fennessey P, Kern F Jr. Contraceptive steroids alter the steady-state kinetics of bile acids. Presented at Aspen Conference on Hepatic Lipoprotein and Cholesterol Metabolism, 1987.

21. Junker L, Straka M, Zogg D, Everson GT, Davis R. Regulation of rat liver cholesterol 7-alpha hydroxylase by microsomal free cholesterol. Hepatology, 7(5):1108, 1987.

22. Junker L, Straka MS, Zogg DL, Everson GT, Davis RA. Regulation of cholesterol 7-alpha hydroxylase by microsomal free cholesterol. Presented at Aspen Conference on Hepatic Lipoprotein and Cholesterol Metabolism, 1987.

23. Everson GT, Leff N, Zogg D, Reichen J, Gabow P. Polycystic liver disease: Quantitative assessment of hepatic and cyst function. Gastroenterology, 94(5 Pt 2):A538, 1988.

24. Everson GT, Kern F Jr. Mechanisms of gallstone formation in post-menopausal women taking conjugated estrogens (Premarin). Gastroenterology, 94:A538, 1988.

25. Everson GT, Leff N, Brown WR, Emmett M. Characteristics of hepatic cysts in autosomal dominant polycystic kidney disease (ADPKD). Hepatology, 8(5):1341, 1988.

26. Kern F Jr, Everson GT. The effects of female sex steroid hormones on cholesterol and bile acid metabolism. Presented at the Bengt Borgstrom Symposium, Falsterbo, Sweden, May/June 1988.

27. Everson GT, McKinley C, Showalter R, Kern F Jr. Influence of dietary cholesterol on biliary lipid metabolism in women taking conjugated estrogens. Clin Res, 37(1):111A, 1989.

28. Everson GT, McKinley C, Showalter R, Kern F Jr. Influence of dietary cholesterol on biliary lipid metabolism in women taking either conjugated estrogens (PremarinR) or medroxyprogesterone (ProveraR). Gastroenterology, 96(5 Pt 2):A596, 1989.

29. Everson GT, Johnson A, Kaehny W, Duley I, Manco-Johnson M, Gabow P. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease (ADPKD). Gastroenterology, 96(5 Pt 2):A144, 1989.

90

30. Everson GT. Bile acid synthesis by HepG2 is regulated by insulin and dexamethasone. Presented at the 32nd IUPAC Congress. Stockholm, Sweden, August 1989.

31. Zaccaro L, Sutherland E, Iwahashi M, Burnett R, Everson G. Acute cholestasis with taurolithocholate is due to direct reversible non-competitive inhibition of sodium-dependent taurocholate uptake. Gastroenterology, 6(2):A675, May 1989.

32. Everson GT. Bile acid synthesis by HepG2 is regulated by insulin and dexamethasone. Presented at the 32nd IUPAC Congress. Stockholm, Sweden, August 1989.

33. Rector WG, DeRoche G, Everson GT. The relationship of portal-systemic shunting and liver function to sodium retention in patients with alcoholic liver disease. Hepatology, 10(4):587, 1989.

34. Kam I, Everson GT, Sokol R, Schroter G, Lawton C, Armstead V, Karrer F. Liver transplant activity of 1st year program at University of Colorado Health Sciences Center. Presented at American College of Surgeons, Colorado Chapter Meeting, May 1990.

35. Everson GT, Malik R, McKinley C. Effects of synthetic progestin (norethindrone) on the enterohepatic circulation and metabolism of bile acids. Hepatology, 12(4):1005, 1990.

36. Everson GT, Valdivieso V, Covarrubias C, Espinosa R, Trombley C, Smith P. Intrahepatic cholestasis of pregnancy: Effects on bile acid metabolism. Hepatology, 12(4 Pt 2):898, 1990.

37. Everson GT, Malik R, McKinley C. Effects of synthetic progestin (norethindrone) on gallbladder motility, intestinal transit, and the kinetics of bile acids. Clin Res, 36(1):95A, 1991.

38. Everson GT, Daggy BP, McKinley C, Story JA. Study of mechanisms of the hypocholesterolemic effect of psyllium in man. Circulation, 84(4 Suppl): II601, Oct 1991.

39. Everson GT, Daggy BP, McKinley C, Story JA. Dietary fiber (psyllium) lowers LDL cholesterol by stimulating bile acid synthesis in man. Hepatology, 14(4 Pt 2):148A, 1991.

40. Pinto PC, Everson GT, Rector WG Jr. Does progressive reduction in hepatic metabolic capacity signal sodium retention in alcoholic cirrhosis? Hepatology, 14(4 Pt 2):86A, 1991.

41. Hall R, Reveille RM, Karrer F, Everson G, Goff J, Kam I. Bile leaks after T-tube removal following orthotopic liver transplantation. American College of Surgeons, Colorado Chapter Meeting, May 1992.

42. Mandell S, Karrer F, Everson GT, Urban K, Kam I. Selective Use of Venous-Venous Bypass in Liver Transplant. International Society for Hepatic Transplantation; Toronto, Canada, 1993.

91

43. Everson GT, Lezotte DL, Clark A, Kam I. Biochemical Profile in The First 21 Days After Hepatic Transplantation: The Uncomplicated Course. International Society for Hepatic Transplantation. Hepatology, 1993.

44. Everson GT, McKinley C, Kam I. Quantitative Tests (QLFT) of Hepatic Function: Assessment of Patients Prior to Hepatic Transplantation (OLTx). International Society for Hepatic Transplantation. Hepatology, 18(4 Pt ):330, 1993.

45. Mandell S, Karrer F, Everson G, Urban K, Kam I. Selective Use of Venous-Venous Bypass in Liver Transplant. International Society for Hepatic Transplantation. Hepatology, 1993.

46. Durham JD, LaBerge J, Altman SD, Stauffer JT, Kam I, Everson GT, Kumpe DA. Departments of Radiology, Hepatology, and Surgery, University of Colorado Health and Sciences Center, Denver, and Department of Radiology. Percutaneous Portal Vein Recanalization and Closure of Competitive Portosystemic Shunts in Patients with Portal Vein Thrombosis Following Orthotopic Liver Transplantation. University of California, San Francisco, International Society for Hepatic Transplantation. Hepatology, 1993.

47. Lindsey KL, Davis GL, Schiff E, Bodenheimer H, Balart L, Dienstag J, Perrillo R, Goff J, Everson GT, Tamburro C, Albrecht J, Sanghvi B. Long-term Response to Higher Doses of Interferon (IFN) Alfa- 2b Treatment of Patients with Chronic Hepatitis C: A Randomized Multicenter Trial. AASLD Meeting 1993. Toronto, Canada, 1993; Hepatology 18(4 Pt 2):106, 1993.

48. Everson GT, McKinley C, Mills M, Cippola T, Showalter R, Peterson F, Department of Medicine, University of Colorado Medical School, Denver, and Sandoz Nutrition, Minneapolis, MN. The Metabolic Basis for Cholesterol Gallstone Formation in Obese Women During Weight Loss. Carmel, CA, 1993.

49. Shrestha R, McKinley C, Russ P, Scherzinger A, Bonner R, Showalter R, Everson GT, Department of Medicine, University of Colorado School of Medicine, Denver, CO. Estrogens Inhibit the Metabolism of Antipyrine in Postmenopausal Women with Autosomal Dominant Polycystic Disease (ADPD). Carmel, CA, 1993.

50. Stegall M, Everson GT, Karrer F, Schroter G, Kam I, University of Colorado Medical Center, Denver, CO. Metabolic Complications After Liver Transplantation: Diabetes and Hypercholesterolemia. ASTS Meeting 1994

51. Slater J, Chan L, Kam I, Schroter G, Karrer F, Bilir B, Howell C, Coll J, Everson GT. Renal Failure and Dialysis as Predictors of Outcome in Liver Transplant Patients. ASTS Meeting, 1994.

52. Everson GT, Stegall M, Karrer F, Schroter G, Howell C, Bilir B, Kam I. The Clinical Characteristics of Adult Patients Who Develop Hypercholesterolemia After Liver Transplantation. 1994.

53. Shrestha R, McKinley C, Russ P, Scherzinger A, Bonner R, Showalter R, Everson GT. Estrogens Inhibit the Metabolism of Antipyrine in Postmenopausal Women with

92

Autosomal Dominant Polycystic Disease (ADPD). World Congresses of Gastroenterology, Gastroenterology, 106(4):A985, DDW Meeting, 1994.

54. Kaur S, Carey WD, Bacon BR, Gollan JL, Rustgi VK, Sandha GS, Everson GT. Performance Characteristics of a Large Scale Screening Program (LSSP) for Viral Hepatitis (VH) B and C - Results of the National Hepatitis Surveillance Program. DDW Meeting, 1994.

55. Kaur, S, Carey WD, Bacon BR, Gollan JL, Rustgi VK, Everson, GT. Risk Factors for Viral Hepatitis (VH) B and C Exposure in Subjects Presenting to a Voluntary Large Scale Screening Program (LSSP) - Results of the National Hepatitis Surveillance. Program. DDW Meeting, 1994.

56. Everson GT, Stegall M, Karrer F, Schroter G, Howell C, Bilir B, Kam I. The Clinical Characteristics of Adult Patients Who Develop Hypercholesterolemia After Liver Transplantation (OLTx). World Congress of Gastroenterology Meeting, 1994.

57. Everson GT, McKinley C, Mills M, Cippola T, Showalter R, Peterson F. Weight Loss in Obese Women Markedly Inhibits bile Acid Synthesis. The Metabolic Basis for Cholesterol Gallstone Formation? World Congress of Gastroenterology, 1994.

58. Shrestha R, McKinley C, Ross P, Scherzinger A, Bonner R, Showalter R, Everson GT. Estrogens Inhibit the Metabolism of Antipyrine in Postmenopausal Women with Autosomal Dominant Polycystic Disease (ADPD). World Congress of Gastroenterology, 1994.

59. Shrestha R, Everson GT, McKinley C, Showalter R, Smith P. Complete Response to Interferon is Associated with Improvement in Hepatic Function. World Congress of Gastroenterology, 1994.

60. Lindsay KL, Spencer G, Nicoloff J, Milestein S, Davis GL, Schiff E, Bodenheimer H, Balart L, Dienstag J, Perrillo R, Tamburro C, Everson GT, Sanghvi B, Albrecht J. Thyroid Peroxidase Antibody--A Potential Predictor of IFN Associated Thyroid Disease. AASLD Meeting. Hepatology, 20 (4 Pt. 2):168A, October 1994.

61. Shrestha R, McKinley C, Showalter R, Everson GT. Quantitative Liver Function Tests (QLFTs) Define the Functional Severity of Liver Disease In Early Stage Cirrhosis. AASLD Meeting. Hepatology, 20 (4 Pt. 2):119A, October 1994.

62. Sokol RJ, McKim JM, Devereaux MW, Everson GT. Vitamin E Reduces Oxidant Injury to Hepatic Mitochondria Caused by Intravenous Taurochenodeoxycholic Acid in the Rat. Hepatology, 20 (4 Pt.2):178A, October 1994.

63. Bilir B, Durham JD, Kumpe DA, Karrer F, Hanks T, Ostrowska A, Kam I, Trujillo N, Lear J, Trouillot T, Shrestha R, Everson GT. Critical Analysis of Intra-Splenic Transplantation of Cryopreserved Human Hepatocytes in a Patient with Acute Liver Failure. AASLD Meeting, Chicago, IL, November 1995.

64. Katz JJ, Mandell MS, Barton B, House RM, Bilir B, Everson GT, Zamudio S. Preservation of CO2-Dependent Regulation of Cerebral Arterial Blood Flow Velocity in End Stage Liver Disease. AASLD Meeting, Chicago, IL,November 1995.

93

65. Shrestha R, Durham JD, Kumpe DA, Bilir B, DeRoche G, Showalter R, Rector W, Everson GT. Outcome after Transjugular Intrahepatic Portal-Systemic Shunt fro Refractory Ascites in Patients with Advanced Cirrhosis. AASLD Meeting, Chicago, IL, November 1995.

66. Gordon SC, Everson GT, McHutchison JG, Reinus J, Regenstein F, Kaplan MM, Koff RS, Fedorczyk D , Plasse T. Natural Alfa Interferon (Alferon N) Treatment of Chronic Hepatitis C in Patients Refractory to Recombinant Interferon Alfa 2B. AASLD Meeting, November 1995.

67. Simon DM, Gordon SC, Kaplan MM, Koff RS, Regenstein F, Everson GT, Weiner F, Plasse T, Fedorczyk D, Einstein A. Natural Alfa Interferon (Alferon N) Treatment of Chronic Hepatitis C in Previously Untreated Patients. AASLD Meeting, November 1995.

68. Stegall MD, Everson GT, Wachs M, Schroter G, Karrer F, Bilir B, Shrestha R, Kam I. Prednisone withdrawal 14 days after adult liver transplantation with mycophenolate mofetil (MM). AASLD Meeting, November 1996. Hepatology 1996; 24(4):174A.

69. Keeffe E, Blatt LM, Dusheiko G, Tong MJ, Hollinger FB, James S, Mullen K, Everson GT, Piemstone N, Heathcote EJL, Donovan J, Conrad A, Schmid P, Albert D, Gerrard T, and the Consensus Interferon Study Group*. Differential response to treatment with consensus interferon (CIFN) and IFN -2b in chronic HCV patients infected with different HCV serotypes. AASLD Meeting, November 1996. Hepatology 1996; 24(4):275A.

70. Bilir B, Durham JD, Krystal J, Karrer F, Kumpe D, Ostrowska A, Guenette D, Trouillot T, Shrestha R, Taylor S, Kam I, Everson GT. Transjugular intra-portal transplantation of cryopreserved human hepatocytes in a patient with acute liver failure. AASLD Meeting, November 1996. Hepatology 1996; 24(4):308A.

71. Bharadhwaj G, Everson GT, Bilir B, Shrestha R, Kam I, Karrer F, Wachs M, Stegall M, Schroter G, Steinberg T, Ford C, Beresford T. Relapse to alcohol consumption in liver transplant recipients followed for more than one year: early analysis of a comprehensive psychosocial evaluation. AASLD Meeting, November 1996. Hepatology 1996; 24(4):244A.

72. Shrestha R, McKinley C, Showalter R, Marsano L, Vivian B, Everson GT. Quantitative liver function tests (QLFTs) define functional severity and predict decompensation of liver disease in early stage cirrhosis. AASLD Meeting, November 1996. Hepatology 1996; 24(4):300A.

73. Colton J, Chapman A, Everson GT. Augmentation of the diuretic response to furosemide by albumin in cirrhotic patients with ascites. AASLD Meeting, November 1996. Hepatology 1996; 24(4):446A.

74. Shrestha R, McKinley C, Showalter R, Bilir B, Durham J, Kumpe D, Krysl J, Everson G. Transjugular intrahepatic portosystemic shunts (TIPS) for ascites: the prognostic and predictive value of quantitative liver function tests (QLFTs). AASLD Meeting, November 1996. Hepatology 1996; 24(4):449A.

94

75. Sokol RJ, Devereaux MW, Straka MS, Everson GT. Melatonin attenuates hydrophobic bile acid toxicity to isolated rat hepatocytes. AASLD Meeting, November 1996. Hepatology 1996; 24(4):338A.

76. Jensen DM, Blatt LM, Tong MJ, Lee WM, Mullen K, Hoefs JC, Keeffe E, Hollinger FB, Heathcote EJL, White H, Foust RT, Krawitt EL, Fromm H, Black M, Albert D, Gerrard T, and Consensus Interferon Study Group*. Treatment of high viral titer chronic HCV patients with consensus interferon (CIFN) results in a significantly greater number of sustained HCV RNA responders as compared to treatment with interferon -2b. AASLD Meeting, November 1996. Hepatology 1996; 24(4):275A.

77. Keeffe E, Blatt LM, Dusheiko G, Tong MJ, Hollinger FB, James S, Mullen K, Everson GT, Pimstone N, Heathcote EJL, Donovan J, Conrad A, Schmid P, Albert D, Gerrard T, and Consensus Interferon Study Group*. Differential response to treatment with consensus interferon (CIFN) and IFN -2b in chronic HCV patients infected with different HCV serotypes. AASLD Meeting, November 1996. Hepatology 1996: (24)4:275A.

78. Trouillot TE, Stegall M, Bilir B, Shrestha R, Kam I, Schroter G, Karrer F, Wachs M, Ford C, Steinberg T, Everson GT. Successful prednisone withdrawal after liver transplantation in patients with autoimmune chronic active hepatitis. ASTP 16th Annual Meeting, May 1997.

79. Everson GT, Bharadhwaj G, House R, Talamantes M, Bilir B, Shrestha R, Kam I, Wachs M, Karrer F, Fey B, Ray C, Steinberg T, Morgan C, Beresford T. Liver transplantation for alcoholic liver disease: long-term results. ASTP 16th Annual Meeting, May 1997.

80. Beresford TP, Bharadhwaj G, Everson GT. Alcohol dependent liver graft recipients: a controlled three year follow-up. ASTP 16th Annual Meeting, May 1997.

81. Stegall MD, Wachs ME, Kam I, Bilir B, Shrestha R, Karrer F, Everson GT. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. ASTP 16th Annual Meeting, May 1997.

82. Trouillot TE, Stegall M, Bilir B, Shrestha R, Kam I, Schroter G, Karrer F, Wachs M, Ford C, Steinberg T, Everson GT. Successful prednisone withdrawal after liver transplantation in patients with autoimmune chronic active hepatitis. ILTS Meeting, October 1997.

83. Beresford TP, Bharadhwaj G, Everson GT. Alcohol dependent liver graft recipients: a controlled three year follow-up. ILTS Meeting, October 1997.

84. Everson GT, Bharadhwaj G, House R, Talamantes M, Bilir B, Shrestha R, Kam I, Wachs M, Karrer F, Fey B, Ray C, Steinberg T, Morgan C, Beresford T. Liver transplantation for alcoholic liver disease: long-term results. ILTS Meeting, October 1997.

85. Trouillot TE, McKinley CL, Showalter RB, Everson GT. Gallbladder motility in obese subjects after diet- induced weight loss relative to gallstone formation. AASLD

95

Meeting, November 1997.

86. Trouillot TE, Eckel RH, McKinley CL, Showalter RB, Yost TJ, Everson GT. The link between weight loss, gallstones, and insulin action: a pathophysiologic study in humans. AASLD Meeting, November 1997.

87. Trouillot TE, Eckel RH, McKinley CL, Showalter RB, Yost TJ, Everson GT. Hepatic and total body insulin sensitivities are disassociated in obese subjects after diet-induced weight loss followed by isocaloric weight maintenance. AASLD Meeting, November 1997.

88. Bilir BM, Guenette D, Ostrowska A, Durham J, Kumpe D, Krysl J, Shrestha R, Trouillot T, Teitelbaum I, Everson GT. Percutaneous hepatocyte transplantation (PHT) in liver failure. AASLD Meeting, November 1997.

89. Amponsah A, Everson GT, Stephens J, Tannenbaum M, Shrestha R, Trouillot T, Bilir B, Wachs M, Kam I, Steinberg T, Morgan C, Fey B, Ray C, Beresford T. Relapse to drinking after liver transplantation: failure of explant histology to predict relapse. AASLD Meeting, November 1997.

90. Sandhu IS, Stephens J, Krysl J, Durham JD, Kumpe DA, Shrestha R, Trouillot TE, Everson GT, Bilir BM Utility of Transjugular Liver Biopsy Using Liver Access Biopsy Automated Needle. DDW, May 16-22, 1998.

91. Bilir BM, Kumpe D, Krysl J, Guenette D, Ostrowska A, Everson GT, Shrestha R, Lin TC, Cole W, Lear J, Durham JD. Hepatocyte Transplantation (HT) in Patients with Liver Cirrhosis. DDW, May 16-22, 1998.

92. Goff JS, Hamman RF, Wamboldt FS, Everson GT, Shrestha R, Kam I, Wachs M, Lezotte DC, Steinberg T, Talamantes M, Bilir B. Quality of life after liver transplantation in patients with hepatitis C. DDW, May 16- 22, 1998.

93. Talamantes M, Everson GT, Shrestha R, Trouillot T, Bilir B, Wachs M, Kam I, Steinberg T, Morgan C, House R, Mandell S. Katz J, Fey B, Ray C. Successful outcome after liver transplantation of patients with a high-risk at pre-transplant psychosocial evaluation. American Society of Transplant Physicians Meeting, 1998.

94. Everson GT, Shrestha R, Wachs M, KAM I, Bilir B, Trouillot T, Nold K, Mandell S, Katz J, Fey B, Ray C, Steinberg T, Morgan C. Components of care responsible for the rising costs incurred during the pre-transplant period in liver transplant recipients. American Society of Transplant Physicians Meeting, 1998.

95. Everson GT, Shrestha R, Trouillot T, Bilir B, Amponsah A, Wachs M, Stegall M, Mandell S, Katz J, Steinberg T, Morgan C, Fey B, Ray C, Kam I. Costs of cyclosporine (Neoral) and tacroliums (Prograf) in the first year after liver transplantation (OLT). American Society of Transplant Physicians Meeting, 1998.

96. Shrestha R, Ryu R, Durham J, Krysl J, Kam I, Wachs M, Bilir B, Trouillot T, Everson GT. Use of transjugular intrahepatic portosystemic shunt as a bridge to transplantation in budd-chiari syndrome. American Society of Transplant Physicians Meeting, 1998.

96

97. Everson GT. Medical management of hepatitis B. University of Maryland Division of Gastroenterology, Third Annual Liver Diseases Seminar, 1999.

98. Everson GT. Management of hepatic failure, upper gastrointestinal bleeding, and lower gastrointestinal bleeding in the intensive care unit, American College of Chest Physicians and Society of Critical Care Medicine Combined Meeting, 1999.

99. Everson GT. Increased incidence of HCV-related hepatocellular (HCC) from 1988 to 1997 in the state of Colorado: implications for liver transplantation (LTx). American Society of Transplantation, May, 1999.

100. Everson GT. Effect of hepatitis C on survival in orthotopic liver transplant recipients undergoing rapid steroid withdrawal. American Society of Transplantation, May, 1999.

101. Everson GT, Folan R, Goff J, Richman L, Anselm C, Trouillot T, Shrestha R, McKinley C, University of Colorado School of Medicine and General Clinical Research Center. The Colorado hepatitis treatment group: early results of the use of combination interferon-alfa-2B (Intron A) plus ribavirin (Rebetrol) in the treatment of non-responders. US Rebetron Investigators Meeting, February, 1999.

102. Everson, GT. Cholestasis following bone marrow transplantation, case presentation. American College of Gastroenterology, October, 1999.

103. Everson GT, Trouillot T, Trotter J, Skilbred J, Tomasi C, McKinley C, Halprin A, Fey B, Ray C, Epp J. Treatment of Decompensated Cirrhotics with a Low-Accelerating Dose Regimen of Interferon alfa-2b and Ribavirin (LADR): Safety and Efficacy. AASLD Annual Meeting, October, 2000.

104. Trotter J, Wachs M, Bak T, Trouillot T, Everson GT, Kam I, Division of Gastroenterology and Hepatology, Division of Transplant Surgery, University of Colorado Health Sciences Center, Denver, CO. Liver Transplantation with Using Sirolimus and Three-Day Corticosteroid Taper. Accepted, AASLD Annual Meeting, October, 2000.

105. Trotter J, Wachs M, Trouillot T, Bak T, Everson GT, Kam I, Division of Gastroenterology and Hepatology, Division of Transplant Surgery, University of Colorado Health Sciences Center. The Effect of Living Donor Liver Transplantation (LDLT) on Median Waiting Times for UNOS Status IIB Cadaveric Recipients at One Center. Accepted, AASLD Annual Meeting, October, 2000.

106. Stolpman N, Kam I, Wachs M, Bak T, Trouillot T, Trotter J, Steinberg T, Stephens J, Everson GT. Mycophenolate Mofetil Does Not Lower the Incidence or Cost of Rejection, Use of OKT3, or Improve Survival After Liver Transplantation and Rapid (14d) Steroid Withdrawal. Accepted, AASLD Annual Meeting, October, 2000.

107. Everson GT, Folan R, Goff J, Richman L, Anselm C, Trouillot T, Shrestha R, McKinley C, University of Colorado School of Medicine and General Clinical Research Center, Denver, CO. The Colorado Hepatitis Treatment Group: Interferon-Alfa 2b (Intron A) Plus Ribavirin (Rebetol) is Efficacious in Non-responders to Prior Interferon Monotherapy. Accepted, AASLD Annual Meeting, October, 2000.

97

108. Heimbach J, Wachs M, Bak T, Steinberg T, Stolpman N, Calkins C, Everson GT, Kam I, Trotter J, University of Colorado Health Sciences Center, Denver, CO. OKT-3 Does Not Increase the Incidence of Lymphoprolifeative Disease After Adult Liver Transplantation. Accepted, AASLD Annual Meeting, October, 2000.

109. Trouillot T, Stolpman N, Wachs M, Bak T, Trotter J, Kam I, Everson GT, Division of Gastroenterology and Hepatology, Division of Transplant Surgery, University of Colorado Health Sciences Center, Denver, CO. Mycophenolate Mofetil-Based Immunosuppression Does Not Increase the Risk of Cytomegalovirus Disease in Patients Treated with Rapid (14d) Steroid Withdrawal After Liver Transplantation. Accepted, AASLD Annual Meeting, October, 2000.

110. Stolpman N, Stephens J, Trouillot T, Trotter J, Kugelmas M, Wachs M, Bak T, Steinberg T, Kam I, Everson, GT. Apparent Slowing of Hepatitis C Recurrence and Progression after Liver Transplantation Using Very Early (14d) Steroid Withdrawal. AST Transplant 2001 Meeting, May, 2001.

111. Everson GT, Halprin A, Trouillot T, Trotter J, Kugelmas M, Skilbred J, Tomasi C, McKinley C, Fey B, Ray C, Epp J, Department of Medicine, University of Colorado School of Medicine, Denver, CO. Treatment of Decompensated Cirrhotics May Reduce Recurrence of Hepatitis C After Liver Transplantation. Accepted, AST Transplant 2001 Meeting, May, 2001.

112. Zeuzem S, Manns M, Rustgi V, Aurora S, Smith C, Shiffman M, Reddy R, Reindollar R, Slaker D, Rai R, Keeffe E, International Interferon alfacon-1 Study Group. Daily Interferon Alfazon-1 (Infergen) Therapy: Interim Results from an Ongoing International Clinical Trial to Compare Daily Interferon Alfacon-1 Therapy (9 mcg) for Treatment of Chronic Hepatitis C Virus. Accepted, European Association for the Study of the Liver Annual Conference, 2001.

113. Trotter J, Schiano T, Wachs M, Kim-Schluger L, Bak T, Kugelmas M, Trouillot T, Everson GT, Miller C, Kam I. Living Donor Liver Transplantation in Hepatitis C Patients: Short-Term Results Compared to Cadaveric Transplantation. AST Transplant 2001 Meeting, May, 2001.

114. Talamantes M, Trotter J, McClure M, Wachs M, Bak T, Trouillot T, Kugelmas M, Steinberg T, Everson GT, Kam I. Assessment of the Impact of Living Donor Liver Transplantation on Quality of Life in Donors. AST Transplant Meeting, May, 2001.

115. Wachs M, Bak T, Everson GT, Trotter J, Trouillot T, Kugelmas M, Steinberg T, McClure M, Brackett T, Kam I, Division of Transplant Surgery. Adult Living Donor Liver Transplant: The University of Colorado Experience. AST Transplant, May, 2001.

116. Trotter J, Wachs M, Trouillot T, Bak T, Kugelmas M, Everson GT, Kam I. Sirolimus is Not Associated with Hypercholesterolemia in the Absence of Prednisone in Liver Transplant Recipients. AST Transplant 2001, May, 2001.

117. Halprin A, Trotter J, Everson GT, Wachs M, Bak T, Kugelmas M, Kam I. Post-Transplant Eradication of Hepatitis C by Pre-Transplant Treatment in Living Donor Liver Transplant Recipients. AASLD, 2001.

118. Pauls T, Trotter J, Wachs M, Bak T, Kugelmas M, Kam I, Everson GT. Increased

98

Immunosuppressant Levels in Hepatitis C Liver Transplant Recipients Receiving Sirolimus. AASLD, 2001.

119. Dunkelberg J, Trotter J, Steinberg T, Wachs M, Bak T, Kugelmas M, Everson GT, Kam I. Sirolimus is Not Associated with a Higher Incidence of Wound or Hepatic Artery Complications in Liver Transplant Recipients. AASLD, 2001.

120. Trotter J, Bock SA, Wachs M, Kam I, Everson GT. Transference of Peanut Allergy Through Liver Transplantation. Accepted, AASLD, 2001.

121. Stevens A, Busuttil R, Han S, Baquerizo A, Fair J, Shrestha R, Johnson M, Bloomer J, McGuire B, Rosenthal P, Ascher N, Freise V, Watanabe F, Rogiers X, Schulte J, Nyberg S, Wiesner RH, Broelsch C, Malago M, Kribben A, Lerut J, Laterre P, Salizzoni M, Lavezzo B, Brown R, Emond J, Lobritto S, De Hemptinne B, Colardyn F, Hoste E, Fagan E, McChesney L, Muraca M, Mas Ordeig A, Salmeron G, Rabkin J, Pratt D, de la Mata M, Montero J, Pozo J, Metselaar H, Everson GT, Pitkin Z, Mullon C, Solomon B, Demetriou A. In Interim Analysis of Phase II/III Prospective Randomized, Multicenter, Controlled Trial of the Hepatassist Bio-artificial Liver Support System for the Treatment of Fulminant Hepatic Failure. AASLD, 2001

122. Trotter J, Stolpman N, Wachs M, Bak T, Kugelmas M, Kam I, Everson GT. Living Donor Liver Transplant Recipients Achieve Higher Immunosuppressive Levels Than Cadaveric Recipients. AASLD, 2001

123. Shiffman M, Everson GT, Lindsay K, DiBisceglie A, Lok A, Bonkovsky H, Everhart J, Dienstag J, Seeff L, Lee W, Wright L, Chihiro M, Ghany M, Morgan T, Hoofnagel J. Retreatment of Interferon and Interferon-Ribavirin Non-Responders with Peg-interferon-Alpha 2A and Ribavirin: Initial Results from the Lead-In Phase of the HALT-C Trial. Oral Presentation, AASLD, 2001.

124. Fontana RJ, Kronfol Z, Wright E, Lindsay K, Seeff L, Shiffman M, DiBisceglie A, Bonkovsky H, Everson G, Lok ASF, Lee WM, Deinstag J, Morgan T, Morishima C, Ghany M for the HALT-C Study Group. There is a High Lifetime Incidence of Substance Abuse but not Mood Disorders in Hepatitis C Non-Responders with Advanced Fibrosis: Results from HALT-C Trial. Oral Presentation, DDW May 2002.

125. Shiffman M, HALt-C Trial Investigators. Retreatment of HCV Non-Responders with Peginterferon and Ribavirin: Results from the Lead-In Phase of the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Oral Presentation, AASLD 2002.

126. Lok AS, Everhart JE, Everson G, Wright EC, Sterling R, Ghany M, Goodman Z, HALT-C Trail Investigators. Clinical Model to Predict Cirrhosis in Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Oral Presentation, AASLD 2002.

127. Kulig CC, Trotter JF, Everson GT. Treatment of lamivudine-resistant chronic hepatitis B with tenofovir. DDW, Orlando, FL, 2003.

128. Osborne JC, Heller MA, Forman L, Kugelmas M, Everson GT, Bak T, Wachs M, Kam I, Trotter JF. Tacrolimus level/dose ratio is significantly higher in hepatitis C liver

99

transplant recipients: impact on cost. AASLD, Boston, MA, 2003.

129. Balan V, Sulkowski M, Nelson D, Everson GT, Bambury J, Recta J, Zhong H, Mesghali J, Murray B, Osborn L, Novello W, Freimuth G, Subramanian G. A Phase ½ Study to Evaluate the Pharmacokinetics, Safety, Tolerability, Immungenicity and Pharmacodynamics of Albuferon™ in Treatment Experiences Subject with Chronic Hepatitis C. AASLD, Boston, MA, 2003.

130. Everson GT, Lauriski S, DeSanto J, Kugelmas M, Shiffman ML, Hofmann C, Sterlling R, Morgan T, Hoefs J, Miline N, Rietker W, Wagner D. Quantitative Tests (QLFTs) Detect Impaired Hepatic Function in a High Proportion of Chronic Hepatitis C Patients with Fibrosis or Compensated Cirrhosis and May Predict Risk of Cirrhosis, Splenomegaly, and Varices. AASLD, Boston, MA, 2003.

131. Osgood MJ, Forman L, Kugelmas M, Everson GT, Bak T, Wachs M, Kam I, Trotter JF. Preliminary analysis: graft loss from recurrent hepatitis C is not increased in patients receiving sirolimus as primary immunosuppression. AASLD, Boston, MA, 2003.

132. Osgood M, Hayashi PH, Ludkowski M, Johnson S, Durham J, Brackett T, Steinberg T, Forman L, Kugelmas M, Trotter J, Bak T, Wachs M, Kam I, Everson GT. Hepatic artery chemoembolization for hepatocellular carcinoma: an intentino-t9=transplant analysis. AASLD, Boston, MA, 2003.

133. Forman L, Kam I, Everson GT. Maintenance of excellent patients survival after liver transplantation for chronic hepatitis C in a single center during three eras of immunosuppression characterized by wide variation in use of OKT3. Am J of Transplant 2004; 4(8). Abstract 722, p. 355. ATC Conference, Boston, MA, 2004.

134. Everson GT, Marder B, Levi M, Laird SP, McNutt T, Pape WJ, Forman L, Kleinschmidt-DeMaster, BK, Tyler KL. Community-Acquired West Nile Virus Encephalomyelitis in Solid Organ and Bone Marrow Transplant Recipients: Clinical, Diagnostic, and Neuropathological Features. Am J of Transplant 2004; 4(8). Abstract 974, p. 424. ATC conference, Boston, MA, 2004.

135. Stolpman NM, Valuck RJ, Lezotte D, Malone DC, Glazner J, Everson GT. A Pharmacoeconomic Assessment of the Benefits and Costs of Managing Immuno-suppression in Post-Liver Transplant Patients: A University Hospital Perspective. Poster Presentation, ISPOR 9th Annual International Meeting, May 2004.

136. Everson GT. Shiffman ML, Hoefs JC, Kugelmas M, Sterling RK, Morgan TR, DeSanto J, McKinley C, Hofmann C, Smith P, Rietkerk W, Lauriski S, Milne N, Wagner D, Doherty MC, Wright EC. Quantitative Liver Function Tests Predict Sustained Virologic Response to Retreatment with Peginterferon alfa-2a plus Ribavirin: Results of the Lead-In Phase of the HALT-C trial. Poster Presentation, AASLD, October 2004.

137. Everson GT, Hoefs JC, Malet P, The HALTC Trial Group. Impaired Virologic Response in Patients with Advanced Liver Disease due to Chronic Hepatitis C is Independently Linked to Severity of Disease: Results from the HALT C Trial. Oral Presentation, AASLD, October 2004.

138. Shiffman ML, Morgan TR, Ghany MG, Wright EC, the HALT-C Trial Group. The Impact

100

of Peginterferon (PEGIFN) and Ribavirin (RBV) Dosing on Sustained Virologic Response (SVR) in Patients with Chronic Hepatitis C Virus (HCV) Undergoing Retreatment in the HALT-C Trial. Poster Presentation, AASLD, October 2004.

139. Lok AS, Everhart JE, Chung RT, Padmanabhan L, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG, Morishima C, for the HALT-C Trial Investigators. Prevalence of insulin resistance (IR) and impact on treatment in chronic hepatitis C (CHC). Poster Presentation, AASLD, October 2004.

140. Talamantes M, McClure M, Bak T, Wachs M, Kam I, Foreman L, Everson GT, Trotter J. Impact of Right Hepatic Lobe Donation on Donor Quality-of-Life: Long-Term Follow-Up of The University of Colorado Cohort. Oral Presentation, AASLD, October 2004.

141. Balan V, Sulkowski M, Nelson D, Everson GT, Lambiase L, Post A, Redfield R, Wiesner, R, Davis G, Neumann A, Rectal J, Moore P, Osborn B, Novello L, Freimuth W, Sumramanian M. Albuferon – A Novel Therapeutic Agent for Hepatitis C: Results of a Phase ½ Study In Treatment Experienced Subjects with Chronic Hepatits C. Oral Presentation, AASLD, October 2004.

142. Everson G, Heathcote J, Pappas SC, Govindarajan S, Lentz E, Lopez-Talavera JC, Hoffman F. Histological Beneit of Pegintergeron Alfa-2A (40KD) (Pegasys ®) Monotherapy in Patients with Advanced Fibrosis or Cirrhosis Due to Chronic Hepatitis C. Poster Presentation, AASLD, October 2004.

143. Moore PA, Balan V, Nelson D, Sulkowski M, Everson G, Lambiase L, Neumann A, Garcia A, Osborn B, Bagchi P, Novello L, Freimuth W, Subramanian M. Modulation of Interferon Specific Gene Expression by Albuferon in Subjects with Chronic Hepatitis C and Correlation with Anti-Viral Response. Poster Presentation, EASL 2005.

144. Martucci MA, Everson GT, Shiffman, ML, Hoefs, JC, HALT-C QLFT Investigators. Minimal Model to Determine First-Pass Hepatic Extraction of Cholate in Humans. Oral Presentation, Western Society for Clinical Investigation Meeting, Carmel, CA February 2005.

145. Terrault NA, Shiffman ML, Lok ASF, Saab S, Gillespie BW, Seeff LB, and the A2ALL Study Group. Transplant Center Experience Explains Differences in the Risk of Graft Failure between Hepatitis C Virus (HCV)-Infected Recipients of Living donor (LDLT) and Decreased donor (DDLT) Liver Transplant Recipients. Presentation, AASLD 2005.

146. Campsen J, Wachs M, Bak T, Kam I, Forman L, Everson G, Trotter JF. Outcomes of donor candidates evaluated fro adult-to-adult right hepatic lobe living donor liver transplantation from a single center. Poster Presentation, AASLD 2005.

147. Campsen J, Wachs M, Bak T, Kam I, Forman L, Everson G, Trotter JF. Outcomes of donor candidates evaluated fro adult-to-adult right hepatic lobe living donor liver transplantation from a single center. Poster Presentation, AASLD 2005.

148. Bonkovsky HL, Di Bisceglie AM, Morishima C, Chung RT, Everosn GT, Ghany MC, Hoofnagle JH, Lindsay KL, Hoefs JC, Lee WM, Lok, As, Shiffman ML, Wright EC. Iron and HFE gene mutations in advance chronic hepatitis C (CHC): results from the lead-in

101

phase of the HALT-C Trial. Poster Presentation, AASLD 2005.

149. Forman L, Everson G. Nonalcoholic fatty liver disease hospitalizations in the United States in 202: characteristics and comparison to chronic hepatitis C. Poster Presentation, AASLD 2005.

150. Everson GT, Shiffman ML, Sterling Rk, Hoef JC, Morgan T, DeSanto J, Lauriski S, Shea S, Hofmann C, Rietker W, Milne N, Wright E, Doherty M. Hepatic function improves after sustained virologic response in hepatitis C paitents with advanced fibrosis and cirrhosis: Results of the lead-in phase of the HALT-C Trial. Poster Presentation, AASLD 2005.

151. Sterling RK, Lok ASF, Seeff LB, Hoefs JC, Wright EC, and the HALT-C Trial Investigators. Clinical Utility of Alpha Fetoprotein (AFP) L3 and Des-gamma Carboxy Prothrombin (DCP) to Predict Hepatocellular Carcinoma in Patients with Hepatitis C and Advanced Fibrosis Results from the lead in phase of the HALT-C Trial. Poster Presentation, DDW 2005

152. Everson GT, Kulig CC, Shiffman ML, Sterling RK, Morgan TR, Hoefs JC, Curto TM, Everhart JE, Wagner D, DeSanto J, McKinley C, Hofmann C, Smith P, Rietkerk W, Lauriski S, Milne N. Altered Hepatic Metabolic Function in Patients with Chronic Hepatitis C is Associated with Obesity, Insulin Resistance, or Hepatic Steatosis, Independent of Cirrhosis: Results from the HALT-C Trial. Poster Presentation, AASLD 2006.

153. Hoefs, JC, Everson GT, Shiffman ML, Morgan TR, Naishadham D, Wright EC. Enhanced Quantitative Liver Spleen Scan (QLSS) Prediction of Liver Disease Severity in Baseline HALT-C Patients with Moderate Fibrosis or Cirrhosis. Poster Presentation, AASLD 2006.

154. Seeff L, Herbal and Milk Thistle Use in the HALT-C Trial of Advanced Chronic Hepatitis C. Poster Presentation, DDW 2007.

155. Jing T, Shah R, Chen Y, Brauer B, Baker M, Everson G. Does pre-transplant ERCP with stenting (ERCPST) or PTC with drainage tubes (PTCDT) impact post-transplant complications in patients with primary sclerosing cholangitis (PSC)? Poster Presentation, DDW 2007.

156. J Lalezari, E Gane, M Rodriguez-Torres, E DeJesus, D Nelson, G Everson, I Jacobson, R Reddy, G Hill, A Beard, WT Symonds, MM Berrey, JG McHutchison. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and Ribavirin: Interim results of R7128 500mg BID for 28 days. Oral Presentation, EASL in Milan, April 2008.

157. Dudekula A, Kulig C, Everson GT. Five year experience with tenofovir for lamivudine resistant hepatitis B virus. Poster Presentation, ACP Internal Medicine 2008, Washington, DC.

158. Everson GT, Jacobson IM, Gordon SC, McHutchison JG, Kaufman R, McNair L, Muir A. Prove 1: Results from a Phase 2 Study of Telaprevir with Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Subjects with Hepatitis C. Presentation at DDW 2008.

102

159. Bzowej NH, Nelson D, Saab S, Everson GT, Teng LL, Prabhakar A, Charlton M. A randomized controlled trial of the efficacy, tolerability, and safety of prophylactic treatment with peginterferon alfa-2a plus ribavirin after orthotopic liver transplantation (OLT) for Hepatitis C: the PHOENIX study. Poster presentation, AASLD 2009 #505.

160. McHutchinson JG, Jacobson IM, Boyer TD, Schiff ER, Everson GT, Lee WM, Pockros P, Chasen RM, Vierling JM, Lawitz E, Kugelmas M, Tsai N, Armstrong BR, Rodell TC, Apelian D. GI-5005 therapeutic vaccine plus peginf/ribavirin improves end of treatment response at 48 weeks versus peginf/ribavirin in naïve genotype 1 chronic HCV patients. Poster presentation, AASLD 2009 #LB15.

161. Everson GT, Dusheiko GM, Ferenci P, Alves K, Bengtsson L, McNair L, McHutchinson JG, Muir A, Pawlotsky J-M, Zeusem S. Telaprevir, peginterferon alfa-2a and ribavirin improved rates of sustained virologic response (SVR) in “difficult-to-cure” patients with chronic Hepatitic C (CHC): a pooled analysis from the PROVE1 and PROVE2 trials. Poster presentation, AASLD 2009 #1565.

162. Everson GT, Hoefs JC, Shiffman ML, Morgan TR, Sterling RK, Curto TM, Wagner D, Wright EC, Everhart JE. Hepatic impairment measured by quantitative tests of liver function (QLFTs) predicts clinical outcome in patients with advanced fibrosis: results from the Hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Poster presentation, AASLD 2009 #1627.

163. Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR. PHOENIX: A randomized controlled trial of peginterferon alfa-2a/ribavirin prophylactic treatment after liver transplant for Hepatitis. Oral presentation, ILTS 2009.

164. Everson GT and Sherman M. Which patients with chronic viral Hepatitis are likely are risk of HCC? Oral presentation, AASLD 2010, PG-24.

165. Kulik L, Fisher RA, Lok AS, Rodrigo DR, Brown RS, Freise CE, Shaked A, Everson GT, Hong JC, Hayashi PH. HCC recurrent and survival in living donor liver transplant (LDLT) compared to deceased donor liver transplant (DDLT): results of the Adult to Adult Living Donor Transplant (A2ALL) cohort. Oral prestation, AALSD 2010, #103.

166. Sherman KE, Flamm STL, Afdhal ZH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Kleber K, Martin M, Sankoh AJ, Kauffman RS, George S, Wright CI, Poordad F. Telaprevir in combination with peginterferon alfa-2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study. Oral presentation, AASLD 2010 #LB-2.

167. Pockros P, Jacobson I, Boyer TD, Schiff ER, Everson GT, Lee WM, Vierling JM, Lawitz E, Kugelmas M, Tsai N, Shiffman ML, Brown RS, Armstrong BR, Mattson A, Rodell TC, Apelian D. GI-5005 Therapeutic vaccine plus peginf/ribavirin improves sustained virologic response versus peginf/ribavirin in prior non-responders with genotype 1 chronic HCV infection. Oral presentation at AALS 2010 #LB-6.

168. Kulik L, Fisher RA, Lok AS, Rodrigo DR, Brown RS, Freise CE, Shaked A, Everson GT, Hong JC, Hayashi PH, Berg CL. HCC recurrence and survival in living donor liver

103

transplant (LDLT) compared to deceased donor liver transplant (DDLT): results of the Adult to Adult Living Donor Transplant (A2ALL) cohort. Oral presentation at AASLD 2010 #103.

169. Hezode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz E, Rustgi VK, Pol S, Weis N, Pockros P, Bourliere M, Serfaty L, Vierling JM, Fried MW, Weiland O, Burnetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski MS, Yin PD, Diva UA, Hughes EA, Wind-Rotolo M, Schnittman SM. BMS-790052, A NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribivirin in treatment-naïve HCV-genotype 1 or 4 patients: phase 2b AI444010 study interim week 12 results. Oral presentation at AALSD 2011 #227.

170. Hoefs JC, Everson GT, Shiffman ML, Morgan T, Chen W-P, Gillen D. Non-invasive measurements of hepatic fibrosis from quantitative liver-spleen scan (QLSS): HALT-C trial results. Poster presentation at AALSD 2011 #423.

171. Hoefs JC, Shiffman ML, Everson GT, Morgan T, Dillen D, Chen W-P. Effective detection of cirrhosis from the quantitative liver-spleen scan (QLSS): HALT-C trial results. Poster presentation at AALSD 2011 #436.

172. Hoefs JC, Everson GT, Shiffman ML, Morgan T, Chen W-P, Gillen D. Is the platelet count determined by hepatic function or hypersplenism: results of the HALT-C trial? Poster presentation at AALSD 2011 #451.

173. Biggins S, Brocato MA, Trotter JF, Chang MF, Burton JR, Forman L, Bambha K, Riccardi S, Everson GT, Kam I, Klintmalm G, Rosen HR. IL28B in IFN-Gamma polymorphisms in HCV-infected liver transplant recipients: a large multicenter matched case-control analysis. Poster presentation at AASLD 2011 #524.

174. Fortune BE, Martinez-Camacho A, Kreidler S, Gralla J, Everson GT. Outcomes of liver transplantation for Hepatitis C: non-proportional hazard analysis of the impact of HCV RNA status at transplantation on graft and patient survival. Poster presentation at AASLD 2011 #538.

175. Kiser JJ, Burton JR, Robert JL, Baouchi F, Wolfe P, Ray M, Bushman L, Levine JS, Everson GT. Intracellular ribavirin pharmacokinetics at first does and steady state in persons with chronic HCV undergoing treatment with peginterferon alfa-2a and ribavirin. Poster presentation at AALSD 2011 #977.

176. Everson GT, Gray TE, Hillson JL, Horga M, Xu D, Fontana D, Freeman JA. Lopez-Talavera J-C. Pegylated interferon lambda ameliorates ribavirin (RBV)-induced anemia in HCV patients by maintaining compensatory erythropoiesis: analysis of EMERGE phase 2B results through week 12. Poster presentation at AASLD 2011 #1343.

177. Helmke SM, Kulig CC, Lauriski S, Herman A, Dudekula A, Everson GT. Significant alteration of the portal circulation in over half of the chronic HCV patients with Ishak fibrosis state F0-F2. Poster presentation at AASLD 2011 #2063.

178. Marcellin P, Sullivan J, Fried MW, Kieffer TL, Dusheiko GM, Martin EC, Nelson DR, Di Bisceglie AM, Wright CI, George S, Bengtsson L, Bartels DJ, Everson GT, Adda N.

104

Sustained virologic response rates and viral resistance profiles were similar in patients treated with a telaprevir-based regimen regardless of liver fibrosis stage. Poster presentationat AASLD 2011 #2105.

179. Everson GT, Dusheiko G, Pol S, Nelson D, Muir A, Andreone P, Kauffman R, Adda N, Wright C, Bengtsson L, Martin M, Sankoh A, George S, Sherman K, Jacobson I, Zeuzem S. Telaprevir in combination with peginterferon alfa-2a and ribavirin increased sustained virologic response in genotype 1 chronic HCV and allowed for shorter treatment duration in treatment-naïve and prior relapse patients. Am J Gastro 2011(106):S2 S113 (ACG Presidential Poster)

180. Everson GT. New data on other combinationas: Danoprevir, mericitabine, p7177, p7181; interferon and RBV free combinations. Latin American Symposium on Viral Hepatitis. June 2011, Santo Domingo, Dominican Republic.

181. Treatment before Liver Transplantation Including Update on New Drugs. ILTS 2012,San Francisco, CA

182. Helmke SM, Wallack A, Herman A, Lauriski S, Everson GT. Non-invasive measurement of the portal circulation using cholates quantifies disease severity in waiting list patients with primary sclerosing cholangitis. Poster presentation, ILTS 2012, San Francisco, CA

183. Terrault NA, Stravitz RT, Lok AS, Everson GT, Brown RS, Kulik LB, Olthoff KM, Saab S, rubinas T, Argo CK, Everhart JE, Rodrigo DR. Long-term Hepatitis C (HCV) graft loss and fibrosis severity is unrelated to donor type: results from the Adult to Adult Living Donor Liver Transplantation (A2ALL) study. Am J Transplant 2012(12):s3 105. Oral presentation at ATC 2012, Boston, MA.

184. Helmke SM, Wallack A, Herman A, Isberg H, Lauriski S, Everson GT. Slow, Moderate, and Rapid Progressors: Three Distinct Categories of Patients with Primary Sclerosing Cholangitis Detected by Functional Assessment using Cholate Testing. Poster presentation at AASLD 2012, Boston, MA.

185. Helmke SM, Desanto JL, Herman A, Lauriski S, Everson GT. Alteration of the Portal Circulation across the Entire Spectrum of Fibrosis in Patients with Chronic Hepatitis C as Measured by Dual Cholate Clearances. Poster presentation at AASLD 2012, Boston, MA.

186. Helmke SM, Desanto JL, Herman A, Lauriski S, Everson GT. A Disease Severity Index Based on Dual Cholate Clearances and Shunt Outperforms Biopsy at Predicting Clinical Outcomes in Chronic Hepatitis C Gastroenterology. Oral presentation at DDW 2013, Orlando, FL, #609.

187. Helmke SM, Wallack A, Isberg H, Bhatt A, Cookson M, Lauriski S, Everson GT. A Disease Severity Index Based on Dual Cholate Clearances and Shunt Identifies PSC Patients at Risk for Clinical Complications. Poster presentation at ATC 2013, Seattle, WA, #D1632 (Poster of Distinction).

188. Helmke SM, Wallack A, Herman A, Isberg H, Brocato M, Bhatt A, Lauriski S, Everson GT. Cholate Testing is Superior to MELD in Assessing Disease Severity in Patients with Primary Sclerosing Cholangitis Liver Transplantation. Oral presentation at ILTS

105

2013, Sydney, AU, #O-39.

189. Helmke SM, Wallack A, Herman A, Isberg H, Brocato M, Bhatt A, Lauriski S, Everson GT. Serial Cholate Testing is Better than ∆MELD in Assessing Disease Progression in Waiting List Patients with Primary Sclerosing Cholangitis Liver Transplantation. Poster presentation at ILTS 2013, Sydney, AU, #P-538.

190. Everson, GT. Hepatic Improvement in Response to Ledipasvir/Sofosbuvir/Ribavirin as Measured by the HepQuant (HQ)- Shunt Test in Liver Transplant (LT) Recipients with Allograft Fibrosis or Cirrhosis and Non-LT Patients with Decompensated Cirrhosis. EASL - International Liver Congress™ (ILC) that will be held in Vienna, Austria from April 22- 26, 2015.

191. Emond JC, Fisher RA., Everson GT, Samstein B, Pomposelli J, Zhao B, Forney S, Olthoff K, Baker T, Gillespie B. Changes in Liver and Spleen Volumes After Living Liver Donation: A Report from the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL) Liver Transplantation 21:151-161, 2015

106

updated 10/2/02 - school of medicine | university of...

Documents